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Abstract 
Library Synthesis of Piperidinone Sulfonamides, Transition Metal-Free C–H 
Trifluoromethylation of Cyclic Enaminones, and Elucidating the Binding Site of 
Epothilones on Beta-Tubulin with Epothilone Photoaffinity Probes 
 
Chapter 1 focuses on synthesizing a library of piperidinone sulfonamides. The 
piperidinones serve as valuables intermediates for the synthesis of nitrogen-containing 
bioactive molecules, various alkaloids, and drug candidates. Amongst the myriads of 
highly derivatized N-heterocyclic compounds, molecules possessing the piperidinone 
sulfonamide moiety in their structures show interesting biological activities. A library of 
18 piperidinone sulfonamides was prepared under a Pilot Scale Library grant and 
submitted to NIH for testing in various biological assays. Two compounds from the 
library were identified as active hits. One of the compounds showed prion protein 5’ 
UTR inhibition while the other showed inhibition of human platelet-activating factor 
acetylhydrolase 1b, catalytic subunit 2. 
 Chapter 2 focuses on direct C–H trifluoromethylation of cyclic enaminones. 
Cyclic enaminones are of interest in natural product synthesis and are regarded as 
valuable synthons due to unique structural and chemical properties. They serve as 
versatile precursors for synthesizing piperidine-containing alkaloids and drug molecules. 
In this project, transition metal free, direct C–H trifluoromethylation of cyclic 
enaminones was developed with trimethyl(trifluoromethyl)silane (TMSCF3). This 
method proceeds under mild conditions at room temperature and possibly involves a 
radical mechanism. The C–H functionalization was successful with both electron-rich 
	  iv	  
and electron-deficient cyclic enaminones. This methodology circumvents substrate 
prefunctionalization and transition metal catalysis, and allows a convenient and direct 
access to a variety of medicinally significant 3-trifluoromethylpiperidine derivatives. This 
chemistry also presents a rare example of a direct trifluoromethylation of an internal 
olefinic C–H bond.  
 Chapter 3 focuses on efforts toward elucidating the binding site of epothilones on 
β-tubulin. Epothilones are potent cytotoxic tubulin-binding polyketide-derived 
macrolides. Even though the binding sites for epothilones and paclitaxel on β-tubulin 
overlap, epothilones show efficacy against paclitaxel-resistant cancer cell lines. This 
implies a significantly different binding mode for epothilones. To date, two epothilone 
binding models have been proposed based on NMR and electron-crystallography data. In 
order to differentiate the proposed binding modes, four epothilone A photoaffinity 
analogues were designed. Three of those analogues were successfully synthesized and 
showed excellent cytotoxicity as well as the required tubulin assembly. It was 
hypothesized that the protein region labeled by these photoprobes is dependent on the 
epothilone conformation at the binding site. For one of the analogues, the probe-labeled 
peptide fragment ‘TARGSQQY’ (residues 274 to 281) in the β-tubulin isoform TBB3 
was identified by MS analysis. Our experimental results corroborated the consensus of 
both the models that Thr 274 and Arg 276 are necessary for binding of epothilones to β-
tubulin. However, based on the photoaffinity labeling studies results and molecular 
modeling studies, an orientation of the epothilone in the binding site is proposed that is 
significantly different from those previously proposed. 
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(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-
1-en-2-yl)-7,11-bis((triethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione 
(3.14)                    93 
(4S,7R,8S,9S,13R,14R,16S)-14-Bromo-13-hydroxy-5,5,7,9-tetramethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.15)                  94 
(4S,7R,8S,9S,13R,14S,16S)-14-Azido-13-hydroxy-5,5,7,9-tetramethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.16)                   94 
(2S,4S,5S,9S,10S,11R,14S)-4-Azido-9,11,13,13-tetramethyl-2-((E)-1-(2-methylthiazol-4-
yl)prop-1-en-2-yl)-12,16-dioxo-10,14-bis((triethylsilyl)oxy)oxacyclohexadecan-5-yl  
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4-nitrobenzoate (3.17)                94 
(4S,7R,8S,9S,13R,14S,16S)-14-Azido-13-hydroxy-5,5,7,9-tetramethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.18)                   94 
(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-
1-en-2-yl)-7,11-bis((triethylsilyl)oxy)-4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione 
(3.19)                               94 
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-
17-ium 2,2,2-trifluoroacetate (3.11)                94 
(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-17-(3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoyl)-
4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione (3.2)             96 
(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-17-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoyl)-
4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione (3.3)             96 
1-(4-bromothiazol-2-yl)-2,2,2-trifluoroethan-1-one (3.29) 98 
(Z)-1-(4-Bromothiazol-2-yl)-2,2,2-trifluoroethan-1-one O-tosyl oxime (3.30) 98 
4-Bromo-2-(3-(trifluoromethyl)diaziridin-3-yl)thiazole (3.31) 98 
4-Bromo-2-(3-(trifluoromethyl)-3H-diazirin-3-yl)thiazole (3.26) 98 
(1S,3S,7S,10R,11S,12S,16R)-3-Acetyl-8,8,10,12-tetramethyl-7,11-
bis((trimethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.32) 99 
Tris(ethylenedioxyboryl)methane (3.33) 100 
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2-Bromo-4-vinylthiazole (3.43) 102 
2,2,2-Trifluoro-1-(4-vinylthiazol-2-yl)ethan-1-one O-tosyl oxime (3.44) 102 
2-(3-(Trifluoromethyl)diaziridin-3-yl)-4-vinylthiazole (3.45) 102 
2-(3-(Trifluoromethyl)-3H-diazirin-3-yl)-4-vinylthiazole (3.40) 102 
(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-(prop-1-en-2-yl)-7,11-
bis((trimethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.46) 102 
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Library Synthesis of Piperidinone Sulfonamides 
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1.1 Rationale for Library Synthesis 
“Chemical Space” is a term used in place of multi-dimensional descriptor space. It is a 
region defined by a particular choice of descriptors with limits placed on them. This 
region is comprised of all energetically stable chemical compounds. About 1060 small 
molecules with molecular weights of less than 500 exist1 in this “Chemical Diversity 
Space (CDS)” out of which only 108 have been synthesized or isolated so far. This means 
that large areas of the diversity space are either not yet explored or under-explored. These 
sparsely populated areas, however, are believed to offer unprecedented opportunities to 
find new molecules that can be developed as probes and drug leads. However, one of the 
problems with new types of organic compounds that are now being explored is that they 
may show remarkable potency when tested against isolated targets in the laboratory 
environment, but within the complex cellular environment they might interact with other 
cellular components and fail to show similar potency.2 “Natural products” are relatively 
robust having passed through evolutionary development, and they are possibly less likely 
to interact with common components of living systems, such as membranes or DNA in a 
harmful manner. Indeed, around 30% of all the drugs approved over the past 20 years are 
natural products or derivatives of them.3 A comparison of the properties of combinatorial 
chemistry libraries, natural products, and drugs shows that combinatorial compounds by 
and large cover a significantly smaller area of chemical space than either natural products 
or drugs (Fig. 1.1).4  
A large database that contained compounds from combinatorial chemistry (a), 
natural products (b) and drugs (c) was analyzed on the basis of a variety of molecular 
properties such as molecular mass, lipophilicity, and topological factors.4 To visualize the 
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diversity of these compounds on the basis of these properties, a statistical approach 
known as principal component analysis (PCA) was used. PCA is a mathematical 
procedure that uses an orthogonal transformation to convert a set of observations of 
possibly correlated variables into a set of values of uncorrelated variables called principal 
components.4 Figure 1.1 is a plot of the first two principal components obtained from a 
database.  
 
Figure 1.1. Comparison of Properties of Combinatorial Chemistry Libraries, Natural 
Products and Drugs. (Figure adapted with permission from the literature reference4. 
Copyright 2014 American Chemical Society). 
 
As seen in Figure 1.1, combinatorial compounds cover a well-defined region in 
diversity space according to the principal components analysis. Natural products and 
drugs together cover not only the same space, but also additional regions of space. 
Interestingly, there is a significant overlap of the plots of natural products and successful 
drug molecules.4 This suggests that by aiming to mimic some properties of natural 
products and drug molecules, new combinatorial compounds could be made that are 
substantially more diverse and have greater biological relevance4 than those currently 
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known. 
Based on those considerations, the NIH launched a national effort and provided 
research grants to investigators to prepare Pilot Scale Libraries (PSL) that contain 
compounds covering novel or underexplored regions of the chemical space and that are 
hypothesized to possess bioactivity. The aim of the PSL projects was to synthesize 
compounds residing in sparsely populated CDS by a variety of novel synthetic chemistry 
strategies. Compounds prepared under the PSL grants were submitted to the Molecular 
Libraries Small Molecular Repository (MLSMR). About 500,000 compounds have been 
collected to date and are mainly comprised of diversity sets. In addition, specialty sets of 
pharmacologically active compounds, targeted libraries for proteases, kinases, GPCRs, 
ion channels, nuclear receptor targets and natural products were collected from various 
sources. It is anticipated that expanding the “chemical space” through these efforts will 
ultimately serve to provide chemical probes for new targets and starting compounds for 
the development of a new classes of therapeutic agents.  
The MLSMR compound collections were provided by investigators from across 
the country to the Molecular Libraries Probe Production Centers Network (MLPCN) and 
used for screening of novel targets. The screening results were subsequently deposited 
into the PubChem database, thus making this information freely available on the Internet. 
As a part of this national effort, the Georg group received a PSL grant to prepare libraries 
with nitrogen-containing cyclic scaffolds, and for the design and synthesis of factorial 
libraries from privileged structures, novel medium-sized ring combinatorial libraries, 
diversity-oriented library synthesis and natural product-derived libraries. It was my task 
to synthesize a piperidinone sulfonamide library as part of the PSL subproject “synthesis 
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of libraries with nitrogen-containing cyclic scaffolds.” The Georg group and others have 
extensively investigated the chemistry of 2,3-dihydropyridin-4(1H)-ones (Figure 1.2). 
Studies have included the development of general and asymmetric synthetic methods, 
chemoselective functionalizations,5-10 and their conversion to piperidones, piperidines, 
and piperidine-containing natural products and bioactive molecules. 
 
Figure 1.2. Structures of 2,3-Dihydropyridones, 4-Pyridones and Piperidines. 
 
Among several possibilities to prepare piperidine-containing pilot scale libraries, a 
literature review revealed that highly derivatized N-heterocyclic sulfonamides had shown 
interesting biological activities. Some of the structures are shown in Figure 1.3. 
Compounds of structure types 1.111,12 and 1.213 showed very good γ–secretase inhibitory 
activity (100-1000 nM). Aggregation/deposition of amyloid beta peptide (Aβ) in the 
brain of Alzheimer’s disease (AD) patients is thought to contribute to the disease 
pathology. AD is a degenerative brain disorder characterized by progressive loss of 
memory, cognition, reasoning, judgment and emotional stability that gradually leads to 
profound mental deterioration and ultimately death.13 It is the fourth most common 
medical cause of death in the United States. Beta amyloid peptide is formed by sequential 
cleavage of amyloid precursor protein (APP) by two aspartyl proteases, β-secretase 
(BACE) and γ-secretase respectively.13 Thus, inhibiting γ-secretase could prove to be 
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useful in preventing Alzheimer’s disease. Compounds of structure type 1.3 showed good 
JNK-2 and JNK-3 inhibitory activity (inhibition of more than 20% of the JNK activity at 
10 µM).14 JNK or c-Jun N-terminal kinases are kinases that bind and phosphorylate c-Jun 
proteins. They belong to the mitogen-activated protein (MAP) kinase family. MAP 
kinases are serine/threonine kinases that are activated by dual phosphorylation on 
threonine and tyrosine residues. In mammalian cells there are at least three separate, but 
parallel pathways that convey information gathered by extra-cellular stimuli to the MAP 
kinases. These pathways include kinase cascades leading to activation of ERKs 
(extracellular regulated kinases), the JNKs and the p38/CSBP kinases. The JNK cascades 
are activated by different external stimuli such as cellular stress, DNA damage following 
UV irradiation, heat shock, osmotic shock, TNF-α, IL-1β, ceramide, and reactive oxygen 
species. They also play a role in the cellular apoptosis pathway.14 It has been shown that 
inhibition of JNK could be sufficient for blocking apoptosis.15 It has also been reported 
that the JNK signaling pathway is implicated in cell proliferation and could play an 
important role in autoimmune diseases that are mediated by T-cell activation and 
proliferation.16 Therefore, compounds inhibiting the JNK pathway could be helpful in 
prevention of diseases, which are preferably mediated by the JNK function. Structures 
1.417 were found to be very good metalloprotease inhibitors effective for several 
conditions in humans including: reduction in inflammation in rheumatoid arthritis, 
inhibition of further erosion of articular cartilage in osteoarthritis, rapid healing in corneal 
abrasion, substantial reduction in scars due to chemical burns, diminishing asthma 
symptoms, reduction in premetastatic tumor size, prevention of oral degeneration, 
prevention in loosening of an implant in the maxilla, prevention in the loosening of the 
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dentures, and prevention of colitis flare ups.  
 
Figure 1.3. Literature Examples of Biologically Active Piperidine Sulfonamides. 
 
Compounds 1.5 showed potent CCR1 (chemokine receptor) antagonistic activity (CCR1 
binding IC50 90-500 nM).18 Chemokines are a growing family of proteins that play an 
important role in leukocyte activation and migration.19 Chemokines bind to receptor 
CCR1, which is expressed on a number of cell types including monocytes, macrophages, 
dendritic cells, and T cells. A substantial body of evidence has linked the chemokine 
receptor CCR1 and its major ligands to the pathogenesis of rheumatoid arthritis.20,21 A 
small molecule CCR1 antagonist showed marked decrease in synovial inflammation and 
a trend toward a decrease in clinical disease activity after 2 weeks of treatment without 
severe side effects.22 Therefore, CCR1 antagonists are currently being explored as anti-
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inflammatory compounds, especially for rheumatoid arthritis. Encouraged by the various 
reported biological activities of the piperidine sulfonamides type scaffolds, it was decided 
to prepare a library of sulfonamide derivatives of cyclic enaminones and 4-piperidinones. 
 
 
1.2 Introduction to Piperidones 
The piperidones are a family of organic chemicals characterized by a 6-membered 
heterocycle possessing a nitrogen atom in the ring and a ketone functional group. 
Particularly, the piperidin-4-ones play a vital role in heterocyclic chemistry, driven by 
their importance in biology and medicinal chemistry.23,24 They are found in the skeletons 
of many biologically active natural products.25-31 Systems having a piperidine-4-one core 
have stimulated great interest in past and in recent years due to the fact that this moiety is 
a part of molecules with a variety of biological properties such as antiviral,32 
antitumor,32,33 central nervous system,34-37 local anesthetic,35-38 anticancer,39 
antithrombogenic,40 blood cholesterol lowering,41 and antiarrythmic activities.42  
Importantly since the carbonyl group can be easily converted into various 
functional groups, piperidin-4-ones serve as valuable advanced intermediates to 
piperidines,24,43-47 some of which are found in many drugs and drug candidates (Figure 
1.4).48-50 Piperidone-derived piperidines are biologically important and are part of many 
bioactive compounds such as neurobinin receptor antagonists,51 analgesic and 
antihypertensive agents.52 Because the piperidin-4-ones have seen extensive use as 
intermediates in the synthesis of physiologically active compounds,53-58 many of the 
chemical studies undertaken in the past with 4-piperidones are related to the synthesis of 
drugs.59,60 Heterocyclic compounds bearing a piperidine skeleton are interesting targets of 
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organic synthesis owing to their pharmacological activity and their wide presence in 
nature.61-63 The piperidine scaffold is undoubtedly one of the most common and 
important structures in natural products and pharmaceutically active molecules.64-66 
Piperdine-containing alkaloids occur in both the plant and the animal kingdom.30,67 
Piperidine derivatives are useful as anti-­‐osteoporotic (raloxifene),68 vasodilator 
(minoxidil),69,70 analgesic (fentanyl),71,72 and the anti-­‐Pakinsonian agent (biperiden).73,74 
 
Figure 1.4. Structures of Representative Piperidine-Containing Drugs. 
 
1.3 Syntheses of Piperidones 
Due to their utility, numerous methods have been devised for the synthesis of 4-
piperidones.75 As will be shown below, many methods exist for their preparation 
including asymmetric syntheses, which is a distinct advantage for structure-activity 
studies once initial chemical hits have been discovered in high throughput screening 
campaigns. 
 
1.3.1 Mannich Condensation 
1.3.1.1 Reactions with Ammonia or Ammonium Salts 
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Among the several methods to synthesize piperidones, the Mannich condensation 
remains the most widely used. In 1912, Petrenko-Kritschenko synthesized a 2,3,5,6-
tetrasubstituted piperidone by combining diethyl-α-ketoglutarate with benzaldehyde and 
ammonia (or ammonium salt).76 In a similar manner, Noller and Baliah synthesized 
2,3,5,6-tetrasubstituted piperidones by boiling a mixture of NH4OAc or an amine, an 
aldehyde, and a ketone in glacial acetic acid (Scheme 1.1, eq 1).77 Edwards et al. 
developed a one-step protocol for the synthesis of 2,6-disubstituted piperidin-4-ones by 
reacting an α,β-unsaturated ketone, an aldehyde and NH4OAc at room temperature 
(Scheme 1.1, eq 2).78 This reaction presumably involves both a Michael and a Mannich 
condensation. Rastogi et al. developed a microwave procedure for synthesizing 2,5,6-
trisubstituted piperidones by subjecting a mixture of a 4-substituted benzaldehyde, 2-
butanone, benzaldehyde and NH4OAc to microwave conditions.79 Compared to the 
conventional approach, the reaction time in the microwave protocol was notably reduced 
from several hours to a few minutes while the yield almost doubled. The Xu group 
developed an efficient route for the construction of 2-substituted-6,6-dimethyl-4-
piperidones via a tandem Mannich reaction of aldehydes, acetone, and ammonia in the 
presence of L-proline as a catalyst at room temperature in ionic liquid (RTIL) 
[bmim][PF6] (Scheme 1.1, eq 3).80 The use of L-proline dramatically enhanced the 
chemoselectivity and gave high yields. The advantages of this process were easily 
available and low-cost starting materials, easy operation, recyclability of catalyst and 
mild reaction conditions. The Soundarrajan group developed a “green” approach by 
substituting ammonium acetate with ethyl aspartate, a naturally occurring amino acid for 
synthesizing 2,6-disubstituted piperidones.81  
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Scheme 1.1. Mannich Condensation Using Ammonia 
 
 
1.3.1.2 Reactions without Ammonia or Ammonium Salts 
The Barker group established a double Mannich reaction protocol of bisaminol ethers and 
substituted β–keto esters using trichloromethylsilane as a Lewis acid, as a quick and 
efficient method to obtain 3,5-substituted 4-piperidones (Scheme 1.2, eq. 1).82 Jia and 
Wang developed a novel approach involving a Mannich reaction of imines and ketones, 
induced by persistent radical cation salts to form β–aminoketones (Mannich bases) 
(Scheme 1.2, eq 2).83 Thus, a novel cyclization to form the 4-piperidone skeleton was 
achieved in a tandem process. In this radical cation process, the ketone served as a 
carbocation trapping agent to form 4-piperidone derivatives under tris(4-bromophenyl)-
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aminium hexachloroantimonate (TBPA+⋅) induced condition. The same group later 
developed an I2-induced stereospecific synthesis of 1,2,6-triaryl-4-piperidones through a 
double Mannich reaction and tandem cyclization.84 In this efficient protocol, unactivated 
ketones served as Mannich donors in the reaction with various imines to produce the 
corresponding 4-piperidone derivatives. Again, in a similar way, the same group 
developed an indium (III) chloride tetrahydrate catalyzed stereoselective synthesis of 
1,2,6-triaryl-4-piperidones.85 
Scheme 1.2. Mannich Condensation without Using Ammonia 
 
 
1.3.2 Addition of Nucleophiles to Cyclic Enaminones 
A frequently used method for the synthesis of 2-substituted-4-piperidones is the addition 
of nucleophiles to cyclic enaminones or 2,3-dihydropyridin-4(1H)-ones. The asymmetric 
versions involve chiral ligands and metal catalysts. 2,3-Dihydropyridin-4(1H)-ones are a 
well known class of molecules that have been extensively studied. Their versatility and 
unique chemical properties continue to spark interest in novel and more efficient methods 
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for their enantiospecific synthesis86 and are of interest in natural product and diversity-
oriented synthesis (DOS).87 2,3-dihydropyridin-4(1H)-ones are versatile structures that 
have utility for the synthesis of piperidine-containing natural products, such as 
indolizidine and quinolizidine alkaloids88,89 and piperidine-containing bioactive 
molecules.24,47,90-93  
Comins reported reduction of N-acyl-2,3-dihydro-4-pyridones using zinc/acetic 
acid to prepare N-acyl-4-piperidones (Scheme 1.3, eq 1),94 while the Hayashi group 
reported the asymmetric addition of arylzinc reagents to 2,3-dihydropyridin-4(1H)-ones 
in a rhodium-catalyzed reaction to obtain 2-aryl-4-piperidones in up to 99% ee (Scheme 
1.3, eq 2).95 Several other groups also developed similar protocols using either alkyl- or 
arylzinc reagents.96-98 Feringa and Minnard developed enantioselective syntheses of 2-
aryl-4-piperidones in up to 99% ee by conjugate addition of arylboroxines in a 
rhodium/phosphoramidite catalyzed reaction.99 The Shi group synthesized 2-aryl-4-
piperidones by axially chiral NHC–Pd(II) complexes catalyzed asymmetric 1,4-addition 
of arylboronic acids to 2,3-dihydropyridin-4(1H)-ones.93 In a similar manner, the 
Knochel group prepared 2-aryl-4-piperidones by 1,4-addition of arylboronic acids to 2,3-
dihydropyridin-4(1H)-ones catalyzed by rhodium-sulfoxide-alkene hybrids as chiral 
ligands.100 The Liao group employed (R,R)-1,2-bis(tert-butylsulfinyl)benzene as a chiral 
ligand in rhodium-catalyzed enantioselective conjugate additions of sodium tetra-
arylborates to 2,3-dihydro-4-pyridones to prepare 2-aryl-4-piperidones (Scheme 1.3, eq 
3).101  
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Scheme 1.3. Addition of Nucleophiles to Cyclic Enaminones 
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Nakao, Hiyama, and Hayashi synthesized 2-(4-fluoro-2-methyl)phenyl-4-piperidone by 
utilizing 4-fluoro-2-methyl)phenyl [2’-(hydroxymethyl)phenyl]dimethylsilane as a mild 
and reproducible agent for the rhodium-catalyzed 1,4-addition reaction on a cyclic 
enaminone (Scheme 1.3, eq 4).102 The Feringa group obtained 2-methyl-4-piperidone by 
1,4-addition of trimethylaluminum to 2,3-dihydro-4-pyridone.103 The chiral catalyst 
needed for this transformation was formed from Cu(OTf)2 and a chiral phosphoramidite 
ligand. A highly enantioselective synthesis of chiral 2-alkenyl-4-piperidones in up to 97% 
ee was realized by the Alexakis group via asymmetric addition of alkenyl alanes to 2,3-
dihydro-4-pyridones with the aid of Cu(II) catalyst and a chiral ligand L1 (Scheme 1.3, 
eq 5).104  
 
1.3.3 Other Approaches 
1.3.3.1 Imino-Diels-Alder Reaction 
Ishimaru and co-workers developed a [4+2] cycloaddition of N-benzylaldimines with 2-
silyloxybuta-1,3-dienes in the presence of TMSOTf to synthesize trans-2,6-disubstituted-
4-piperidones. Increases in the diastereoselectivities of the products was attempted with 
greater bulkiness of the α-substituent of the aldimine.105 However, high 
diastereoselectivities could not be achieved with benzaldimine because of the moderate 
bulkiness of the aromatic ring at the α-position of the aldimines. The same group later 
reported a protocol with more effective diastereocontrol (Scheme 1.4, eq 1). In this route, 
the benzaldimine derivatives were attached to a planar chiral tricarbonyl(1,2- or 1,3-
disubstituted arene)chromium complex for enhancing the diastereoselectivities of the 
reaction.31 
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Scheme 1.4. Imino-Diels-Alder Chemistry 
 
 
Aznar and co-workers established a synthesis of meso-2,6-diaryl-4-piperidones (both N-
substituted and N-unsubstituted) by an L-proline catalyzed imino-Diels-Alder reaction 
between acyclic α,β-unsaturated ketones and aldimines at room temperature (Scheme 
1.4, eq 2).106  
 
1.3.3.2 Reductive Cleavage of Cycloadducts 
The Padwa group synthesized substituted 4-piperidones by subjecting 7-oxa-1-
azanorbornane cycloadducts to reductive cleavage (H2, Pd/C) of the N-O bond (Scheme 
1.5).107 These isoxazolidine cycloadducts were in turn synthesized by reacting oximes 
with 2,3-bis(phenylsulfonyl)-1,3-butadiene.108,109 
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Scheme 1.5. Reductive Cleavage of Cycloadducts  
 
 
1.3.3.3 Double Aza-Michael Addition 
Selvaraj et al. first synthesized meso-N-methyl-2,6-diaryl-4-piperidones by reacting 2-
methyl-1,5-diaryl-1,4-pentadien-3-ones with aqueous methylamine solution at room 
temperature.110 Padmavathi and co-workers extended this protocol to synthesize N-
methyl-2-phenyl-3-methyl-6-arylpiperidin-4-ones by using 2-methyl-1-phenyl-5-aryl-1,4-
pentadien-3-ones as the starting ketones (Scheme 1.6, eq 1).111 Dörrenbächer et al. 
developed a one-pot domino Stille coupling/Michael addition protocol starting from 
easily available vinyl stannanes to synthesize 2,5-disubstituted-4-piperidones (Scheme 
1.6, eq 2).112 In this straightforward method, a vinyl stannane was coupled with an α,β-
unsaturated acid chloride using a Stille coupling in the presence of Pd(II) and 
triphenylphosphine to generate the 2,5-disubstituted-1,4-pentadien-3-ones in situ to 
which an alkylamine was added. The amine reacted in a double 1,4-addition generating 
the desired products. Owing to its significant Lewis acid activity, the Pd(II) not only 
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greatly helped the Michael addition, but also enabled the entire process to be conducted 
in one-pot. 
Scheme 1.6. Double Aza-Michael Addition 
 
 
1.3.3.4 Carbanion Cyclization 
Sun and co-workers synthesized N-substituted-4-piperidones employing a Dieckmann 
condensation followed by decarboxylation. Refluxing N,N-bis[2(methoxycarbonyl)ethyl] 
substituted amines with sodium methoxide followed by extraction with HCl, refluxing 
again, and finally treating with NaOH (Scheme 1.7, eq 1) furnished the desired 
piperidones.113 The N,N-bis [2(methoxycarbonyl)ethyl] substituted amines were in turn 
obtained by a Michael addition of substituted amines, methyl acrylate and acetic acid. 
Bing and Guo-Qiang developed a protocol to access chiral 2-aryl/alkyl-4-piperdiones 
(Scheme 1.7, eq 2).114 The key ring-formation reaction relied on the competitive 
intramolecular attack of the carbanion generated by the lithium-iodine exchange at the 
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ester moiety. This method can also generate 2-aryl or 2-alkyl-4-piperidones.   
Scheme 1.7. Carbanion Cyclization 
 
 
The above review showcases that a variety of methods exist for the synthesis of 
piperidones including asymmetric methods that could be used for structure-activity 
studies if the piperidone skeleton was identified in a high throughput screening campaign. 
 
1.4 Synthesis of Piperidinone Sulfonamides Library 
The piperidinone sulfonamide library was prepared as shown in Scheme 1.8. In order to 
synthesize the required cyclic enaminones 1.7-1.11, we decided to take advantage of the 
well-established Comin’s chemistry.115,116  
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Scheme 1.8. Synthesis of Piperidinone Library 
 
 
1.4.1 Synthesis of Cyclic Enaminones 
4-Methoxypyridine (1.6) was treated with Cbz-chloride followed by addition of an 
appropriate Grignard reagent. Next, the reaction mixture was treated with saturated 
aqueous oxalic acid solution. After column chromatography, the cyclic enaminones 1.7 to 
1.11 were furnished smoothly in 65-100% yields.  
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Table 1.1. Synthesis of Cyclic Enaminones 
 
Entry R1  Product Yield (%) 
1 
 
1.7 100 
2 
 
1.8 75 
3 
 
1.9 65 
4 
 
1.10 66 
5 
 
1.11 67 
 
1.4.2 Synthesis of 2-Substituted Piperidinones 
In order to get the piperidinones, it was necessary to reduce the double bond as well as 
remove the Cbz group off of nitrogen. Initially, we followed literature precedent117 and 
used L-selectride to reduce the double bond (Scheme 1.9), and obtained 52% yield of 
benzyl 4-oxo-2-phenylpiperidine-1-carboxylate (1.12). Then, the Cbz group was 
deprotected using hydrogen gas and 10% Pd/C catalyst. This protocol provided a 
quantitative yield of the 2-phenylpiperidin-4-one (1.13).  
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Scheme 1.9. Two-step Synthesis of Piperidinone from Cyclic Enaminone 
 
 
However, we had observed a low yield in the double bond reduction reaction. Based on 
literature precedent118,119, we surmised that this two-step process could be shortened by 
directly subjecting the cyclic enaminones 1.7 to 1.11 to hydrogenolysis. Hydrogenolysis 
of 1.7 not only removed the Cbz group, but also saturated the C5-C6 double bond to 
generate the 2-phenylpiperidin-4-one (1.13) in quantitative yield (crude). We therefore 
subjected all enaminones to hydrogenolysis to get the 2-substituted piperidinones 1.13 to 
1.17 in good yields (45-100%) (Table 1.2). Reduction of compound 1.11 under these 
conditions furnished the Cbz-deprotected compound 2-(thiophen-2-yl)-2,3-
dihydropyridin-4(1H)-one (1.17), because the C5-C6 double bond could not be reduced 
with this strategy.  However, it was decided to carry forward the crude product 1.17 to 
next step. The piperidones 1.13-1.17 were used in the next step without purification. 
Piperidin-4-one (1.18) was commercially available as a monohydrochloride monohydrate 
salt and was used directly without any purification in the next step. 
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Table 1.2. Synthesis of Piperidinones 
 
Entry Product Yield (%) 
1 
     1.13  
100 
2 
 1.14   
70 
3 
 1.15 
100 
4 
1.16 
45 
5 
1.17 
45%  
(62% brsm) 
6 
1.18 
Commercially 
available 
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1.4.3 Synthesis of Piperidinone Sulfonamides 
Piperidinones 1.13 to 1.18 were then converted to sulfonamide with commercially 
available 4-substituted benzenesulfonyl chlorides. Initial attempts of stirring piperidinone 
1.14 with tosyl chloride in pyridine as a solvent and base did not furnish the required 
product 1.22 (Scheme 1.10).120,121 Subjecting a THF solution of piperidinone 1.14 to 
sodium hydride followed by addition of tosyl chloride also did not lead to product 
formation 1.22.122 In another attempt, adding tosyl chloride to a slurry of a piperidinone 
1.14 in a biphasic mixture of 1:1 water/chloroform and potassium carbonate did not yield 
any product 1.22.123  
Scheme 1.10. Failed Attempts at Synthesizing Piperidinone Sulfonamides 
 
 
At last, piperidinone 1.14 was dissolved in acetonitrile, and potassium carbonate and 
tosyl chloride were added sequentially.124 The reaction mixture was stirred for 1 day at 
room temperature to yield the required piperidinone sulfonamide 1.22 in 48% yield. 
Encouraged by this result, all piperidinones 1.13–1.18 were subjected to the above 
sulfonylation conditions to provide the targeted piperidinone sulfonamides 1.19 to 1.36 in 
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27-93% yield (Table 1.3). 
Table 1.3. Synthesis of Piperidinone Sulfonamides 
 
Entry R1  R2 Product Yield
a 
(%) 
1 Ph Me 
1.19 
64 
2 Ph F 
1.20 
38 
3 Ph Cl 
1.21 
34 
4 PMP Me 
1.22 
48 
5 PMP F 
1.23 
27 
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6 PMP Cl 
1.24 
30 
7 Et Me 
1.25 
44 
8 Et F 
1.26 
51 
9 Et Cl 
1.27 
50 
10 4-Cl-C6H4 Me 
1.28 
80 
11 4-Cl-C6H4 F 
1.29 
80 
12 4-Cl-C6H4 Cl 
1.30 
78 
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13 H Me 
1.31 
91 
14 H F 
1.32 
93 
15 H Cl 
1.33 
85 
16 Thiophen-2-yl Me 
1.34 
52 
17 Thiophen-2-yl F 
1.35 
43 
18 Thiophen-2-yl Cl 
1.36 
55 
aAll the yields are unoptimized. PMP = para-methoxyphenyl. 
 
1.5 Results of HTS Assays at NIH 
The piperidinone sulfonamides (25 mg of each compound) were placed into pre-tared, 
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bar-coded vials and submitted to NIH for testing in various biological assays. From the 
18 submitted library members, 2 compounds, 1.19 and 1.31, (Figure 1.5) were identified 
as primary hits in high throughput screening campaigns. 
 
Figure 1.5. Structures of Biologically Active Hits. 
 
Compound 1.19 was identified as an inhibitor of prion protein (PrP) 5’ UTR in the 
primary in vitro screening. The build-up of prion proteins with the disease causing 
conformation (PrPSc) in neuronal cells is associated with cell death and encephalopathy. 
One possible way to alleviate the succession of prion-based diseases is to decrease the 
overall levels of PrP in the nerve cells. This can be achieved by inhibiting the expression 
of PrP at the message translation level. In order to identify compounds that might reduce 
translation of the PrP message, the compounds were assayed against H4 neuroblastoma 
cells transfected with a plasmid reporter construct. The reporter consisted of a stem-loop 
sequence from the human Prion protein variant 2 (PrP) 5’UTR fused to a luciferase gene 
as well as a viral internal ribosome entry site driving Green Fluorescent Protein (GFP). 
This screening looked for compounds which interact with the PrP 5’ UTR and reduce the 
protein expression by observing luciferase activity.125 The other compound 1.31 was 
found to be inhibiting the human platelet-activating factor acetylhydrolase 1b, catalytic 
subunit 2 (PAFAH1B2). Human platelet activating factor acetylhydrolase (pPAFAH) is a 
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Ca2+ independent phospholipase A2 (PLA2) identified in human plasma as the enzyme 
responsible for the hydrolysis/inactivation of platelet activating factor (PAF),126 a potent 
pro-inflammatory phospholipid signaling molecule.127 In this assay, recombinant 
PAFAH1B2 protein was incubated with test compounds for a defined period followed by 
addition of the FP-rhodamine probe and measurement of fluorescence polarization at a 
specific time point. As per the assay design, test compounds that act as PAFAH1B2 
inhibitors will prevent PAFAH1B2-probe interactions, thereby increasing the proportion 
of free (unbound) fluorescent probe in the well, leading to low fluorescence 
polarization.128 Development of selective inhibitors of PAFAH would help in the 
investigation of its involvement in the dysregulated biochemical pathways that support 
tumorigenesis. As a result, identifying such inhibitors would also elucidate the 
physiological role of this enzyme and its contribution to atherosclerosis, cancer and other 
inflammatory pathologies. 
 
1.6 Summary 
In summary, a small library of 18 piperidinone sulfonamides was synthesized in three 
steps in good yields. All compounds were submitted to NIH for high throughput 
screening assays. Piperidinone sulfonamides 1.19 and 1.31 were identified as primary 
hits. Compound 1.19 showed prion protein (PrP) 5’ UTR inhibitory activity, and 
compound 1.31 displayed human platelet-activating factor acetylhydrolase 1b, catalytic 
subunit 2 (PAFAH1B2) inhibitory activity.  
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Chapter 2 
Transition-Metal-Free C–H Trifluoromethylation of Cyclic Enaminones 
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2.1 Introduction 
Although inorganic fluorides are plentiful on earth, nature does not produce more 
than a dozen of compounds containing a fluorine atom,129 while on the other hand, almost 
30–40% of all commercial agrochemicals and 20–30% of all pharmaceuticals have at 
least one fluorine atom in their structures.130 Among all the fluorinated compounds, 
molecules possessing a trifluoromethyl (CF3) group comprise an important class of 
compounds. These compounds have generated a lot of interest due to their unique 
properties such as increased electronegativity, hydrophobicity, and metabolic 
stability.130,131 Structural modification via trifluoromethylation is a common practice in 
both the pharmaceutical and agrochemical industries.130,132 Classic methods to synthesize 
trifluoromethylated compounds largely employ Lewis acid-promoted exchange of 
chloride by fluoride via the Swarts-type reaction (Scheme 2.1).133 These harsh conditions 
limit their synthetic application. Newer synthetic methods are urgently needed due to the 
increasing significance of fluorinated compounds.   
Scheme 2.1. Traditional Trifluoromethylation Protocol 
 
 
In the past decade, Pd– and Cu–catalyzed trifluoromethylation cross-coupling reactions 
have been developed that show high regioselectivity, good functional group tolerance, 
and reaction efficiency.134-140 However, most of these coupling methods required 
substrate prefunctionalization resulting in low atom-economy, thereby, limiting their 
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usefulness for industrial applications. A more sustainable approach is through direct C–H 
activation. However, innate C–H trifluoromethylation is very challenging largely because 
until very recently, mild and robust methods had not been available.141-143 	  
2.2 Recent Advances in Trifluoromethylation Chemistry 
2.2.1 Direct Trifluoromethylation of sp C–H Bonds 
 There is a very limited number of examples of direct C–H trifluoromethylation on 
sp carbon centers due to the dimerization of alkynes. In 2010, Qing and co-workers 
reported the first example of a Cu-mediated oxidative trifluoromethylation of terminal 
alkynes with TMSCF3 (Scheme 2.2).144 The reaction required stoichiometric amounts of 
CuI in order to proceed efficiently. The same group later published a modified version of 
the above reaction employing catalytic amounts of Cu(I), which was achieved by slow 
addition of reagents through a syringe pump.145 Following this, the Qing group reported 
an improved protocol for trifluoromethylation of terminal alkynes using in situ generated 
(phen)Cu(CF3) at room temperature with a small amount of TMSCF3.146  
Scheme 2.2. First Example of sp C–H Trifluoromethylation 
 
 
2.2.2 Direct Trifluoromethylation of sp2 C–H Bonds 
Trifluoromethylated (hetero)arenes are present in agrochemicals, pharmaceuticals, and 
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advanced materials. Direct trifluoromethylations of sp2 C–H bonds are currently therefore 
a popular topic, because they are the most effective methods to synthesize (hetero)arenes 
containing CF3 in their structures.134,137,139,142,143 These established protocols can be 
categorized into three classes based on the three CF3 sources used: CF3+, CF3–, and 
CF3•.147  
 
2.2.2.1 Trifluoromethylation with CF3+ Reagents 
An electrophilic ortho-trifluoromethylation reaction of arenes tethered with directing 
groups using Umemoto’s reagent (Scheme 2.3, eq. 1) was first reported by Yu et al.148 A 
variety of N-heterocyclic directing groups such as pyridine, pyrimidine, imidazole, and 
thiazole, could be used. This revolutionary chemistry was catalyzed via a proposed 
Pd(II)/Pd(IV) catalytic cycle necessitating a stoichiometric amount of Cu(OAc)2 as the 
oxidant. Subsequently, the same group also developed a similar electrophilic 
trifluoromethylation reaction using an amide as the directing group.149 In particular, N-
methylformamide as an additive was crucial for the coupling process. In a similar 
manner, Shi and co-workers successfully developed regioselective ortho-
trifluoromethylations of arenes using the acetamino group as an alternative directing 
group (Scheme 2.3, eq. 2).150 Later, the Sanford group reported that the oxidation of the 
cyclometalated Pd(II) dimer with CF3+ reagents produces a monomeric CF3–Pd(IV) 
intermediate, which undergoes selective reductive elimination to form a C–CF3 bond.151 
Very recently, the Besset group developed Cu(I)-mediated β-trifluoromethylation of α,β-
substituted N,N-diethylacrylamides with TFA and N-methylformamide as additives 
(Scheme 2.3, eq. 3).152  
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Scheme 2.3. Directed Electrophilic ortho-Trifluoromethylation Using Umemoto’s 
Reagent 
 
 
Togni’s reagent is another remarkable CF3+ source (Scheme 2.4). Togni and co-workers 
had initially reported that no catalysts were needed for electrophilic aromatic 
trifluoromethylation on a broad range of arenes and N-heteroarenes, although Togni’s 
reagent had shown increased electrophilicity in the presence of a Lewis acid.153 Next, 
Sodeoka and co-workers developed a Cu(OAc)2-catalyzed regioselective 
trifluoromethylation of indole derivatives using Togni’s reagent under very mild 
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conditions (Scheme 2.4, eq 1).154 Recently, the same group reported a 
difunctionalization-type trifluoromethylation reaction of activated alkenes bearing allylic 
protons using Togni’s reagent.155 This Cu(I)-catalyzed protocol provides 
trifluoromethylated carbocycles and heterocycles in good to excellent yields. Loh and co-
workers reported the first example of C–H trifluoromethylation of alkenes (Scheme 2.4, 
eq 2).156 In this Cu(I)-catalyzed methodology, a series of enamides were β-
trifluoromethylated with Togni’s reagent in good to excellent yields. 
Scheme 2.4. Electrophilic Trifluoromethylation Using Togni’s Reagent 
 
 
2.2.2.2 Trifluoromethylation With CF3– Reagents 
TMSCF3 (Ruppert-Prakash reagent) is the most commonly used CF3– reagent. Liu and 
co-workers developed a Pd-catalyzed oxidative trifluoromethylation of indoles using 
TMSCF3 (Scheme 2.5, eq 1)157 in which PhI(OAc)2 (PIDA) was employed as an oxidant 
and the proposed mechanism of the reaction was thought to involve a Pd(II)/Pd(IV) 
species. The same group next developed a tandem oxidative aryl trifluoromethylation of 
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activated alkenes using analogous conditions;158 a bifunctionalization reaction that 
offered a variety of CF3-containing oxindoles in good yields. More recently, Qing and co-
workers reported a Cu-catalyzed C–H trifluoromethylation reaction of heteroarenes and 
electron-deficient arenes with TMSCF3 (Scheme 2.5, eq 2).159 The key to this 
regioselective transformation was the acidity of the targeted C–H proton. Under 
optimized conditions a wide range of aromatic compounds including benzoxazoles, 
oxadiazoles, benzothiazoles, benzoimidazoles, indoles, and perfluoroarenes were 
compatible.  
Scheme 2.5. Nucleophilic Trifluoromethylation Using the Ruppert-Prakash Reagent 
 
 
2.2.2.3 Trifluoromethylation Involving CF3• Reagents 
Trifluoromethylation of various (hetero)aromatic compounds using CF3I in the presence 
of a Fe(II) catalyst, H2O2, and DMSO was demonstrated by the Yamakawa group.160 
Mainly the general trend of aromatic electrophilic substitution directed the 
regioselectivity. Later, the Sanford group reported a silver-mediated direct 
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trifluoromethylation of arenes with TMSCF3 (Scheme 2.6, eq 1).161 The key intermediate 
to produce the CF3• radical was proposed to be a Ag–CF3 species. Even though a wide 
scope of substrates was generally tolerated, this methodology had a few drawbacks 
including the need for using stoichiometric amounts of silver salts and problematic 
regioselectivity. An extension of this Ag-mediated protocol to aryl triazene substrates 
with good ortho-selectivity was achieved by Bräse and co-workers (Scheme 2.6, eq 2).162  
Scheme 2.6. Ag(I)-Mediated C–H Trifluoromethylation 
	  	  
Recently there have been a few breakthroughs in radical direct C–H trifluoromethylation 
using inexpensive reagents that proceed under mild conditions.135,163 The MacMillan 
group invented a novel photoredox protocol involving Ru(II)-catalyzed direct C–H 
trifluoromethylation on a wide variety of arenes and heteroarenes (Scheme 2.7).164 In this 
methodology, CF3SO2Cl (i.e. TfCl) was employed as a CF3• source. The low cost of TfCl 
and the mild conditions used in this protocol made it a very promising procedure. Since 
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then, a series of successive developments based on this photoredox protocol have been 
accomplished. For example, the Cho group achieved direct trifluoromethylation of a wide 
range of heteroarenes with good to excellent yields using CF3I as a CF3• source.165  
Scheme 2.7. MacMillan’s Photoredox Trifluoromethylation Protocol 
	  	  
At the same time, Baran’s group developed a metal-free trifluoromethylation reaction 
with peroxides as radical initiators using CF3SO2Na (Langlois’ reagent); a benchtop-
stable and inexpensive solid (Scheme 2.8).166  
Scheme 2.8. Baran’s Radical-based Trifluoromethylation Protocol 
 
 
The versatility of this reaction lies in the fact that both electron-rich and electron-
deficient heteroarenes can be efficiently used with high functional group tolerance. 
Although, the regioselectivity was modest, the choice of solvent sometimes could help 
modify the innate substrate reactivity. Very recently, Fu and co-workers developed a 
domino synthesis of 3-(trifluoromethyl)-indolin-2-one derivatives in good to excellent 
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yields using Langlois’ reagent with N-alkyl-N-phenylacrylamides as starting materials.167 
These two methods, developed by MacMillan and Baran, are very beneficial for 
medicinal chemistry, because of their robust conditions and broad functional group 
tolerance allowing one to achieve late stage trifluoromethylation to prepare diversified 
drug analogs.163  
 
2.2.3 Direct Trifluoromethylation of sp3 C–H Bonds 
Direct trifluoromethylation of sp3 C–H bonds is as challenging as those for sp C–H 
bonds. Currently available approaches are applicable to only a few substrate examples, 
for example, allylic C–H bonds and α–carbonyl C–H bonds.168-177 Liu and co-workers 
first reported a rare Cu(I)-catalyzed C–H trifluoromethylation of terminal alkenes via 
allylic C–H activation/functionalization using Umemoto’s reagent (Scheme 2.9, eq 1).171 
Both the experimental and theoretical analyses indicated that the reaction may proceed 
via a Heck-like four-membered-ring transition state. This method worked with an array 
of terminal alkenes without 2-substitutents, however 2-substituted terminal alkenes or 
internal and cyclic alkenes were not compatible. Followed by this, Buchwald172 and 
Wang173 also independently reported Cu(I)-catalyzed allylic C–H trifluoromethylation 
reactions using Togni’s reagent (Scheme 2.9, eq 2 and eq 3). Both of these methods 
tolerated a wide range of functional groups and gave good yields. Interestingly, branched 
terminal alkenes and cyclic alkenes were not compatible in Buchwald’s method, but 
worked well in Wang’s method at higher temperature.  
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Scheme 2.9. Allylic C–H Trifluoromethylation 
	  	  
Later, Qing and co-workers developed a Cu-catalyzed oxidative trifluoromethylation of 
terminal alkenes using TMSCF3 (Ruppert-Prakash reagent) (Scheme 2.9, eq 4).174 This 
method provided a complementary pathway for direct allylic trifluoromethylations 
without using Umemoto’s reagent or Togni’s reagent. The MacMillan group pioneered 
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the direct trifluoromethylation of α-carbonyl C–H bonds using their above mentioned 
photoredox chemistry. Previously they had reported a highly enantioselective α-
trifluoromethylation of a series of aldehydes using CF3I as a CF3• source (Scheme 
2.10).175 Shortly after this, they expanded the scope of substrates from aldehydes to 
ketones, esters, and amides by first converting the carbonyl compounds to enolsilanes. 
This strategy further enhanced the utility of this novel protocol and also gave very good 
yields.177 Concurrently, the same group had reported a non-photolytic enantioselective α-
trifluoromethylation of aldehydes using Togni’s reagents instead of CF3I.176  
Scheme 2.10. Enantioselective α–Trifluoromethylation of Aldehydes 
	  	  
Although the trifluoromethylation chemistry is currently a popular topic and there have 
been rapid advances in this field, the existing methods and substrates are still nevertheless 
not sufficient. Of particular interest, the direct trifluoromethylation of alkenyl C–H bonds 
is especially uncommon; only three such methods have been reported to date. First, the 
Loh group developed trifluoromethylation of enamides using Togni’s reagent (Scheme 
2.4, eq 2).156 Second, very recently the Besset group developed a Cu(I)-mediated β-
trifluoromethylation of α,β-substituted N,N-diethylacrylamides with TFA and N-
methylformamide as additives (Scheme 2.3, eq. 3).152 Third, at almost the same time, Yu 
and co-workers achieved Cu(II)-catalyzed trifluoromethylation of α-oxo-ketene 
dithioacetals (internal olefins) using TMSCF3 as a trifluoromethylating agent.178 Other 
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than these findings, the trifluoromethylation of internal or cyclic alkenes has remained 
elusive.  
 
2.3 Rationale for Development of Direct Trifluoromethylation of Cyclic Enaminones  
Amongst the trifluoromethylated compounds particularly the trifluoromethylated 
piperidine derivatives have been widely applied as common moieties in medicinal 
structure-activity relationship (SAR) studies.179-185 
	  
Figure 2.1. Recent Examples of Potent Bioactive 3-Trifluoromethylpiperidine 
Derivatives. 
 
The trifluoromethylated piperidines are found in compounds with a variety of biological 
activities, such as orexin receptor OX1 antagonists (for sleep disorders),180 Pim1 kinase 
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inhibitors (for cancers),181 and mPGES-1 inhibitors (for inflammatory diseases)182 (Figure  
2.1). Conventional syntheses usually entail the expensive commercially available 3-
trifluoromethylpiperidine as a precursor,179,182,185 while substituted piperidines often stem 
from prefunctionalized 3-trifluoromethylated pyridines and lack the versatility for late-
stage functionalization.180,181 The high cost, long reaction sequences, and inflexibility 
limit the practicality for industrial applications. A more sustainable and flexible 
trifluoromethylation approach is much desired.141,142,186 
Scheme 2.11. Distinct Cyclic Enaminone Chemistry– Functionalizations of Olefinic C–H 
Bonds and Their Applications 
 
 
Cyclic enaminones, namely 2,3-dihydropyrid-4(1H)-ones, are regarded as excellent 
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piperidine surrogates (Scheme 2.11). These non-aromatic substrates have been 
extensively employed as synthetic intermediates in a plethora of alkaloid syntheses,187-189 
including recent reports from the Georg group of (+)-antofine and (R)-tylocrebrine and 
related analogues with potent antiproliferative properties.190 Key to the versatile 
application is the distinctive reactivity profile of cyclic enaminones.191 In order to further 
increase their synthetic utility, the Georg group has developed a number of efficient, 
regioselective C–H functionalization reactions based on enaminone olefin moiety.6-
10,192,193 These atom-economical transformations have already improved the syntheses of 
phenanthropiperidine alkaloids194,195 (Scheme 2.11a) and 1,3,5-trisubstituted chalcones193 
(Scheme 2.11b). Inspired by this earlier success, we proposed that combining C–H 
trifluoromethylation with the divergent enaminone chemistry could be more 
advantageous (Scheme 2.11c).  
With the above mentioned intrinsic reactivities and inherent nucleophilicity at the 
α-position, non-aromatic cyclic enaminones offer a promising platform to assess the 
feasibility of innate trifluoromethylation of alkenyl C–H bonds, which would potentially 
furnish a direct route to access 3-trifluoromethylpiperidine derivatives. Not only do cyclic 
enaminones offer an excellent platform as cyclic alkenes for C–H trifluoromethylation, 
but achieving this transformation would in addition furnish a straightforward pathway to 
synthesize 3-trifluoromethylpiperidine derivatives, which are important structural motifs 
in structure-activity relationship (SAR) studies.179,180 Despite the rapid advance in the 
field of C–H trifluoromethylation,141,142,186 direct construction of the intended olefinic C–
CF3 bond from an olefinic C–H bond is surprisingly sparse compared to numerous 
(hetero)arene counterparts.148,153,154,157,159,161,162,164,166 The lack of methods is partly 
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because the migration of the double bond could form an allylic substrate when α-
hydrogens are present,171-174 or the high reactivity of olefins could easily lead to 
difunctionalizations.158,196,197 To date, the reported examples of C–H trifluoromethylation 
of olefins have largely relied on terminal olefins and required transition-metal 
catalysis.198-200 On the other hand, C–H trifluoromethylation of less reactive 
internal/cyclic olefins remains less accessible.201-203 Hence, more olefin substrates and 
green, mild methods are still needed. Cyclic enaminones offer an excellent platform as 
internal/cyclic olefins with well-tuned reactivities.  
 
2.4 Reaction Optimization 
2.4.1 Screening of Existing Protocols 
We first subjected cyclic enaminone 2.1 to the existing methods in order to determine the 
most effective protocol. Dr. Yiyun Yu from our lab carried out the initial screening of 
existing trifluoromethylation methods (Scheme 2.12) and observed that electrophilic 
trifluoromethylation using Umemoto’s reagent with and without the use of transition 
metals failed to give any desired product 2.2.  
Scheme 2.12. Screening of Various Conditions 
 
 
Using Togni’s reagent with and without transition metals only gave yields from 11–25%. 
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Dr. Yiyun Yu also screened for radical-based protocols. MacMillan’s photoredox 
chemistry showed discrete results. Electron-rich enaminones only produced 12% of the 
desired product, whereas in sharp contrast electron-deficient enaminone afforded a much 
better 62% yield. Baran’s radical protocol also gave varied results. The reported solvent 
mixture (DCM/H2O) only generated a trace amount of product 2.2 over an extended 
period of time (48 h). Replacing DCM with a more polar solvent DMSO increased the 
yield to 40%.	   A few TMSCF3-based protocols were also tested. Unfortunately, Cu-
catalyzed trifluoromethylation failed to furnish any desired product. Attempts to adopt 
Sanford’s protocol involving stoichiometric amounts of AgOTf also did not yield any 
desired product. Lastly, a Pd-catalyzed, PIDA-mediated protocol developed by Liu and 
coworkers was tried. This protocol gave 32% of the product 2.2. Adding TEMPO (0.5 
equiv) to the reaction increased the yield to 41%. In all, two existing protocols afforded 
satisfactory yields after the preliminary investigation: 1) Baran’s tBuOOH-mediated 
radical trifluoromethylation and 2) Liu’s PIDA-mediated nucleophilic 
trifluoromethylation. Although both methods use operationally easy procedures and 
readily available reagents, Liu’s protocol offers more variables for optimization. 
Therefore, he proceeded with Liu’s conditions157 for subsequent optimization. Compound 
2.1 was used as the starting material with TMSCF3, PhI(OAc)2, CsF, and Pd(OAc)2 as the 
catalyst in EtOAc at room temperature. It became evident that only PIDA was effective 
as the oxidant and the desired C–H trifluoromethylation proceeded almost as well in the 
absence of a Pd(II) catalyst. It is worth noting that metal-free PhI(OAc)2-mediated C–H 
trifluoromethylation of arenes has been reported very recently by Qing and co-workers204 
and the effective trifluoromethylating agent was proposed to be an acyclic hypervalent 
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[PhICF3]+ species.201 Its strong electrophilicity seemingly coincides with the C5-
nucleophilicity of cyclic enaminones. This finding encouraged us to pursue a “greener” 
transition-metal-free protocol for C–H trifluoromethylation of cyclic enaminones. 
 
2.4.2 Further Optimization 
2.4.2.1 Solvent Screening 
Using the modified conditions of Liu et al.157 as a starting point, we optimized various 
parameters of the reaction. Table 2.1 shows the survey results with nine solvents. More 
polar solvents, such as DMSO, NMP, DMF, dioxane (entries 3–6) only furnished a trace 
amount of 2.2. THF and acetone were detrimental to the reaction (entries 7, 9). Less-polar 
solvents such DCM failed to deliver a better yield (entry 8). MeCN (entry 2) turned out to 
be more effective than EtOAc (entry 1) making it the best solvent. 
Table 2.1. Screening of Solventsa 
 
Entry Solvent % Yieldb 
1 EtOAc 46 
2 MeCN 50 
3 DMSO trace 
4 NMP trace 
5 DMF trace 
6 Dioxane trace 
7 THF 1 
8 DCM 41 
9 Acetone 13 
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a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), 
CsF (4.0 equiv), in solvent (1 mL) at rt for 24 h. b 1H NMR yields with Ph3SiMe (1.0 
equiv) as the internal standard. 
 
2.4.2.2 Base Screening 
After optimizing the solvent, we next focused on the efficacy of F– sources (bases) in 
generating the CF3– species. Table 2.2 shows the survey results of seven bases. When 
CsF (entry 1) was replaced with KF or AgF, the reaction afforded nearly the same yield 
(entries 3, 4). NaF and ZnF2 gave lower yields (entries 2, 5). NiF2 and CuF2 failed to 
provide any desired product (entries 6, 7). Ultimately, KF was chosen over AgF because 
of its lower cost and because it does not generate heavy metal waste. 
Table 2.2. Screening of Basesa 
 
Entry Base % Yieldb 
1 CsF 50 
2 NaF 29 
3 KF 59 
4 AgF 58 
5 ZnF2 23 
6 NiF2 0 
7 CuF2 0 
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a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), 
base (4.0 equiv), in MeCN (1 mL) at rt for 24 h. b 1H NMR yields with Ph3SiMe (1.0 
equiv) as the internal standard. 
 
2.4.2.3 Oxidant Screening 
After optimizing the base, we next focused on the oxidants. Table 2.3 shows the survey 
results with three oxidants. We evaluated other hypervalent iodine reagents such as 
PhI(TFA)2 (PIFA) and PhI(OPiv)2 (entries 2, 3) along with PIDA (entry 1). Interestingly, 
the PIFA-mediated conditions could not install the CF3 group possibly due to its strong 
oxidizing property, while PhI(OPiv)2 furnished a modest yield (16%, entry 3), but was 
nearly four times less effective than PIDA (59%, entry 1). Therefore, PIDA was chosen 
as the best oxidant. 
Table 2.3. Screening of Oxidantsa 
 
Entry Oxidant % Yieldb 
1 PhI(OAc)2 59 
2 PhI(TFA)2 trace 
3 PhI(OPiv)2 16 
a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), oxidant (2.0 equiv), KF 
(4.0 equiv), in MeCN (1 mL) at rt for 24 h. b 1H NMR yields with Ph3SiMe (1.0 equiv) as 
the internal standard. 
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2.4.2.4 Temperature Screening 
In order to further improve the yield, we screened various reaction temperatures from 0 
°C up to 80 ºC. Table 2.4 shows the survey results for five temperatures. Carrying out the 
reaction at 0 °C gave a good yield of 40% (entry 1). Temperatures higher than the 
ambient temperature only resulted in lower yields and more side reactions (entries 3–5). 
Based on the screening, room temperature was chosen as the optimum temperature for 
the course of the reaction. 
Table 2.4. Screening of Temperaturesa 
 
Entry Temperature (°C) % Yieldb 
1 0 40 
2 rt 59 
3 40 38 
4 60 37 
5 80 32 
a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), KF 
(4.0 equiv), in MeCN (1 mL) for 24 h. b 1H NMR yields with Ph3SiMe (1.0 equiv) as the 
internal standard. 
 
2.4.2.5 Stoichiometry Screening 
We also screened the effects of stoichiometry on the outcome of the reaction. Table 2.5 
shows the survey results of six stoichiometries. Using only 1 equivalent of PIDA while 
using 4 equivalents each of the KF and TMSCF3 was unfavorable for the reaction 
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resulting in only 10% yield (entry 1). Increasing the PIDA equivalents to 3 gave a similar 
yield (entry 3, 58%) to that using 2 equivalents (entry 2, 59%). Using 4 equivalents of 
PIDA actually slightly decreased the yield to 52% (entry 4). Decreasing or increasing the 
equivalents of both KF and TMSCF3 while simultaneously keeping the PIDA at 2 
equivalents did not increase the yield (entries 5, 6). We concluded, thereby, that using 2 
equivalents of PIDA and 4 equivalents of both KF and TMSCF3 was the best 
stoichiometric combination for the reaction. 
Table 2.5. Screening of Stoichiometrya 
 
Entry PhI(OAc)2 (equiv) TMSCF3 (equiv) KF (equiv) % Yieldb 
1 1 4 4 10 
2 2 4 4 59 
3 3 4 4 58 
4 4 4 4 52 
5 2 2 2 46 
6 2 6 6 51 
a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3, PhI(OAc)2, KF, in MeCN (1 mL) at rt 
for 24 h. b 1H NMR yields with Ph3SiMe (1.0 equiv) as the internal standard. 
 
2.4.2.6 Concentration Screening 
We screened various concentrations in efforts to further improve the yield of the reaction. 
Table 2.6 shows the survey results for five concentrations. Diluting the reaction 
concentration to 0.01 M had negative effects on the reaction (entry 1). Keeping the 
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concentration at 0.05 M increased the yield to 36% (entry 2), but was lower than the 
starting condition of 0.1 M (entry 3, 59%). Further concentrating the reaction mixture 
resulted in decreasing the product yield (entries 4, 5). Therefore, 0.1 M was chosen as an 
optimum concentration for the reaction.  
Table 2.6. Screening of Concentrationsa 
 
Entry Concentration (M) % Yieldb 
1 0.01 4 
2 0.05 36 
3 0.1 59 
4 0.25 40 
5 0.5 34 
a Conditions: enaminone 2.1, TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), KF (4.0 
equiv), in MeCN at rt for 24 h. b 1H NMR yields with Ph3SiMe (1.0 equiv) as the internal 
standard. 
 
2.4.2.7 Reaction Time Screening 
Table 2.7 shows the survey results of various times that were screened. Stirring the 
reaction for 2 h resulted in a 38% yield (entry 1). Successively increasing the time to 4, 8, 
12 and 48 h did not change the yields much (entries 2–4, 6). It was ultimately found that 
24 h is the optimum time for the reaction. 
 
 
	   53	  
Table 2.7. Screening of Reaction Timea 
 
Entry Time (h) % Yieldb 
1 2 38 
2 4 42 
3 8 36 
4 12 42 
5 24 59 
6 48 43 
 
a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), KF 
(4.0 equiv), in MeCN at rt for 24 h. b 1H NMR yields with Ph3SiMe (1.0 equiv) as the 
internal standard. 
 
2.4.2.8 Additives Screening 
Next, a series of additives was introduced to the reaction conditions (Table 2.8). 
Yb(OTf)3 completely inhibited the trifluoromethylation (entry 2). Weak carboxylic acids, 
like benzoic acid and pivalic acid, did not increase the yields (entries 3–4). We also tested 
a few radical scavengers, such as 2,6-di-t-butyl-4-methylphenol and TEMPO (entries 5–
6), yet interestingly, both of them failed to improve the yield. Therefore, having no 
additive was found to be the best condition for the reaction (entry 1). 
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Table 2.8. Screening of Additivesa 
 
Entry Additive (equiv) % Yieldb 
1 – 59 
2 Yb(OTf)3 (0.5) 0 
3 Benzoic Acid (0.5) 38 
4 Pivalic Acid (0.5) 37 
5 2,6-Di-tBu-4-methylphenol (0.5) 7 
6 TEMPO (0.5) 16 
a Conditions: enaminone 2.1 (0.1 mmol), TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), 
additive (0.5 equiv), KF (4.0 equiv), in MeCN at rt for 24 h. b 1H NMR yields with 
Ph3SiMe (1.0 equiv) as the internal standard. 
 
After optimizing 8 parameters, we confirmed that reacting enaminone 2.1 (0.1 M) with 
TMSCF3 (4.0 equiv), PhI(OAc)2 (2.0 equiv), and KF (4.0 equiv) in MeCN (1 mL) over 
24 h at rt were the best reaction conditions to regiospecifically introduce the CF3 group to 
the cyclic enaminone scaffold 2.2. 
 
2.5 Investigation of Scope of Cyclic Enaminones 
With the optimized conditions determined, we next examined the reaction scope of cyclic 
enaminones (Table 2.9). In general, the reaction tolerated a number of diversified cyclic 
enaminones with moderate to excellent yields. It is noteworthy that in previous studies, 
the N- and C6-substituents were critical to the C5-nucleophilicity/reactivity, which could 
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only be preserved when N-electron-donating-groups (EDGs) and sterically less-
demanding C6-substituents were present.6-10 In the present case, substitution abiding by 
these rules was tolerated as anticipated.  
Table 2.9. Scope of Cyclic Enaminones for Direct C-H Trifluoromethylation 
a Isolated yield,   b Yield based on recovered starting material. 
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For instance, cyclic enaminones with an aryl (e.g. PMP) or alkyl (e.g. i-Pr) group on the 
C2-position afforded the desired products in good yields (2.2, 2.3). Bicyclic enaminones 
also furnished good yields (2.4, 2.5). Those with N-EDGs offered yields up to 81% (2.6–
2.8). On the other hand, we were surprised to observe an increased yield when employing 
an enaminone bearing a bulky C6-phenyl group (75%, 2.9 vs. 67%, 2.6), which had 
completely inhibited C–H arylation in the past.8 In addition, previously nonreactive6-10 
enaminones due to N-electron-withdrawing-groups (EWGs, e.g. Boc and Cbz) were also 
enabled toward C–H functionalization for the first time. The corresponding products 2.10 
and 2.11 were generated in similar yields as those carrying N-EDGs. The unsubstituted 
N-H enaminone provided only a low yield of 2.12 (23%), indicating that N-substituents 
play a key role in the reaction. We also tested a few structurally analogous scaffolds. N-
Benzyl-4-pyridone, a synthetic precursor for cyclic enaminones,10 notably only furnished 
the mono-trifluoromethylated product 2.13. Similarly, N-methyl-4-quinolone, an 
important substrate for antimicrobial and anticancer agents,205-207 was converted smoothly 
to 2.14 in moderate yield. Moreover, because uracil’s C5-position is of interest for the 
labeling and the preparation of bioactive uracil derivatives,208-210 we were pleased to see 
the amenability of 1,3-dimethyluracil (2.15) to our protocol. Lastly, E-enaminones were 
considered. The yields of the corresponding products 2.16–2.18, albeit low, demonstrate 
the potential of these substrates to be utilized for direct C–H functionalization. 
 
2.6 Investigation of Reaction Mechanism 
In light of the unexpected compatibility for both electron-rich and electron-deficient 
enaminones in this reaction, it is likely that the trifluoromethylation takes place via a 
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mechanism that is different from previously observed electrophilic substitution.6-10 We 
reasoned that if the electrophilic trifluoromethylation were in play, electron-deficient 
cyclic enaminones would suffer from reduced nucleophilicity and afford lower yields 
than their electron-rich counterparts. However, in fact, an opposite relationship was 
observed. For example, less nucleophilic N-phenylenaminone delivered a higher yield 
(2.7, 81%) than N-benzylenaminone (2.6, 67%).  
Scheme 2.13. Radical Trapping Experiments 
	  
 
Under acidic conditions, TEMPO will undergo disproportionation to form an 
oxoammonium ion, which then can react with TMSCF3 to generate TEMPO–CF3 via an 
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ionic pathway.211 Indeed, AcOH is formed as a by-product of the trifluoromethylation 
reaction. Therefore, in order to test this possibility, we subjected TEMPO to the reaction 
conditions without the presence of cyclic enaminones (Scheme 2.13, eq 1). TEMPO (15.6 
mg, 0.1 mmol), PhI(OAc)2 (64.4 mg, 0.2 mmol) and KF (23.5 mg, 0.4 mmol) were added 
into a 2-dram PTFE sealed glass vial, followed by TMSCF3 (59.7 µL, 0.4 mmol) and 
anhydrous MeCN (1.0 mL) through syringes. The reaction mixture was stirred at room 
temperature for 1 hour. An internal standard α,α,α-trifluorotoluene (0.1 mmol) was then 
added. If the ionic pathway was indeed in action, there shouldn’t be any formation of 
TEMPO–CF3. However, we still detected the formation of the byproduct TEMPO–CF3. 
This clearly implies the intermediacy of the CF3 radical (Scheme 2.13, eq 1).  
 
Figure 2.2. 19F NMR of the Crude Mixture. (Scheme 2.13, eq 1). 
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19F NMR of the crude product (Figure 2.2) showed that TEMPO–CF3 was formed (peak 
at –56.6 ppm) in 87% yield (based on α,α,α-trifluorotoluene as an internal standard, peak 
at –63.72 ppm). It is worth noting that PhI(OAc)2 does not oxidize TEMPO to form an 
oxoammonium cation, nor does TEMPO undergo disproportionation under non-acidic 
conditions as in Scheme 2.13, eq 1.211 Hence, the formation of TEMPO–CF3 by the 
reaction of the oxoammonium cation with TMSCF3 via an ionic pathway might be 
excluded. In order to gain more insight into the mechanism, we introduced radical 
scavengers (i.e. TEMPO and BHT) into the reaction (Scheme 2.13) and found that the 
yields decreased to 7% in the presence of these additives (Scheme 2.13, eq 2–4). This 
inhibition effect suggests that the reaction involved radical species. In order to further 
corroborate the involvement of the trifluoromethyl radical under our reaction conditions, 
we tested diethyl diallylmalonate as a radical clock (Scheme 2.14). Two cyclopentane 
derivatives 2.19212 and 2.20 were isolated as the major products. They should stem from a 
radical 5-exo-trig cyclization after addition of a CF3 radical to the double bond. These 
observations are consistent with a mechanism involving a CF3 radical.  
Scheme 2.14. Radical Clock Experiment 
 
 
Given the experimental facts and recent reports on PIDA-mediated 
trifluoromethylations,204,213,214 a radical mechanism is postulated (Scheme 2.15). First, a 
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ligand exchange between PIDA and TMSCF3 in the presence of KF forms hypervalent 
iodine(III) 2.21,201,213 which was detected by mass spectrometry. For the mass detection 
of the intermediate PhI(OAc)CF3.(2.21) we carried out an experiment in which, 
PhI(OAc)2 (64.4 mg, 0.2 mmol) and KF (23.5 mg, 0.4 mmol) were added into a 2-dram 
TFE sealed glass vial, followed by TMSCF3 (59.7 µL, 0.4 mmol) and anhydrous MeCN 
(1.0 mL) through syringes. The reaction mixture was then stirred at room temperature. 
Samples were taken after 15 minutes of stirring and diluted with MeCN prior to injection 
into the mass spectrometer. The results are shown in Figure 2.3. We found that the 
majority of PhI(OAc)2 (at m/z = 361.0) had been consumed. The proposed intermediate 
PhI(OAc)CF3 (2.21) (at m/z = 333.0) was also detected, but quickly underwent 
dissociation to form [PhICF3]+ (at m/z = 273.0). This finding is consistent with previous 
MS studies by other groups.201,213 Therefore, the possibility of the formation of the 
PhI(OAc)CF3 (2.21) was confirmed experimentally. 
 
Scheme 2.15. Proposed Radical Mechanism for C–H Trifluoromethylation of Cyclic 
Enaminones 
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  Figure 2.3. Mass Spectrum for the Detection of the Intermediate 2.21. 
 
The second step of the postulated mechanism involves homolysis of the PhI(OAc)CF3 
(2.21) generating two radicals (2.22 and •CF3).213,214 The CF3 radical attacks enaminone I 
to afford the intermediate II, which is subsequently converted to a cationic species III 
through a single electron transfer (SET) oxidation by the iodine radical 2.22.213,215 Lastly, 
deprotonation by the acetate anion furnishes the final product IV. Although other 
mechanisms including the above mentioned electrophilic trifluoromethylation cannot be 
completely ruled out, the proposed mechanism is more likely, because it could account 
for the tolerance of previously unreactive enaminones. For example, we presume that N-
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substituents (as R3 in Scheme 2.15) that are capable of stabilizing the intermediate II 
through conjugation should facilitate the CF3 radical attack. Indeed, we observed good 
yields for the formation of C5–trifluoromethyl enaminones 2.7, 2.10, and 2.11 with 
EWGs such as N-Boc and N-Cbz, which had been detrimental to C–H functionalizations 
before. In a similar vein, adding a C6-phenyl group (Scheme 2.15, R4 = Ph) would also 
stabilize intermediates II and III. Despite its steric bulk, we speculate that the stabilizing 
effect of the phenyl group overcomes its steric repulsion against the relatively small CF3 
radical, generating a high yield in the reaction (75%, 2.9).  
 
2.7 Utility of the Newly Synthesized Trifluoromethyl Cyclic Enaminones 
After synthesizing the trifluoromethylated cyclic enaminones, their elaboration was also 
briefly explored (Scheme 2.16). The unique structural core of cyclic enaminones offers 
four nucleophilic sites and two electrophilic sites for modification from which a plethora 
of chemoselective transformations have already been well established,191 such as the 
enolate chemistry,216 1,2-addition,217 and [2+2] cycloaddition.218 In addition, we chose to 
chemoselectively deconjugate the cyclic enaminones (such as 2.6) with L-Selectride (Eq. 
1). The resultant isolation of the carbonyl and amine moieties leads to a γ-piperidone core 
(as in 2.21), which is both synthetically versatile and pharmaceutically important.75,219 
Meanwhile, we also considered the preparation of “ready-to-install” trifluoromethylated 
enaminone precursors. Since the yield of enaminone 2.12 was less satisfactory, N-
deprotection of enaminone 2.11 was achieved smoothly under H2 with good functional 
group tolerance (Eq. 2). Product 2.22 should be easily engrafted onto desired lead 
molecules.220,221 
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Scheme 2.16. Partial reduction and N–Deprotection of Selected 5-Trifluoromethylated 
Cyclic Enaminones 
 
 
2.8 Summary 
In summary, we have developed a transition-metal-free C–H trifluoromethylation 
protocol for a variety of cyclic enaminones. This method proceeds smoothly at room 
temperature and it tolerates a broad scope of functionalities including both electron-rich 
and electron-deficient cyclic enaminones. A radical mechanism is proposed for this 
transformation. While this method is not specific for piperidine synthesis, the 
combination of the efficient C–H trifluoromethylation and the broad synthetic utilities of 
cyclic enaminones provide an unprecedented and easy route to access a multitude of 3-
trifluoromethylpiperidine derivatives, and therefore should serve as an additional method 
to benefit medicinal chemistry SAR studies.  
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Chapter 3 
Elucidating the Binding Site of Epothilones on Beta-Tubulin with 
Epothilone Photoaffinity Probes 
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3.1 Introduction 
The epothilones are a family of potent cytotoxic polyketide macrolide natural products.222 
They are metabolites that are produced by the soil-dwelling myxobacterium Sorangium 
cellulosum and were first isolated in 1992 by Höfle and collaborators.222,223 Six major 
epothilones (epothilone A to F) from 37 variants have been identified and characterized. 
As shown in Figure 3.1, the epothilones have a characteristic lactone functional group in 
their structures. They carry hydroxyl groups at C3 and C7 and a ketone functional group 
at C5.  
 
Figure 3.1. Structures of Epothilones A to F and Ixabepilone. 
 
Epothilones A and B possess a C12–C13 epoxide moiety, a C20 methyl group on the 
thiazole ring and either a proton (epothilone A) or a methyl group on C12 (epothilone B). 
Epothilones C and D lack the C12-C13 epoxide moiety and instead have an olefinic bond 
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at C12–C13. Epothilones E and F are metabolized forms of epothilones A and B with a 
hydroxymethyl substituent at the C20 position on the thiazole ring. The FDA approved 
epothilone B analogue Ixempra® (Figure 3.1) in 2007 for the treatment of metastatic or 
locally advanced breast cancer. In addition, epothilone D is currently in clinical trials for 
the treatment of Alzheimer’s disease.224 This treatment is based on Trojanowski and 
Lee’s theory, which surmised that tubulin-stabilizing agents could be used for the 
treatment of Alzheimer’s disease.225 The pathological characteristics of Alzheimer’s 
disease are the deposition of β-amyloid proteins and neurofibrillary tangles (primarily tau 
proteins) in the brain. Tau, a microtubule-associated protein, stabilizes the intraneuronal 
microtubular structure that is necessary for the transport of neurotransmitters and 
essential nutrients. In Alzheimer’s disease, tau proteins are abnormally 
hyperphosphorylated and can no longer stabilize the microtubular structure inside nerve 
cells resulting in death of neurons. Since taxol and the epothilones induce tubulin 
polymerization and stabilize microtubules, they were proposed as possible Alzheimer’s 
disease therapeutics assuming they could preserve the integrity of the microtubular 
structure.225,226 The epothilones were shown to have a neuroprotective effect on nerve 
cells, which are non-dividing and post-mitotic. Unlike taxol, the epothilones cross the 
blood-brain barrier and thus, epothilone D (Figure 3.1) eventually entered clinical 
trials.224  
 
3.2 Biological Activity and Mechanism of Action of Epothilones 
Epothilones were originally identified as natural product fungicidal and cytotoxic 
macrolides.222 After noticing the taxol-like activity of the epothilones in 1995,227 they 
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became the subject of thorough investigations, including semisyntheses, total syntheses, 
SAR studies, pharmacological, and clinical studies.228 Studies point out that the principle 
mechanism of action of epothilones is similar to taxanes. Epothilones trigger microtubule 
bundling, formation of multipolar spindles and mitotic arrest.227,229 The mechanism by 
which epothilones induce the microtubule polymerization seems to be similar to that of 
paclitaxel, in that epothilones compete with paclitaxel for binding to microtubules and 
repress microtubule dynamics in a manner similar to that of paclitaxel.227,230,231 The 
epothilones have a number of advantages compared to taxol. They can be produced in 
large quantities by fermentation, are highly active against taxol-resistant and multi-drug 
resistant cancers, they cross the blood-brain barrier, and they are more water-soluble than 
taxol.228 By 2010, five natural, synthetic, and semisynthetic epothilone derivatives had 
entered advanced cancer clinical trials.228  
 
3.2.1 Microtubules 
3.2.1.1 Structure 
Tubulin is a member of a small family of globular proteins. The tubulin superfamily 
comprises five discrete families: α-, β-, γ-, δ-, and ε-tubulins. Out of these, the α- and β-
tubulin family of proteins weighing approximately 55 KDa each, are the most common 
and make up the microtubules.232 Microtubules are a component of the cytoskeleton and 
are found throughout the cytoplasm. They are important in a number of cellular processes 
such as the maintenance of cell structure, protein trafficking, providing a platform for 
intracellular transport, chromosomal segregation, and cell division (mitosis and meosis) 
including mitotic spindle formation.233 Although they serve as the robust cytoskeleton of 
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the cell, the microtubules are not static, but very dynamic polymers. The α- and β-tubulin 
dimers polymerize end-to-end in protofilaments forming long, hollow cylindrical 
microtubules.234 Microtubules display polarity that is critical for their biological function. 
For the end-to-end tubulin polymerization, the α-subunits of one tubulin dimer contacts 
the β-subunits of the next. Therefore, in a protofilament, one end will have the α-subunits 
exposed while the other end will have the β-subunits exposed. These ends are designated 
as the (−) and (+) ends, respectively. The protofilaments bundle parallel to one another. 
Thus, in a microtubule in one end, the (+) end, only the β-subunits are exposed, while the 
other end, the (−) end, only α-subunits are exposed. Elongation of microtubules typically 
only occurs from the (+) end.235 
 
3.2.1.2 Dynamic Instability of Microtubules 
The coexistence of assembly and disassembly at the (+) end of a microtubule is referred 
to as the dynamic instability (Figure 3.2). The microtubule can dynamically change 
between growing and shrinking stages in this region.236 During polymerization, both the 
α- and β-subunits of the tubulin dimer are bound to a GTP molecule.234 The GTP bound 
to the α-tubulin is stable and has a structural function. The GTP bound to the β-tubulin 
may be hydrolyzed to GDP shortly after assembly, which results in the addition of new 
dimers. The kinetics of the GDP-bound tubulin is different from that of the GTP-bound 
tubulin in that the GDP-bound tubulin is prone to depolymerization.237	  The GDP-bound 
tubulin subunit at the tip of a microtubule can fall off. However, the GDP-bound tubulin 
in the middle of a microtubule cannot spontaneously leave. Since tubulin appends onto 
the end of the microtubule only in the GTP-bound state, there is a cap of GTP-bound 
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tubulin at the tip of the microtubule, protecting it from disassembly. When hydrolysis 
reaches up to the tip of the microtubule, it begins a rapid depolymerization and shrinkage. 
This switch from growth to shrinking is defined as a “catastrophe”. The GTP-bound 
tubulin can begin adding to the tip of the microtubule again, affording a new cap and 
protecting the microtubule from shrinking. This is termed as “rescue”.238 
 
Figure 3.2. Dynamic Instability of Microtubules. 
 
A large number of drug molecules can bind to tubulin and modify its activation state. 
This results in disturbing the microtubule dynamics. This interference with microtubule 
dynamics can in turn arrest the cell cycle and ultimately lead to apoptosis. The 
epothilones and the taxanes block the dynamic instability by stabilizing GDP-bound 
tubulin in the microtubule. When the hydrolysis of GTP reaches the tip of the 
microtubule, depolymerization stops and the microtubule is prevented from shrinking 
back. In contrast, the Vinca alkaloids (e.g. vincristine) block the polymerization of 
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tubulin into microtubules.  
 
3.2.2 Mechanism of Action 
The principle mechanism of action of epothilones is similar to taxanes. It was 
experimentally found that the epothilones competitively bind at the taxol-binding site on 
β-tubulin, suggesting that the binding site for the epothilones and the taxanes must be 
overlapping.227,230,231 Two groups suggested that the epothilones and the taxanes possess 
a common pharmacophore for microtubule binding.239,240 However, epothilones have 
shown impressive efficacy against paclitaxel-resistant cancer cell lines, suggesting a 
significantly different mode of binding.241 There are three reasons for resistance to 
paclitaxel: Overexpression of P-glycoprotein (Pgp) (thus lowering the intracellular 
concentration of drug), overexpression β-tubulin isotype β-III, and tubulin point 
mutations in key amino acid residues essential for taxane binding.241 Epothilones evade 
Pgp efflux, and are active against the paclitaxel-resistant cancer cell lines due to the 
tubulin point mutations of key amino acid residues. The Himes group identified 
differences in the interaction between these drugs and yeast microtubules.242 Epothilones 
were found to promote the assembly of yeast tubulin while paclitaxel was not. The 
difference in the behavior of these drugs was rationalized based on the models of 
paclitaxel and epothilone binding to mammalian microtubules239,240,243 available at that 
time. Data from several different experimental approaches244-246 denoted that the 1–31, 
217–231, 270–289, 358–372 amino acid regions of β-tubulin interact or form 
hydrophobic sites for paclitaxel; whereas a model for epothilone binding240 suggested 
that epothilones make contacts with the residues in the 217–231 and 270–282 regions. 
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With the exception of a few crucial differences, most of the residues in the four regions 
that have been proposed to be involved in paclitaxel binding are the same in brain and 
yeast β-tubulin. These differences are at positions 19, 23, 26, 227, 231, and 270.  
 
Figure 3.3. Structures of Paclitaxel and Epothilones. 
 
Based on one of the models illustrating paclitaxel binding to brain tubulin,243 the 
isopropyl group of Val23 is adjacent to the C3’-benzamidophenyl ring (Figure 3.3). A 
threonine residue is present at this position in yeast tubulin, increasing the polarity and 
thus possibly affecting paclitaxel binding. The same model predicts that the methylene 
groups of Lys19, Glu22, Asp26 will make short contacts with the C3’-benzamidophenyl 
ring.243 Yeast tubulin contains alanine at the 19 position instead of lysine and glycine at 
the 26 position instead of aspartate, thus causing substantial reduction in the number of 
methylene groups. The residues Lys19, Val23, and Asp26 were identified in a peptide 
that was found to cross-link to a photoaffinity analog of paclitaxel.245 The epothilone 
binding model,240 did not associate these residues with epothilone binding, and thus the 
changes in these residues do not disrupt epothilone binding to yeast tubulin. Another 
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important site for paclitaxel binding is the position 227 in β-tubulin. In brain β-tubulin, 
this position is occupied by histidine. The paclitaxel binding model240 predicts that 
His227 lies in between the C2 phenyl and the C13 side chain and forms π-stacking 
interactions with the C2 phenyl and C3’ benzamidophenyl rings. Yeast tubulin has 
asparagine residue at the 227 position, which eliminates the possibility of π-stacking, 
thereby, weakening the binding of paclitaxel. 
 
3.3 Structure–Activity Relationships and Binding on β-Tubulin of Epothilones 
3.3.1 Structure–Activity Relationships 
The structure-activity data currently available, presents some insight into the interaction 
between epothilones and microtubules. A variety of epothilone analogs have been 
synthesized and evaluated for their activity in microtubule assembly and cytotoxicity 
assays. Increasing microtubule-stabilizing activity does not always result in increased 
cytotoxicity, most likely because of the importance of other variables such as cellular 
accumulation and metabolic stability.247 Naturally occurring epothilones have been 
isolated in two variants: those with a C12–hydrogen (epothilone A-like) or with a C12 
methyl (epothilone B-like). Irrespective of the structure, epothilone B-like epothilones are 
five to 20 times more active in cytotoxicity and tubulin polymerization assays. 
Particularly, epothilone B is approximately twice as potent as epothilone A or paclitaxel 
in inducing tubulin polymerization in vitro.230,248 Not surprisingly, therefore most in vivo 
studies and clinical trials have been performed with epothilone B-like epothilones. 
Various structural modifications that affect the activity of epothilones are shown in 
Figure 3.4a and 3.4b. For manifesting the required biological activity, a 16-membered 
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macrocycle and the configuration of all the seven stereocenters are absolutely needed.249 
Moderate activity was seen with a few 18-membered epothilones. However, 14-, 15- and 
17-membered analogs were very weakly active or inactive.249-251 Replacing the lactone 
moiety of epothilone B with a lactam (i.e., ixabepilone) reduces cytotoxicity and tubulin 
binding only slightly, but improves other properties such as resistance to esterase 
cleavage, protein binding, and therapeutic window.229,252 No other bioisosteric 
replacement of the lactone group with a ketone or an ether has been reported yet. 
Removing the C3 OH and the presence of a C2–C3 (E)-olefinic bond yields epothilones 
that are moderately active. This observation indicates that the C3 OH does not act as a 
hydrogen bond donor or a hydrogen bond acceptor when the epothilones are bound to β-
tubulin. However, the stereochemistry at the C3 position is crucial for maintaining the 
activity. 3β-Nitrile analogs with the natural configuration are highly active whereas the 
3α-nitrile analogs are inactive.253 This observation suggests that there are considerable 
steric restraints. For the same reason, most likely the ester and ether analogs of C3 and 
C7 hydroxyl groups are also inactive. Oxidizing the C3 and C7 alcohols to ketones or 
reducing the C5 ketone to epimeric alcohols results in a complete loss of activity. Both 
epimeric C4–monomethylepothilones are highly active,254 but linking both C4 methyl 
groups and forming a cyclopropane results in an analog with significantly reduced 
activity.255,256 Replacing the C8 methyl with hydrogen also reduces the activity.255,256 The 
reason behind this could be a result of the absence of the C6 methyl/C8 methyl syn 
interaction and a change of C3–C4–C5 bond angles altering the conformation. 
Substituting the C6 methyl group with an ethyl group causes the activity to increase four 
times, but placing an allyl or propyl substituent on C6 results in slightly less active 
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compounds compared to the parent compounds.257  
 
Figure 3.4a and 3.4b. SAR Studies on Epothilones. 
 
Based on the crystal structure258 and NMR in solution (D2O)259, it is known that the 
carbon backbone C8–C12 assumes a anti-periplanar conformation and thus, the C9–
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C10260-263 and C10–C11 trans olefinic analogs are highly active254,264,265, while the C9–
C10 cis isomer266 and the C9–C10 alkyne derivative266 are inactive. The C10-oxa 
derivative is also inactive for unknown reasons.267 The C12–C13 epoxide and olefin have 
been extensively modified. Replacing the epoxide with a cyclopropane268-270, 
cyclobutane270, oxazoline271, aziridine, N-acyl and N-alkyl aziridine272 maintains or 
improves the cytotoxicity. This observation disproves the initial hypothesis that 
epothilones covalently bind to tubulins via epoxide opening. However, the acetonides of 
C12, C13–diols are less active273 and the C12–C13 benzo analog is completely 
inactive.274 C12–C13 epoxides and other related analogs in the unnatural β-configuration 
are inactive. Epothilones C and D, which lack the C12–C13 epoxide and instead have a 
double bond, are equally active or even more active in the tubulin polymerization assay 
compared to the epoxide containing analogs, however, significantly less cytotoxic.275-278 
Interestingly, the desoxyepothilones with an unnatural C12–C13 (E)-double bond are also 
similarly highly active.279 The C12 methyl group is vital for high in vitro and in vivo 
activity of epothilone B-like epothilones. Replacing this methyl group with small alkyl, 
alkenyl or alkynyl groups or modifying the C12 methyl group by introduction of a 
halogen or oxygen substituents retains the activity. A fluorescent epothilone D analog 
with a large m-dimethylaminobenzoyloxy substituent at the C12 methyl group is as active 
as paclitaxel.280 Adding an extra methyl group at C14 in the α-configuration slightly 
reduces the activity while a C14β-methyl group results in complete loss of activity.281 
The C16–C17 vinyl spacer in the side chain and the (E)-configuration are crucial for the 
biological activity.275,282 However, the C16 methyl is not that important.254,283 Epothilone 
derivatives which lack the C16–C17 spacer,275,284 or have a single atom extension,285 or 
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contain an alkyne spacer,282 or have a C16–C17 epoxide,277 or have conformationally 
flexible spacers with a C16–C17 single bond are not active.286 
 The thiazole ring can be replaced with an oxazole ring or an α–pyridyl ring with 
no observed loss in the activity. The β–pyridyl and the γ-pyridyl derivatives are 
moderately active or inactive.254-256,287,288 Based on these observations, it was deduced 
that the position where the nitrogen atom is naturally situated in the epothilone molecule 
is very important for acting as a hydrogen bond acceptor in the tubulin bound state. This 
inference is supported by the fact that N-methylthiazolium epothilone B is inactive 
whereas the thiazole N-oxides are still active due to hydrogen bond acceptor like 
behavior of the N-oxide.289 C19-substituted thiazole analogs290 or accordingly substituted 
pyridyl analogs287,288 result in complete loss activity due to a possibility that the 
conformational restraints may place the nitrogen atom out of its ideal orientation. 
Condensing the heterocycle with a benzene ring probably locks the nitrogen in its most 
favorable position thus rendering highly active analogs such as benzothiazoles, 
benzoxazoles, benzimidazoles and benzoquinolines.257,291,292 Surprisingly though, the 
quinoline analog of epothilone D with the nitrogen in the para position is 100 times less 
active while the regioisomers of the quinoline analogs of epothilone B show high 
activity.293-295 Highly active analogs can be prepared by replacing the C20 methyl of the 
epothilone thiazole side chain with hydrogen, small alkyl, alkenyl, or alkynyl groups.289 
The C20 methyl group can also be modified by an array of substituents like halogens, 
oxygen, nitrogen, and sulfur, or oxidized to an aldehyde and further functionalized while 
retaining the activity as long as the length of the residue does not exceed three to four 
atoms.289 However, the thiazole C20 carboxylic acid analog is still inactive.289 
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3.3.2 Epothilone Binding 
Competitive binding studies revealed that epothilones can displace taxol from 
microtubules, which suggested that they have the same or overlapping binding sites.227 
However, epothilones occupy only half of the taxol binding site on β-tubulin.296 Although 
the binding sites for the epothilones and taxol on β-tubulin overlap, epothilones show 
impressive efficacy against taxol-resistant cancer cell lines, suggesting a significantly 
different binding mode.241 Comparison of the crystal structures of both taxol and 
epothilones, their NMR solution structures, cross-resistance to β–tubulin mutations,240,297-
299 and computationally derived overlays of their structures, led to several proposed 
common pharmacophore models.239,258,296,300-303  
In 2004, a model of the conformation and binding mode of epothilone A, based on 
electron crystallography of Zn2+-induced tubulin sheets, was reported (Figure 3.5b).258 A 
similar structure determination had been reported earlier for the taxol/α,β-tubulin 
complex (Figure 3.5a).243 However, due to the relatively low resolution, the structures 
could only be solved with the help of additional NMR studies and molecular modeling.258 
As shown in Figure 3.5b, the C3 and C7 hydroxyl groups and the C5 carbonyl of 
epothilone A form hydrogen bonds with Arg282 and Thr274, the C1 lactone carbonyl 
with Arg276, and the thiazole nitrogen with His227 in the H7 helix. The C12-C13 
epoxide is folded inwards towards a protein pocket and explains the observations that 
additional substituents can be attached at that site without loss of binding. In this model, 
Gln292 and Ala231 are needed to maintain the correct conformation of the M-loop and 
H7 helix respectively, although they are remote from the actual binding site. This 
conformation and binding mode is very different from that derived from NMR 
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measurements in the presence of tubulin (Figure 3.6), but supported by SAR studies,291 
and explains the requirements of a nitrogen anti-periplanar to C15 for biological activity.  
a)           b)                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
Green = Hydrophobic amino acids  
Red = Negatively charged amino acids  
Blue = Positively charged amino acids  
Cyan = Amino acids with Coulombic interactions  
Gray = Solvent exposed 
 
Figure 3.5a and 3.5b. Electron Crystallography-Derived 2D Models of (a) Taxol and (b) 
Epothilone A Bound to Zinc-Stabilized α,β-Tubulin Sheets. (Images generated in 
PyMol).  
  
 
The competing model was obtained from NMR NOE-transfer studies of epothilone A 
bound to unpolymerized α,β-tubulin dimers in solution (Figure 3.6).259 A significant 
difference in this model is that the C3 hydroxy group is not involved in hydrogen 
bonding with the protein, a result that is supported by SAR studies at that site.292,304 
Another difference is that the C7 hydroxyl group has electrostatic interactions with 
Arg282 (rather than with Thr274), which in turn induces electrostatic interactions 
between Arg282 and Thr274. It also locks Arg276 in such a position so that it forms a 
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salt bridge with Asp224. The thiazole and His227 engage in a π-π interaction instead of 
hydrogen bonding with His227 as seen in the electron-crystallography model. The NMR 
model shows involvement of a hydrophobic pocket hosting Phe270, which is important 
for taxol activity and also binds the C12 methyl group of epothilone B, thus accounting 
for its 10-fold increase in activity over epothilone A.  
 
                                       
 
 
 
 
 
 
 
 
 
 
 
 
Green = Hydrophobic amino acids  
Red = Negatively charged amino acids  
Blue = Positively charged amino acids  
Cyan = Amino acids with Coulombic interactions  
Gray = Solvent exposed 
 
Figure 3.6. NMR-Derived 2D Model of Epothilone A Bound to Monomeric Tubulin. 
(Images generated in PyMol). 
 
In both models epothilones cause rigidification and alignment of the M-loop and the H7 
helix leading to conformational change in the α,β-tubulin dimer. However both of them 
are models and the exact conformation of epothilone A required for binding and activity 
is still not known. One of the problems is that the electron crystallography-derived 
structure consists of antiparallel protofilaments instead of parallel ones as seen in natural 
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microtubules, which may distort the binding site as well as the epothilone conformations. 
The relevance of the NMR/modeling results are also subject to concerns because the 
soluble monomers, oligomers, or microtubule protofilaments are not well defined in the 
NMR studies and binding to the various tubulin species could be different. A second low-
affinity binding site for Taxol305 may also be involved in the ligand exchange,306 which is 
not considered in the NMR model. As a result, it is not clear which of the two proposed 
binding models is correct or whether others need to be considered. Figure 3.7 shows four 
three-dimensional structures of epothilone conformers that have been observed or 
proposed: (3.7a) epothilone A bound to zinc-stabilized α, β-tubulin; (3.7b) epothilone A 
in aqueous medium in the presence of α, β-tubulin monomers; (3.7c) epothilone A X-ray 
structure crystallized from dichloromethane, and the conformation (3.7d) derived from 
the crystal structure of epothilone B bound to cytochrome P450. While there is some 
similarity among the structures with regard to the conformation of the macrocycles that 
are shown in Figure 3.7, it is also clear that the orientations of the epoxide and the 
thiazole group at C15 are quite different. In the tubulin-bound electron crystallography 
structure (3.7a) the epoxide is pointing inward, whereas the epoxide is pointing outward 
in the three other structures. The orientation of the presumably highly flexible thiazole 
group in structure 3.7b, derived from NMR studies and structure 3.6c, derived from X-
ray are similar in that C16 and C19 are in a syn orientation, whereas that is not the case in 
structures (3.7a) and (3.7c) that were derived crystallographically.   
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(a) Tubulin-bound 
electron 
crystallography  
	  
(b) Tubulin-bound 
NMR 
(c) X-ray structure (d) Cytochrome 
P450-bound X-ray 
crystallography 
Figure 3.7. Structures of 3-D Epothilone A and B Conformers Obtained by Different 
Methods. (Images reproduced from the literature reference296 with permission). 
 
3.4 Photoaffinity Probes 
Additional evidence is needed to decide which of the two models (electron 
crystallography or NMR) for the structure of the epothilone-tubulin complex is correct. 
One solution to resolve this ambiguity is to carry out photoaffinity labeling studies with 
epothilone derivatives having photolabile substituents at the C21 methyl group of the 
thiazole side chain or on the aziridine nitrogen atom in case of the C12–C13 aziridine 
analogs. Both of these positions can be modified without having an impact on the binding 
of epothilones to tubulin.272,289  
 
3.4.1 Background 
Photoaffinity reagents are compounds that are attached to a molecule that binds to a 
biological target with a photolabile moiety that remains dormant until photoactivated. 
This concept was established in the 1960’s by Westheimer’s group.307,308 The 
photolabeling strategy has been newly rejuvenated by proteomic methods for identifying 
labeled targets. This method has conventionally been employed in identifying probe 
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labeled proteins but is now being increasingly applied to locating specific sites within 
proteins.309 In a typical photoaffinity labeling study, the probe containing a photolabile 
moiety is added to the biological environment containing its target. The probe is assumed 
to bind its target at equilibrium. Upon photolysis, the inert photolabile moiety becomes 
activated and generates a reactive radical, carbene or nitrene intermediate depending 
upon its structure, and reacts covalently with a functional group on the target in its 
vicinity. Unlike for a chemical affinity probe, there is no need for a chemical 
complementarity between the probe and the target in case of the photoaffinity probe. 
Even though binding to a target is biospecific, probe–target coupling is comparatively 
arbitrary.310  
 
Figure 3.8. Structures of Some Common Photoaffinity Probes. 
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As seen in the Figure 3.8, the most commonly used photoaffinity probes have a 
benzophenone, an aryl azide, a diazoacetyl or a trifluoromethyldiazirino-type of 
photolabile group in their structures. Galardy and co-workers were the first to introduce 
benzophenones for photoaffinity labeling.311 The benzophenone photolabel gives rise to 
radical formation upon photoactivation. In most of the cases, a triplet excited state is 
formed, which abstracts a hydrogen atom from a donor producing two radicals that 
subsequently couple.311 Unreacted excited species relax to the ground state and may be 
excited over and over again until they react. A typical mechanism of benzophenone 
activation is shown in Scheme 3.1. 
Scheme 3.1. Activation of Benzophenone Photolabel to Generate Radical Species 
 
 
The aryl azides were introduced as photoaffinity reagents by Fleet et al.312 They are 
generally stable at room temperature. However, aryl azides require photoactivation at 
shorter wavelengths (λmax 250–290 nm) that can be damaging to proteins. Upon 
photolysis the aryl azide-containing photoprobes generate nitrenes. Nitrenes are 
molecules that have monovalent nitrogen in their structures and are relatively less 
reactive compared to carbenes. The reactive aryl nitrenes can efficiently insert into N–H, 
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O–H, and S–H bonds but are generally not very proficient at inserting into C–H bonds. 
Aryl nitrenes can rearrange from singlet state to less reactive and long-lived species such 
as azacycloheptatetraenes or benzaziridines that can also react with nucleophiles (Scheme 
3.2).313-317 
Scheme 3.2. Reactions of Aryl Nitrenes 
 
 
Diazocarbonyl-containing photoprobes were first synthesized by the Westheimer group 
in their original photoaffinity labeling experiment.308 The diazo compounds possess a 
strong absorption band in the UV region (λmax 240–280 nm) and a very weak band at 
longer wavelengths (~ 340 nm). Their photolysis gives rise to formation of carbene 
intermediates (Scheme 3.3, Path A). In order to achieve complete photolysis, prolonged 
irradiation at >300 nm with the usual lamps is needed. Such prolonged periods damage 
the proteins. Therefore, the photolysis properties of the diazo compounds are not the best 
for photoaffinity labeling. One of the major disadvantages of the diazoacetyl group is that 
it is unstable at low pH and is reactive in the dark towards protein functional groups. To 
partially overcome the challenges faced by the diazoacyl compounds, the Westheimer 
group synthesized improved and more stable 2-diazo-3,3,3-trifluoropropionyl318 and tosyl 
diazoacetyl319 containing photoprobes. These are much more stable at lower pH and 
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possess improved absorption properties. However, all of the diazoacyl photoprobes not 
only generate carbene species upon photolysis but these carbenes further undergo Wolff 
rearrangement and give rise to ketene intermediates (Scheme 3.3, Path B), which are 
highly reactive and can result in formation of unwanted side products. 
Scheme 3.3. Reactions of Diazoacyl Photoprobes 
 
 
Diazirine containing photoaffinity probes were first synthesized by Smith and 
Knowles.320,321 The three-membered ring has exceptionally high chemical and thermal 
stability.322,323 The 3H-3-phenyldiaziridine was reported to be unstable on storage as a 
neat liquid, but its stability was improved in hexanes solution at –20 °C.321 Higher 
molecular weight derivatives of this compound have been stored for months in solution at 
–80 °C without decomposition. The diazirines possess characteristic absorption bands in 
the near UV region (λmax 350–380 nm). Among the diazirine containing photoaffinity 
probes, the trifluoromethyl-3-H-diazirine is an important class. They undergo efficient 
photolysis giving rise to formation of a carbene, which do not rearrange. A typical 
mechanism of photoactivation is shown in Scheme 3.4. These carbenes can form stable 
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covalent cross-links with the receptor and are capable of inserting into C–H, N–H, O–H 
or S–H bonds. None of the naturally occurring 20 amino acid side chains are immune to 
attack from the carbenes. The carbenes are therefore not only useful for labeling enzyme 
active sites, which are anticipated to contain nucleophiles, but also other receptors, which 
might predominantly contain hydrocarbon residues in their binding sites. They have 
better photostability compared to nitrenes or radicals and are easily and efficiently 
activated. Another advantage of the diazirines is that they only require short irradiation 
times to form carbenes, which assures that the integrity of the protein is maintained under 
the irradiation conditions. 
Scheme 3.4. Photoactivation of A Trifluoromethyl-3-H-diazirine Probe 
 
 
3.4.2 Epothilone Photoaffinity Labels  
Although mammalian brain tubulin has been studied extensively, it is highly 
heterogeneous largely because of posttranslational modifications and therefore, 
significant advances in understanding of microtubule stabilizing agents have yet to be 
made.228 Photoaffinity labeling studies to characterize the taxol and discodermolide 
binding sites have been reported, but so far photolabeling of tubulin with epothilones has 
remained elusive. Earlier photoaffinity labels designed and tested in the Georg laboratory 
(Figure 3.9) resulted only in non-specific labeling.324-326 The analog A, a C25 benzyloxy 
substituted epothilone C, was prepared to probe whether an ether-linked benzyl group 
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was tolerated at this site for the planned introduction of a benzyl azide or benzyl 
aziridine. Yet, this analog displayed drastically reduced biological activity in cytotoxicity 
and microtubule assembly assays. Molecular modeling simulations suggested that 
excessive steric demand at the C25 position might disrupt the key hydrogen-bonding 
interactions ultimately resulting in weaker ligand binding and reduced activity.326  
 
Figure 3.9. Structures of Earlier Synthesized Epothilone Photoaffinity Probes. 
 
Analog B, a C22–functionalized epothilone C, showed good activity in microtubule 
assembly assays, but suffered from reduced cytotoxicity. Molecular modeling studies 
indicated that steric bulk at C22 could be accommodated by the hydrophobic binding 
pocket.324 However the photoaffinity labeling studies were inconclusive. The covalent 
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labeling was non-specific. In case of the analogs C, only the azidobenzoyl derivatives 
were actively cytotoxic and promoted microtubule assembly.325 Docking studies 
suggested that the azidobenzoyl derivatives could bind to the epothilone-binding site. 
Photolabeling studies with the 3-azidobenzoyl analog could not identify covalently 
labeled peptide fragments. This result suggested that the phenylazido side chain was 
predominantly solvent-exposed in the bound conformation and therefore was unable to 
make a covalent bond to the tubulin protein. The benzophenone derivative was inactive in 
both the assays. Docking studies suggested that the benzophenone derivative underwent a 
sterically driven ligand arrangement interrupting all hydrogen bonding and hence the 
protein binding.  
Taking into account these results and the extensive SAR studies data, new 
epothilone A photoaffinity probes were designed (Figure 3.10) that should allow 
differentiation between the proposed binding modes. We hypothesized that the protein 
region, which will be labeled, is dependent on the epothilone conformation at the binding 
site.	  Thus, affinity labels were placed at the thiazole and aziridine moieties, which occupy 
distinctly different positions in the two proposed binding models. Compound 3.1, 
carrying a diazo/triazolo moiety, and compounds 3.2, 3.3, and 3.4, carrying 
trifluoromethyldiazirine groups, would generate highly reactive carbenes when subjected 
to photolysis. Additionally, we presumed that having a variety of photoaffinity probes 
with photoreactive groups at the different positions in their structures would more likely 
label different amino acid residues once bound to β-tubulin, thus giving a complete 
picture of the optimum conformation for binding. 
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Figure 3.10. Structures of Newly Designed Epothilone A Photoaffinity Probes. 
 
3.5 Synthesis of Newly Designed Epothilone A Photoaffinity Probes 
3.5.1 Synthesis of 21-Diazo/triazolo Epothilone A Photoprobe 3.1 
Synthesis of the 21-diazo/triazolo epothilone A photoprobe is shown in Scheme 3.5.289 
Epothilone A was oxidized with m-CPBA to provide thiazole N-oxide 3.6. The N-oxide 
was then subjected to a Polonovski rearrangement by treating N-oxide 3.6 with 
trifluoroacetic anhydride and 2,6-lutidine to furnish the trifluoroacetate intermediate 3.7 
in 40% overall yield over 2 steps. This intermediate was then dissolved in THF and 
saponified with ammonia to obtain 20-(hydroxymethyl) epothilone A (epothilone E, 3.8) 
in 90% yield.  
 
	   90	  
Scheme 3.5. Synthesis of 21-Diazo/triazolo Epothilone A Photoprobe 3.1 
 
The allylic (C21-) alcohol of epothilone E 3.8 was oxidized to C21 aldehyde 3.9 in 79% 
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yield using manganese dioxide. Aldehyde 3.9 was converted to a mixture of E- and Z-
hydrazones 3.10 in 99% yield by treatment with hydrazine hydrate. The next step was to 
oxidize the hydrazones 3.10. Attempts with PIDA (diaceto(phenyl)iodide) oxidation of 
3.10 did not succeed. The mixture of hydrazones 3.10 was then subjected to nickel 
peroxide oxidation at room temperature to furnish the required 21–diazo/triazolo 
epothilone A photoprobe 3.1 in 48% yield.  
21–Diazo/triazolo epothilone A 3.1 had been synthesized earlier by Nicole Glaser 
and shown to exist in two tautomeric forms in equilibrium,289 the most predominant 
tautomer being the triazolo derivative (98%). The diazo derivative is a minor tautomer 
and exists only as 2% of the total compound.289 Only the diazo tautomer is 
photocleavable and therefore the tautomerization is a rate-determining step in the 
photolabeling studies. The ratio of the tautomers was determined based on the intensity of 
the IR band at 2078 cm–1.289 Moreover, the diazo/triazolo epothilone A 3.1 was shown to 
convert to pyrrolothiazole epothilone A (Scheme 3.6) by cycloaddition with dimethyl 
acetylenedicarboxylate.289 Also, it was shown that, the diazo/triazolo epothilone A 3.1 is 
stable as a neat compound or in solution but underwent decomposition on irradiation in 
methanol to give epothilone E 21–methyl ether (Scheme 3.6).289 These reactions prove 
the presence of the diazo tautomer in equilibrium with the triazolo tautomer. 
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Scheme 3.6. Reactions of 21–Diazo/triazolo Epothilone A Photoprobe 3.1 
 
 
3.5.2 Synthesis of 3-(Trifluoromethyldiazrino)benzoyl-12,13-Aziridine Epothilone A 
or the ‘meta-Photoprobe’ 3.2 and 4-(Trifluoromethyldiazrino)benzoyl-12,13-
Aziridine Epothilone A or the ‘para-Photoprobe’ 3.3 
The retrosynthetic scheme for the photoprobes 3.2 and 3.3 (Scheme 3.7) shows that the 
probes could be synthesized by acylation of epothilone A aziridine 23 with meta- or 
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para-(trifluoromethyldiazirino)benzoic acids. 
Scheme 3.7. Retrosynthetic Analysis for meta-Photoprobe 3.2 and para-Photoprobe 3.3 
 
 
In a forward sense, epothilone A aziridine 3.11 was synthesized as shown in Scheme 3.8 
using a literature protocol.272 Protection of both the C3 and C7 hydroxyl groups of 
epothilone A by reaction with TES-chloride in the presence of N,N-
diisopropylethylamine (DIPEA or Hünig’s base) generated the bis-triethylsilyl ether 3.14 
in 92% yield. The bis-triethylsilyl ether 3.14 was treated with magnesium bromide 
etherate at low temperature (–20 °C) to open the epoxide and form the corresponding 
regioselective C12α–OH/C13β–Br bromohydrin 3.15 in 63% yield. Nucleophilic 
substitution of the bromide of bromohydrin 3.15 was carried out with sodium azide to 
produce the cis-azido alcohol 3.16 in 62% yield. The cis-azido alcohol 3.16 was 
converted to trans-azido alcohol 3.18 in 77% yield (over 2 steps) by Mitsunobu inversion 
at the C12 position using p-nitrobenzoic acid. The p-nitrobenzoate ester 3.17 was 
obtained from 3.16 in 77% yield, which was subjected to ester hydrolysis conditions 
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using 2.0 M liquid ammonia solution in methanol to furnish the trans-azido alcohol 3.18 
in quantitative yield. The C12β–OH of the trans-azido alcohol 3.18 was activated by 
reaction with mesyl chloride to form the azido mesylate intermediate, which without 
isolation, was subjected to reduction with trimethylphosphine and in situ cyclization to 
obtain bis-TES epothilone A 12α, 13α-aziridine 3.19 in 85% yield. Removal of both the 
TES groups from the alcohols of 3.19 furnished the required epothilone A 12α, 13α-
aziridine 3.11 in 91% yield.  
Scheme 3.8. Synthesis of Epothilone A Aziridine 3.11 
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meta-(Trifluoromethyldiazirino)benzoic acid (3.12) was provided to us by our 
collaborator Dr. Gerhard Höfle and was prepared as shown in Scheme 3.9. The hydroxyl 
group of the bromobenzyl alcohol (3.20) was first protected as TBS ether 3.21 and then 
subjected to lithium-halogen exchange with n-butyl lithium followed by addition of N,N-
diethyl trifluoroacetamide to provide trifluoromethyl ketone 3.22. 
Scheme 3.9. Synthesis of m-Trifluoromethyldiazirino Benzoic Acid 3.12 
 
 
Ketone 3.22 was reacted with hydroxylamine hydrochloride to generate a mixture of E- 
and Z-oximes, which were treated with tosyl chloride to provide a mixture of tosyloximes 
3.23 in 66% yield starting from bromobenzyl alcohol (3.20). Tosyloximes 3.23 were 
treated with condensed liquid ammonia to diaziridine 3.24 in 79% yield, which was 
oxidized with molecular iodine to the diazirine 3.25 in 97% yield. Deprotection of the 
silyl group of diazirine 3.25 with aqueous hydrochloric acid, followed by basic potassium 
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permanganate oxidation converted the alcohol to the carboxylic acid, producing the 
required m-(trifluoromethyldiazirino)benzoic acid (3.12) in 91% yield. The 
corresponding p-(trifluoromethyldiazirino)benzoic acid (3.13) is commercially available.  
Scheme 3.10. Synthesis of Photoprobes 3.2 and 3.3 
 
 
The epothilone A photoprobes 3.2 and 3.3 were prepared by acylation of aziridine 3.11 
with acids 3.12 and 3.13 (Scheme 3.10). Epothilone A aziridine 3.11 and the m-
(trifluoromethyldiazirino)benzoic acid (3.12) were reacted in the dark using benzotriazol-
1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) as a coupling 
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agent and Hünig’s base to furnish the meta-photoprobe 3.2 in 81% yield. In a similar 
manner, the para-photoprobe 3.3 was synthesized by acylating epothilone A aziridine 
3.11 with p-(trifluoromethyldiazirino)benzoic acid (3.13) in 91% yield. 
 
3.5.3 Attempts Towards the Synthesis of the 20-Trifluoromethyldiazirino 
Epothilone A Photoprobe 3.4 
3.5.3.1 Suzuki Coupling 
A retrosynthetic analysis for photoprobe 3.4 is shown in Scheme 3.11, suggesting that a 
Suzuki coupling of fragments 3.26 and 3.27 could be employed to prepare the designed 
photoprobe. 
Scheme 3.11. Retrosynthetic Analysis for 20-Trifluoromethyldiazirino Epothilone A 3.4 
 
 
The synthesis of fragment 3.26 (Scheme 3.12) started with lithium halogen exchange at 
the C2 position of 2,4-dibromothiazole (3.28) using n-butyllithium at –78 °C, followed 
by addition of N,N-diethyl trifluoroacetamide to furnish the trifluoromethyl ketone 3.29. 
The crude trifluoromethyl ketone 3.29 was refluxed in pyridine with hydroxylamine 
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hydrochloride to obtain a mixture of E- and Z-oximes, which was further treated with 
tosyl chloride to generate a mixture of tosyloximes 3.30 in 50% yield starting from 2,4-
dibromothiazole (3.28) over 3 steps. The mixture of tosyloximes 3.30 was dissolved in 
ether and treated with condensed liquid ammonia at –78 °C to furnish trifluoromethyl 
diaziridine 3.31 in 79% yield. Finally, the trifluoromethyl diaziridine 3.31 was oxidized 
with silver (I) oxide to obtain the volatile 2-(trifluoromethyldiazirino)-4-bromothiazole 
(3.26) in 70% yield. 
Scheme 3.12. Synthesis of 2-(Trifluoromethyldiazirino)-4-Bromothiazole 3.26 
 
 
 
Next, we focused on preparing the boronic acid fragment 3.27. The proposed synthesis 
route is shown in Scheme 3.13. The C15 ketone epothilone A 3.32, which was provided 
to us by our collaborator Dr. Höfle, was prepared by subjecting epothilone A (3.5) to 
ozonolysis at –70 °C. The hydroxyl groups of the crude C15 methyl ketone were 
protected as trimethylsilyl ethers to furnish the bistrimethylsilyl epothilone A ketone 
3.32. In order to convert the ketone 3.32 into the corresponding vinylogous boronic acid 
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we needed to prepare a special boronic ester reagent, tris(ethylenedioxyboryl)methane 
(3.33, Scheme 3.14). 
Scheme 3.13. Synthesis of Epothilone A Boronic Acid Fragment 3.27 
 
 
Tris(ethylenedioxyboryl)methane (3.33) was synthesized as shown in Scheme 3.14 
following a literature procedure327 with some modifications. Instead of condensing the 
boron chloride gas into a reaction flask at low temperature, we mixed a 1.0 M solution of 
boron trichloride (3.35) with a trimethoxyborane (3.36) solution at –50 °C. To this 
solution, chloroform was added to obtain ‘mixture A’, which contained dimethoxyboron 
chloride (3.37). Mixture A was then added to lithium metal at –40 °C to obtain 
tris(dimethoxyboryl)methane (3.39). Reacting 3.39 with ethylene glycol followed by 
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recrystallization furnished the required tris(ethylenedioxyboryl)methane (3.33) in 16% 
overall yield. 
Scheme 3.14. Synthesis of Tris(ethylenedioxyboryl)methane (3.33) 
 
 
In order to synthesize the epothilone A boronic acid fragment 3.27, 
tris(ethylenedioxyboryl)methane (3.33) was dissolved in a 1:1 mixture of THF/DCM, 
cooled to –78 °C and n-BuLi was slowly added. To the above solution, a 1:1 THF/DCM 
solution of bistrimethylsilyl epothilone A ketone 3.32 was added slowly and allowed to 
react. Unfortunately, the TLC analysis revealed that most of the bistrimethylsilyl 
epothilone A ketone 3.32 had decomposed, while some of it remained unreacted. The 
sequence of addition was altered but unfortunately it did not result in the formation of the 
product. These failed attempts forced us to abandon this route. Therefore, another route to 
synthesize the 20-trifluoromethyldiazirino epothilone A photoprobe 3.4 was needed. 
 
3.5.3.2 Cross Metathesis 
It was envisioned that photoprobe 3.4 could be obtained by cross metathesis of fragments 
3.40 and 3.41 as shown in Scheme 3.15.   
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Scheme 3.15. Retrosynthetic Analysis for Photoprobe 3.4 
 
 
For the synthesis of the vinyl thiazole fragment 3.40 we started with 4-formyl-2-
bromothiazole (3.42, Scheme 3.16). Subjecting 3.42 to Wittig reaction conditions 
furnished the 2-bromo-4-vinylthiazole (3.43) in 79% yield. Lithium-halogen exchange at 
the C2 position of 2-bromo-4-vinylthiazole (3.43) using n-butyllithium at –78 °C 
followed by addition of N,N-diethyl trifluoroacetamide yielded the corresponding 
trifluoromethyl ketone. The crude trifluoromethyl ketone was refluxed in pyridine with 
hydroxylamine hydrochloride to get a mixture of E- and Z-oximes, which was further 
treated with tosyl chloride to get a mixture of tosyloximes 3.44 in 62% yield starting from 
the 2-bromo-4-vinylthiazole 3.43. The mixture of tosyloximes 3.44 was dissolved in ether 
and treated with condensed liquid ammonia at –78 °C to furnish trifluoromethyl 
diaziridine 3.45 in 93% yield. Finally, the trifluoromethyl diaziridine 3.45 was oxidized 
with silver (I) oxide to produce the volatile 2-(trifluoromethyldiazirino)-4-vinylthiazole 
(3.40) in 84% yield. 
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Scheme 3.16. Synthesis of Vinyl (Trifluoromethyldiazirino)-thiazole 3.40 
 
 
Next, we focused our attention on the synthesis of the epothilone A alkene fragment 3.46 
(Scheme 3.17). We first synthesized bistrimethylsilyl epothilone A ketone 3.32 from 
epothilone A (3.5) as described earlier in Scheme 3.13.  
Scheme 3.17. Conversion of Epothilone A Ketone 3.32 to Epothilone A Alkene 3.46 
 
 
We subjected ketone 3.32 to Wittig reaction conditions wherein 1.5 equiv. of solid 
potassium tert-butoxide were dissolved in THF and cooled to 0 °C. Then 2 equivalents of 
methyl triphenylphosphonium bromide were added to the above solution and the mixture 
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was refluxed for 1 hour and then cooled to room temperature. Ketone 3.32 was dissolved 
in THF, added to the above mixture upon cooling and then stirred. This reaction resulted 
in the formation of 20% of the required product along with the C2-C3 dehydrated product 
3.47, the structure of which is shown in Scheme 3.18.  
Scheme 3.18. Wittig Reaction on Epothilone A Ketone 3.32 
 
 
Optimization attempts for the Wittig reaction are shown in Table 3.1. In spite of using 
different equivalents of the Wittig salt and the base or using a THF solution of the base, 
changing solvents or changing the order of addition of reagents the yield of the desired 
product could not be improved. 
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Table 3.1. Wittig Reaction Optimization Studies 
Form of 
Base Solvent 
Equiv. 
of Salt 
Equiv. 
of 
Base 
Product 
Yield 
(%) 
Comments and Results 
Solid THF 2 1.5 11 Dehydrated Product + Required Product 
1.0 M in 
THF THF 2.5 1.3 0 Dehydrated Product 
1.0 M in 
THF THF 1 0.95 0 Dehydrated Product 
1.0 M in 
THF THF 1.4 1.05 0 Complex Mixture 
1.0 M in 
THF Toluene 1.1 1 9 Unreacted SM 
1.0 M in 
THF Ether 1.1 1 0 Decomposition 
1.0 M in 
THF THF 1.1 1 0 
At 0 °C, 1 d 
No reaction 
1.0 M in 
THF THF 1.1 1 0 
At 0 °C, reverse addition 
No reaction 
 
Since the formation of the dehydrated product 3.47 can be traced to the inherent basicity 
of the Wittig ylide, we turned to the less basic Tebbe reagent in efforts to increase the 
yield of the olefin 3.46 and reduce the amount of the undesired elimination product 3.47.  
When ketone 3.32 was subjected to Tebbe olefination condition using 1 equivalent of the 
Tebbe reagent 45% of the desired epothilone A alkene 3.36 was obtained and no other 
side products were formed. After optimizing the reaction, we found that using 1.6 equiv. 
of the Tebbe reagent provides a 53% yield of product 3.36 (Scheme 3.19). Based on the 
TLC analysis, some starting material was identified, although this was not isolated and 
quantified. Increasing or decreasing the equivalents of the Tebbe reagent reduced the 
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yield of product 3.36. 
Scheme 3.19. Tebbe Olefination of Epothilone A Ketone 3.32 to Epothilone A Alkene 
3.46 
 
 
Next cross metathesis reactions were attempted between vinyl (trifluoromethyldiazirino)-
thiazole 3.40 and epothilone A ketone 3.46. We first employed the Hoveyda-Grubbs 2nd 
generation catalyst in this reaction (Scheme 3.20) but the desired product was not formed. 
TLC analysis showed that the starting materials remained unreacted. Increasing the 
reaction time to more than 96 hours also did not yield any product.	  	  
Scheme 3.20. Cross Metathesis of Fragments 3.46 and 3.40 
 
 
Attempts with higher temperatures in higher boiling point solvents and longer reaction 
times did not lead to product formation. Changing the metathesis catalysts was also tried. 
The structures of the catalysts used are shown in Figure 3.11.  
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Figure 3.11. Structures of Cross Metathesis Catalysts.  
 
1,1-Disubstituted double bonds are very unreactive to cross metathesis conditions and 
only a single examples of such a transformation can be found in the literature.328 Stewart 
et al. reported using catalyst 3.50 (Figure 3.11) to cross metathesize 1,1-disubstituted 
double bonds with a simple terminal alkene. Employing this catalyst in our system did 
not furnish any product. Various cross metathesis conditions that were tried are 
summarized in Table 3.2. None of these conditions gave any product. Based on these 
results we discontinued our attempts to synthesize photoprobe 3.4. 
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Table 3.2. Summary of Cross Metathesis Conditions Explored 
Catalyst Solvent Temperature (°C) 
Time 
(h) 
Product 
Yield 
(%) 
Hoveyda-
Grubbs 
2nd gen. 
DCM 40 
1, 
12, 
24, 
48, 
96 
0 
Hoveyda-
Grubbs 
2nd gen. 
Toluene 111 
24, 
48, 
96 
0 
Hoveyda-
Grubbs 
2nd gen. 
DCE 85 
24, 
48, 
96 
0 
Stewart-
Grubbs DCM 40 
24, 
48, 
96 
0 
Stewart-
Grubbs DCE 85 
24, 
48, 
96 
0 
Stewart-
Grubbs Toluene 111 
24, 
48, 
96 
0 
 
3.6 Biological Studies 
3.6.1 Biological Assays 
The photoprobes 3.1, 3.2, and 3.3 were examined for cytotoxicity, in a tubulin-assembly 
assay, and for inhibition of [3H]paclitaxel binding (Table 3.3, Table 3.4 and Table 3.5). 
These studies were conducted in the laboratories of our collaborators, Dr. Hamel, at the 
NCI and Dr. Höfle, at the HZI, Germany. 
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Table 3.3. Cytotoxicity Studies of Photoprobes 3.1, 3.2, and 3.3 
Entry* Compound OVCAR-8a 
IC50 ± SD (nM) 
NCI/ADR-RESb 
IC50 ± SD (nM) 
1 Paclitaxel 5.3 ± 2 800 ± 200 
2 Docetaxel 7.0 ± 2 290 ± 10 
3 Epothilone A (3.5) 7.0 ± 1 140 ± 20 
4 Epothilone B 4.0 ± 0 15 ± 0 
5 Diazo-probe 3.1 8.0 ± 1 160 ± 40 
6 Meta-probe 3.2 5.0 ± 1 130 ± 40 
7 Para-probe 3.3 7.0 ± 2 150 ± 70 
* Studies carried out by Dr. Ruoli Bai at NCI, NIH, USA 
aOVCAR-8 = Ovarian cancer lines 
bADR-RES = Multi-drug resistant cancer cell lines 
Table 3.4. Cytotoxicity Studies of the ‘meta-Probe’ 3.2 and the ‘para-Probe’ 3.3 
Entry* Compound L929a 
IC50 (ng/mL) 
PtK2b IC50 
(ng/mL) 
1 Epothilone A (3.5) 4 - 
2 Epothilone A 
aziridine 3.11 
1.9 2 
3 Meta-probe 3.2 20 7 
4 Para-probe 3.3 14 2 
*Studies carried out by Dr. Florenz Sasse at Helmholtz Centre for Infection Research, 
Braunschweig, Germany  
aL929 cells = murine fibrosarcoma cell line 
bPtK2 Cells = Male rat kangaroo kidney epithelial cell line 
Table 3.5. Inhibition of [3H]Paclitaxel Binding Assay 
Entry Compound % Inhibitiona 
1 Epothilone A (3.5) 67 
2 Epothilone B 82 
3 Diazo-probe 3.1 64 
4 Meta-probe 3.2 17 
5 Para-probe 3.3 2.3 
# Studies carried out by Dr. Ruoli Bai at NCI, NIH, USA 
aConcentrations used: tubulin = 2 µM, [3H]paclitaxel = 4 µM, compounds = 20 µM 
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As seen from the above tables, the newly synthesized photoprobes exhibited excellent 
cytotoxicity. In addition, photoprobe 3.1 showed a 64% [3H]paclitaxel inhibition, which 
is comparable to epothilone A (82% inhibition), thereby demonstrating that the probe 
binds in the taxol-binding cavity on β-tubulin. Photoprobes 3.2 and 3.3 showed 17 and 
2.3% inhibition respectively in this assay. Next, the photoprobes were examined for their 
ability to promote tubulin assembly. For this assay, the photoprobes and epothilone A and 
epothilone B were treated at room temperature for 15 minutes with purified tubulin in 0.4 
M monosodium glutamate + 0.5 mM MgCl2, followed by centrifugation at 14000 rpm. 
	  
Triangles = Epothilone B (EC50 = 9.8 µM) 
Squares = Photoprobe 3.1 (EC50 = 15 µM) 
Circles = Epothilone A (EC50 = 45 µM) 
Figure 3.12. Tubulin Assembly Assay for Photoprobe 3.1. 
 
The supernatant containing unpolymerized tubulin was assayed by the Lowry method 329 
for protein content. The EC50 for this assay is defined as the concentration of the drug that 
reduces the protein content of the supernatant by 50% vs. the drug-free control. The 
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curves can be shifted to either the left (by increasing the glutamate concentration) or to 
the right (by decreasing the glutamate concentration) to allow one to measure either 
active or relatively inactive compounds. It was shown that photoprobe 3.1 was more 
active (EC50 = 15 µM) (Figure 3.12) than epothilone A (EC50 = 45 µM) and was therefore 
considered a viable photoaffinity probe. Photoprobes 3.2 and 3.3 failed to show the 
required tubulin assembly in this assay as well as in a medium sensitivity assembly assay. 
Therefore, a low sensitivity tubulin assembly assay (turbidimetry assay) was carried out 
with photoprobes 3.2 and 3.3, in which both the analogs showed good activity (Figure 
3.13).  
 
0 = No Drug Added 
3.2 = Photoprobe 3.2 
3.3 = Photoprobe 3.3 
3.5 = Epothilone A (3.5) 
Figure 3.13. Low Sensitivity Assay for Photoprobes 3.2 and 3.3.  
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For this assay, mixtures of tubulin at (10  µM), heat-treated MAPs (0.75 mg/mL), 4-
morpholineethane sulfonate (Mes) (0.1 M), MgCl2 (0.5 mM), GTP (0.1 mM) at pH 6.9 
with 4% DMSO, and the phototprobes (40 µM) were prepared. Turbidity at 400 nm was 
measured. The Gilford 250 spectrophotometer equipped with electronic temperature 
controller was used. This experiment showed strong assembly at low temperatures with 
epothilone A, and weak assembly at higher temperatures with the photoprobes 3.2 and 
3.3.  
In the UV-Vis experiments, the diazo/triazolo photoprobe 3.1 showed the 
expected band at 300 nm whereas the photoprobes 3.2 and 3.3 showed the expected band 
at 350 nm.  
 
3.6.2 Mass Spectrometric Studies 
The results from the cytotoxicity studies, tubulin assembly assays and UV-Vis 
experiments suggested that photoillumination studies should be carried out with 
photoprobe 3.1. Dr. Hamel, according to the protocol shown in Figure 3.14, carried out 
the photoaffinity labeling studies and our collaborator Dr. Higgins (University of 
Minnesota) performed the mass spectrometric studies. 
The photoprobe 3.1 was incubated with preformed microtubules prepared from 
the electrophoretically homogenized bovine brain tubulin and illuminated with UV light 
at 300 nm. Two samples were created in this process. Sample A had a 10 min exposure to 
the UV light whereas sample B had a 60 min exposure. Rapid loss of epothilone binding 
ability was observed with exposures greater than 60 min due to denaturation of the 
protein. After irradiation, the microtubules were harvested by centrifugation and the 
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samples were frozen and sent to our collaborator Dr. Higgins at the University of 
Minnesota Proteomic Core Facility. Both samples (15 µg each) of the centrifuged 
mixture of microtubules were initially subjected to trypsin digestion. 
 
Figure 3.14. Photoillumination Protocol. 
 
The peptide mixtures were analyzed by 2D LC-ESI-MS330 on an “LTQ Orbitrap Velos” 
mass spectrometer331 in two scan modes: data dependent acquisition (DDA) and full scan 
MS. In DDA mode, peptides are selected for MS/MS (or MS2) acquisition using higher 
energy collision induced dissociation (HCD) activation in an automated fashion from 
MS1 scans with an absolute intensitiy threshold and charge state restriction. In full scan 
mode MS1 data is acquired only. “PEAKS” software (Bioinformatics Solutions) was 
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used for peptide tandem MS data interpretation, which combines de novo peptide 
sequencing with mass-based database searching against a species-specific protein 
sequence dastabase (UniProt Bos taurus taxonomy ID 9913). Peaks results show peptide 
matches, partial peptide matches and protein groups for all detected proteins. Eleven 
alpha and beta tubulin isoforms were detected; amino acid coverage range was 59 – 77%. 
Trypsin digestion of the tubulin preparation yielded many peptides that were not 
amenable to efficient fragmentation by HCD and could not be sequenced. Alternatively, 
the microtubule samples (15 µg each) were subjected to chymotrypsin digestion and 
analyzed as described above for automated interpretation of peptide tandem MS data. 
Nine alpha and beta tubulin isoforms were detected; amino acid coverage range was 63 –
86%. Since probe reactivity is high and non-specific for amino acids and bond-types, the 
search for modified peptides using PEAKS (in the amino acid modification library) was 
not effective and manual interpretation of data was employed.  
Because it was possible that probe-specific fragment ions could exist in the 
peptide tandem MS spectra, the neat probe compounds were subjected to tandem MS in 
order to identify peaks that could assist in manual data interpretation. Firstly, photoprobe 
3.1 was infused into the Orbitrap Velos at 2 µL/min in 80:20, methanol:water at an 
approximate concentration of 2 micromolar and subjected to HCD activation. Probe 
fragmentation produced 135, 141, 164, 176, 178, 304, 316, 386, 404, 474 and 492 m/z 
values in the tandem MS (Figure 3.15). The probe-specific fragment ions were 
subserquently used as ‘signature’ ions in the pursuit of probe-modified peptides during 
the manual inspection of the chymotrypsin peptide data. 
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Figure 3.15. Neat Infusion of Photoprobe 3.1. 
 
Extracted ion chromatograms (XIC’s) for probe-specific ‘signature ion’ peaks 
(m/z values 304, 241 and 164) were generated for every raw MS file; tandem MS that 
contained all the three fragment ions were visually inspected for the presence of 
additional probe specific fragment ions. Two spectra were identified as candidates for 
possible probe-modified peptides. Two spectra with doubly charged precursor ions 
701.34 m/z from sample A and 709.34 m/z from sample B (Figure 3.16), showed 
numerous probe-related signature ions (135, 141, 164, 176, 178, 304, 316, 386, 404, 474, 
492 m/z). The doubly charged precursor values were manually deconvoluted to neutral, 
monoisotopic peptide masses. The difference between the deconvoluted precursor mass 
1416.66 (sample B) and 1400.66 (sample A) is 16 Da, which corresponds to a single 
oxidation. Sample A had light exposure for 10 min whereas sample B was exposed for 60 
min. Therefore it is possible that the extra 50 min could oxidize an amino acid residue of 
a candidate peptide.  Theoretical chymotrypsin neutral, monoisotopic peptide masses for 
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bovine brain beta-tubulin isoform 3 (Q2T9S0 (TBB_BOVIN) from UniProt) was 
generated using “Protein Prospector” with 1 missed cleave site and oxidized methionine 
as a variable modification and copied into Excel. The theoretical monoisotopic mass of 
the probe was added to all peptide masses and the list was compared to the experimental 
peptide masses calculated manually from the spectra with the probe-specific signature 
ions. The doubly charged experimental precursor 701.34 m/z matched the peptide 
TARGSQQY and the doubly charged experimental precursor 709.34 m/z matched the 
oxidized version of peptide TARGSQQY.  
Further examination of the MS/MS with doubly charged ions 701.34 and 709.34 
m/z showed 910.43 and 926.43 as singly charged ions respectively (Figures 3.17 and 
3.18) as the base peaks. The base peaks in both MS/MS spectra represent intact peptide 
[M + H]+1 values, which indicate that the probe (monoisotopic neutral mass 490.23) 
dissociated from the peptide with a neutral loss of 490.23 Da (Figures 3.17 and 3.18). 
Potential dissociation of labile amino acid modifications and loss of site specificity 
information is well documented for certain classes of modified peptides and certain forms 
of peptides. Classical examples include phosophorylated peptide dissociation in ion trap 
and triple quadrupole MS systems332,333 and glycopeptide analysis.334 Further inspection 
of all fragment ions in the tandem MS revealed that probe dissociation was very labile 
and no peptide b- or y-type fragment ions with the probe attached were present, and site 
localization of the probe (to a specific amino acid) was not possible.  However, numerous 
peptide b- or y-type peptide fragment ions formed after probe dissociation, and the amino 
acid sequences were confirmed unambiguously. The observation that the probe easily 
falls off in the MS analysis probably points out that the probe formed a relatively labile 
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covalent bond with the amino acid residues at the binding site. It is highly unlikely for a 
carbene of the probe to form a C–C bond and fall off easiliy in the MS analysis. This 
could mean that the carbene of the probe inserted into an O–H bond of side chains of Thr 
(T), Ser (S) or Tyr (Y) residues forming a C–O bond, which is relatively weaker than the 
C–C bond and hence more prone to falling off during the MS analysis. Alternatively, the 
carbene of the probe could also have possibly inserted into an N–H bond of side chains of 
either Arg (R) or Gln (Q) residues forming a weak C–N bond, before falling off during 
MS analysis.  
 
 
Figure 3.16. Doubly Charged Precursor Ion 709.34 (from Sample B). 
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Figure 3.17. MS/MS of Sample A (Chymotrypsin Digestion) of Photoprobe 3.1.  
 
 
Figure 3.18. MS/MS of Sample B (Chymotrypsin Digestion) of Photoprobe 3.1. 
 
Comparison of the two experimental tandem MS that contained probe-specific ions to the 
peptide fragment “TARGSQQY” in the bovine TBB3 isoform (residues 274 to 281), 
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provided strong support for the peptide match. To address the issue of specificity another 
experiment was carried out. In this experiment the photoprobe 3.1 was incubated with 
preformed microtubules prepared from the electrophoretically homogenized bovine brain 
tubulin with and without a 20-fold excess epothilone B. The two samples were 
simultaneously illuminated with UV light at 300 nm for 5 min. Other than that, the same 
photoillumination protocol was followed as shown in Figure 3.14. The target peptide in 
the specimen “without added epothilone B” was identified. And as expected, the target 
peptide was not found in the specimen “with added epothilone B”. This experiment 
demonstrated the specificity of binding of the analog to microtubules.  
Similar to the photoprobe 3.1, one sample each was prepared from photoprobes 
3.2 and 3.3 by incubation and UV irradiation at 350 nm for 10 minutes. None of the 
samples showed any labeled peptide fragments. Studies were repeated by carrying out the 
UV irradiation at 365 and 300 nm as well to check for a possibility of labeling, but no 
labeling was observed. Finally, the α- and the β-strands of tubulin were isolated and the 
photoprobes 3.2 and 3.3 were exclusively incubated with β-tubulin, followed by UV 
irradiation at 300 nm for 10 min. These samples also failed to show any peptide labeling.  
 
3.6.3 Docking Studies 
Based on the electron crystallography258 and NMR259 models, it is already known that 
Thr274 and Arg276 are necessary for binding of epothilones in the taxol-binding cavity 
of β-tubulin. However, both the models predict a very different conformation of 
epothilone compared to what was found experimentally. The fact that the reactive 
carbene species generated from the photolysis of the photoprobe 3.1 binds to the peptide 
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sequence “TARGSQQY” from amino acids 274 to 281 in TBB3 indicates that the 
thiazole portion of the epothilones must be in vicinity to the aforementioned amino acid 
residues to facilitate the covalent binding upon photoactivation. In order to visualize this 
possibility, we carried out docking studies of the photoprobe 3.1 in a homology model of 
the bovine brain TBB3. Homology modeling was performed using Prime335 and the 
docking simulations were performed using Glide.336 Figure 3.19 shows a 2D model of 
photoprobe 3.1 docked in homology model of bovine brain tubulin TBB3. The C21 of the 
photoprobe 3.1 is within H-bond forming distance from the residue Gln280, making the 
probe possible to bind covalently with the residue upon photolysis.  
           
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Green = Hydrophobic amino acids, Red = Negatively charged amino acids, Blue = 
Positively charged amino acids, Cyan = Amino acids with Coulombic interactions, Gray 
= Solvent exposed 
 
Figure 3.19. 2D Model of Photoprobe 3.1 Docked in Homology Model of Bovine Brain 
Tubulin TBB3. 
 
	   120	  
Figure 3.20 shows a comparison of the 3D conformations of epothilone A based on the 
electron-crystallography model (a), NMR model (b) and the conformation of our the 
photoprobe 3.1 docked in the homology model (c). It can be seen that epothilone still 
occupies the same binding cavity as predicted by the NMR and EC models, however with 
a completely different orientation. In both the EC and the NMR model, the thiazole ring 
is seen in the southwest corner of the binding pocket, whereas in the homology model, 
the thiazole ring of the photoprobe 3.1 is seen in the northeast corner of the binding 
pocket. This change in the orientation of the epothilone helps explain the vicinity of the 
thiazole portion with the region of amino acid residues 270 to 289.  	  a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	  b) 
 
 
 
 
 
 c) 
  
 
 
 
 
Red = oxygen, Blue = nitrogen, Yellow = sulfur, Gray = carbon, hydrogen 
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Figure 3.20. Comparison of Binding Poses of Epothilone A and Photoprobe 3.1. a) 
Epothilone A in β-Tubulin from Electron Crystallography Model, b) Epothilone A in β-
Tubulin from NMR Model, c) Photoprobe 3.1 Docked in Homology Model of Bovine 
Brain Tubulin TBB3. 
 
3.7 Summary and Discussion 
In conclusion, we designed and synthesized epothilone A photoaffinity probes 3.1, 3.2 
and 3.3 but were not able to achieve the synthesis of photoprobe 3.4. Using photoprobe 
3.1 the peptide fragment ‘TARGSQQY’ (from amino acid 274 to 281) in the β-tubulin 
isoform TBB3 was identified.  This data represents the first labeling of β-tubulin by an 
epothilone photoaffinity label. The results from the photolabeling studies with the 
photoprobe 3.1 show a completely different binding mode of epothilones compared to 
what was predicted by both the electron-crystallography and the NMR models. However, 
since the photolabile group in the photoprobe 3.1 was situated on C21 of epothilone, we 
could only get information about the 270–289 region of the β-tubulin. If we had obtained 
any data from the labeling studies of photoprobes 3.2 and 3.3, which have the photolabile 
group at C12–C13 aziridine, then that would have probably given us information about 
other regions of β-tubulin, thereby giving us a global picture of epothilone binding to the 
β-tubulin. Nevertheless, since the photoprobes 3.2 and 3.3 showed excellent cytotoxicity 
and also tubulin assembly activity, we hypothesized that the incorporation of these two 
photolabels into the tubulin protein may have taken place at such a low level that any 
labeled peptide fragments could not be detected in the MS studies. Therefore, additional 
studies are underway with photoprobes 3.2 and 3.3. Very recently the photolabeling 
studies of HeLa and MCF-7 cell line tubulins with the photoprobes 3.2 and 3.3 were 
planned. For this study, our collaborator Dr. Hamel carried out a photoillumination 
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protocol where, he incubated 25 µM of the photoprobe (3.2 and 3.3) with 0.75 M 
glutamate, 100 µM ddGTP, and 2.5 µM of the tubulin. After a 30 min assembly phase at 
37 °C, the samples were exposed to 365 nm UV light. After irradiation, the microtubules 
were harvested by centrifugation and the collected pellet was sent to our collaborator Dr. 
LeeAnn Higgins for further MS studies. We are currently awaiting the results from these 
studies. Additionally, the photolabeling studies with photoprobes 3.2 and 3.3 using 
chicken erythrocyte (CE) tubulin could also be done. The CE tubulin has only one α-1 
and one β-VI isotype, therefore it is less complicated than the bovine brain tubulin and 
hence relatively easier for mass spectrometry analysis. Also, alternatively, the synthesis 
and use of radioactive photoprobes derived from compounds 3.2 and 3.3 is another 
possible approach to detect low levels of labeled peptide fragments that could be pursued 
in the future. 
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Chapter 4 
Experimental Section 
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4.1 General Information 
All starting materials, reagents and anhydrous solvents were purchased and directly used 
without further purification or drying unless otherwise specified. Flash column 
chromatography was carried out on silica gel (230–400 mesh). TLC was conducted on 
silica gel 250 micron, F254 plates. TLC visualization was performed by fluorescence 
quenching or by using stains such as KMnO4, p-anisaldehyde, vanillin and iodine. 1H 
NMR spectra were recorded on a 400 MHz NMR instrument. Chemical shifts are 
reported in ppm relative to chloroform (δ = 7.26 ppm) or with TMS as an internal 
standard (δ = 0.0 ppm). Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, br = broad, m = multiplet), 
integration and coupling constants (Hz). 13C NMR spectra were recorded on a 100 MHz 
NMR spectrometer with complete proton decoupling. Chemical shifts are reported in 
ppm relative to chloroform (d = 77.2 ppm). High-resolution mass spectrometry was 
performed using an electrospray ionization (ESI) technique and analyzed by a time-of-
flight (TOF) mass analyzer. IR spectra were recorded on a FT-IR spectrometer and are 
reported in terms of frequency of absorption (cm-1). 
 
4.2 Chapter 1 
4.2.1 Synthesis of Cyclic Enaminones 1.7 to 1.11 
General procedure: To a solution of 4-methoxypyridine (1.6) (0.50 g, 4.58 mmol, 1.00 
equiv), in of anhydrous THF (70 mL) at –23 °C was added benzyloxycarbonyl chloride 
(0.82 g, 4.81 mmol, 1.05 equiv) dropwise. The mixture was stirred at –23 °C for 1.5 h. To 
this, an appropriate Grignard reagent solution (5.50 mmol, 1.20 equiv) was added 
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dropwise and the resulting mixture was stirred at –23 °C for 2 h. Then, a saturated oxalic 
acid solution (20 mL) was added to quench the reaction and the mixture was allowed to 
warm to rt and stirred for additional 2 h. After this, the aqueous layer was extracted with 
diethyl ether (3 X 50 mL). The combined ether extracts were washed with sat. aq. 
Na2CO3, brine, dried over K2CO3, filtered through Celitepad and concentrated in vacuo.  
 
 
Benzyl 4-Oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (1.7). The residue was 
purified by silica gel flash chromatography (30% EtOAc/hexanes) to afford the title 
compound 1.7 as a colorless oil (1.41 g, 100%). 1H NMR (400 MHz, CDCl3) δ 2.80 (d, 
1H, J = 16 Hz), 3.15 (dd, 1H, J1 = 8 Hz, J2 = 18 Hz), 5.19–5.27 (m, 2H), 5.39 (d, 1H, J 
= 8 Hz), 5.73 (d, 1H, J = 8 Hz), 7.19–7.34 (m, 10H), 7.98 (d, 1H, J = 8 Hz); 13C NMR 
(100 MHz, CDCl3) δ 41.8, 56.0, 69.2, 108.0, 125.9, 128.0, 128.3, 128.6, 128.7, 128.9, 
134.8, 138.4, 142.3, 152.7, 191.1; HRMS calculated for (C19H17NO3) requires m/z 
[M+Na] 330.1106, found m/z 330.1118. 
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Benzyl 2-(4-Methoxyphenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (1.8). 
The residue was purified by silica gel flash chromatography (30% EtOAc/hexanes) to 
furnish the title compound 1.8 as colorless oil (1.16 g, 75%). 1H NMR (400 MHz, CDCl3) 
δ 2.73 (d, 1H, J = 16 Hz), 3.07 (dd, 1H, J1 = 8 Hz, J2 = 16 Hz), 3.72 (s, 3H), 5.17–5.26 
(m, 2H), 5.35 (d, 1H, J = 8 Hz), 5.67 (d, 1H, J = 8 Hz), 6.78 (d, 2H, J = 8 Hz), 7.12 (d, 
2H, J = 8 Hz), 7.26–7.31 (m, 5H), 7.92 (d, 1H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 
41.8, 55.2, 55.4, 69.0, 107.8, 114.1, 127.3, 128.3, 128.4, 128.6, 130.6, 134.9, 142.2, 
152.7, 159.2, 192.1; HRMS calculated for (C20H19NO4) requires m/z [M+Na] 360.1212, 
found m/z 360.1222. 
 
 
Benzyl 2-Ethyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (1.9). The residue was 
purified by silica gel flash chromatography (30% EtOAc/hexanes) to give the title 
compound 1.9 (0.75 g, 65%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 0.84 (t, 
3H, J = 6 Hz), 1.54–1.68 (m, 2H), 2.40 (d, 1H, J = 16 Hz), 2.72 (dd, 1H, J1 = 8 Hz, J2 = 
12 Hz), 4.47–4.48 (m, 1H), 5.23–5.27 (m, 3H), 7.28–7.37 (m, 5H), 7.74 (d, 1H, J = 8 
Hz); 13C NMR (100 MHz, CDCl3) δ 10.2, 23.6, 39.2, 54.6, 68.8, 107.0, 126.7, 128.3, 
128.7, 135.1, 141.6, 152.5, 192.8; HRMS calculated for (C15H17NO3) requires m/z 
[M+Na] 282.1106, found m/z 282.1089. 
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Benzyl 2-(4-Chlorophenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (1.10). The 
residue was purified by silica gel flash chromatography (30% EtOAc/hexanes) to get the 
title compound 1.10 (1.04 g, 66%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 2.68 (d, 
1H, J = 16 Hz), 3.05 (dd, 1H, J1 = 8 Hz, J2 = 16 Hz), 5.15–5.24 (m, 2H), 5.33 (d, 1H, J 
= 8 Hz), 5.65 (d, 1H, J = 4 Hz), 7.09 (d, 2H, J = 8 Hz), 7.18–7.29 (m, 7H), 7.92 (d, 1H, J 
= 8 Hz); 13C NMR (100 MHz, CDCl3) δ 41.5, 55.3, 69.1, 107.8, 127.3, 128.2, 128.6, 
128.7, 128.9, 133.7, 134.7, 137.1, 142.1, 152.4, 191.2; HRMS calculated for 
(C19H16ClNO3) requires m/z [M+Na] 364.0716, found m/z 364.0722. 
 
 
Benzyl 4-Oxo-2-(thiophen-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate (1.11). The 
residue was purified by silica gel flash chromatography (30% EtOAc/hexanes) to yield 
the title compound 1.11 (0.96 g, 67%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 2.79 
(d, 1H, J = 16 Hz), 3.02 (dd, 1H, J1 = 8 Hz, J2 = 16 Hz), 5.23–5.29 (m, 2H), 5.35 (d, 1H, 
J = 8 Hz), 5.91 (d, 1H, J = 8 Hz), 6.81–6.84 (m, 1H), 6.91 (s, 1H), 7.13 (d, 1H, J = 8 
Hz), 7.27–7.34 (m, 5H), 7.72 (d, 1H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 41.5, 
	   128	  
52.0, 69.2, 107.7, 125.4, 126.1, 126.4, 128.4, 128.6, 128.7, 134.7, 140.9, 152.2, 191.6; 
HRMS calculated for (C17H15NO3S) requires m/z [M+Na] 336.0670, found m/z 336.0684. 
 
4.2.2 Synthesis of Piperidinones 1.13 to 1.18 
General Procedure for the Synthesis of Piperidinones 1.13 to 1.18. Dihydropyridones 
1.7 to 1.11 (1.00 equiv) were dissolved in MeOH (0.50 M). 10% Pd/C was added to the 
reaction mixture. The flask was evacuated and filled with hydrogen gas using a hydrogen 
balloon. The reaction mixture was stirred at rt for 12 h and then filtered over a short 
Celite pad and concentrated in vacuo. The crude products obtained were directly used in 
the next step without further purification. Compound 1.18, piperidin-4-one was 
commercially available as a monohydrochloride monohydrate salt and was used directly 
as is.  
 
4.2.3 Synthesis of Piperidinone Sulfonamides 1.19 to 1.36 
General Procedure for the Synthesis of Piperidinone sulfonamides 1.19 to 1.36. To a 
MeCN (0.30 M) solution of piperidinone 1.13 to 1.18 (1.00 equiv), appropriate 
arylsulfonyl chloride (1.20 equiv) and K2CO3 (2.00 equiv) were added. The reaction 
mixture was stirred at rt for 24 h. After the reaction was complete as deemed by the TLC, 
the solvent was removed and EtOAc and water were added to the residue. After 
extraction, the organic layer was separated and dried over Na2SO4 and concentrated in 
vacuo. The crude product thus obtained was then purified by silica gel chromatography to 
furnish the title compound.   
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2-Phenyl-1-tosylpiperidin-4-one (1.19). The residue was purified by silica gel flash 
chromatography (30% EtOAc/hexanes) to afford the title compound 1.19 (338 mg, 64%) 
as a colorless film. 1H NMR (400 MHz, CDCl3) δ 2.20–2.26 (m, 1H), 2.38–2.47 (m, 1H), 
2.68–2.73 (m, 1H), 2.89–2.94 (m, 1H), 3.10–3.18 (m, 1H), 3.97–4.03 (m, 1H), 5.62 (d, 
1H, J = 4 Hz), 7.23–7.35 (m, 7H), 7.82 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 
21.6, 40.3, 43.4, 56.4, 127.1, 127.3, 128.0, 128.8, 130.1, 137.4, 138.4, 144.0, 206.2; 
HRMS calculated for (C18H19NO3S) requires m/z [M+Na] 352.0983, found m/z 352.0998. 
 
 
1-((4-Fluorophenyl)sulfonyl)-2-phenylpiperidin-4-one (1.20). The residue was purified 
by silica gel flash chromatography (30% EtOAc/hexanes) to furnish the title compound 
1.20 (200 mg, 38%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.28–2.33 (m, 1H), 2.45–
2.52 (m, 1H), 2.75–2.81 (m, 1H), 2.92–2.97 (m, 1H), 3.14–3.22 (m, 1H), 3.97–4.03 (m, 
1H), 5.61 (d, 1H, J = 8 Hz), 7.18–7.23 (m, 4H), 7.24–7.31 (m, 3H), 7.91–7.94 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 40.4, 40.5, 43.8, 56.6, 116.8, 127.2, 128.2, 128.9, 129.9, 
136.5, 138.1, 166.5, 205.8; HRMS calculated for (C17H16ClNO3S) requires m/z [M+Na] 
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356.0773, found m/z 356.0779. 
 
 
1-((4-Chlorophenyl)sulfonyl)-2-phenylpiperidin-4-one (1.21). The residue was 
purified by silica gel flash chromatography (30% EtOAc/hexanes) to yield the title 
compound 1.21 (190 mg, 34%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.28–2.32 (m, 
1H), 2.44–2.52 (m, 1H), 2.73–2.79 (m, 1H), 2.92–2.97 (m, 1H), 3.15–3.22 (m, 1H), 3.96–
4.03 (m, 1H), 5.61 (d, 1H, J = 8 Hz), 7.18–7.20 (m, 2H), 7.26–7.32 (m, 3H), 7.50 (d, 2H, 
J = 8 Hz), 7.84 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 40.4, 40.5, 43.8, 56.6, 
127.2, 128.2, 128.5, 128.9, 129.7, 138.0, 138.9, 139.5, 205.7; HRMS calculated for 
(C17H16ClNO3S) requires m/z [M+Na] 372.0437, found m/z 372.0444. 
 
 
2-(4-Methoxyphenyl)-1-tosylpiperidin-4-one (1.22). The residue was purified by silica 
gel chromatography (30% EtOAc/hexanes) to get the title compound 1.22 (59 mg, 48%) 
as a film. 1H NMR (400 MHz, CDCl3) δ 2.21–2.25 (m, 1H), 2.38–2.47 (m, 4H), 2.66–
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2.72 (m, 1H), 2.86–2.91 (m, 1H), 3.09–3.16 (m, 1H), 3.77 (s, 3H), 3.96–4.03 (m, 1H), 
5.58 (d, 1H, J = 8 Hz), 6.81 (d, 2H, J = 8 Hz), 7.15 (d, 2H, J = 8 Hz), 7.34 (d, 2H, J = 8 
Hz), 7.82 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 21.6, 40.1, 40.3, 43.6, 55.3, 
56.0, 114.1, 127.1, 128.6, 130.1, 130.3, 137.6, 144.0, 159.3, 206.4; HRMS calculated for 
(C19H21NO4S) requires m/z [M+Na] 382.1089, found m/z 382.1098. 
 
 
1-((4-Fluorophenyl)sulfonyl)-2-(4-methoxyphenyl)piperidin-4-one (1.23). The residue 
was purified by silica gel chromatography (gradient, 10–25% EtOAc/hexanes) to give the 
title compound 1.23 (41 mg, 23%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.28–2.33 
(m, 1H), 2.46–2.54 (m, 1H), 2.75–2.80 (m, 1H), 2.90–2.94 (m, 1H), 3.12–3.20 (m, 1H), 
3.78 (s, 3H), 3.95–4.02 (m, 1H), 5.57 (d, 1H, J = 8 Hz), 6.81 (d, 2H, J = 8 Hz), 7.09 (d, 
2H, J = 8 Hz), 7.20–7.24 (m, 2H), 7.91–7.94 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
40.2, 40.6, 44.0, 55.3, 56.2, 114.2, 116.8, 128.6, 129.8, 136.6, 159.4, 163.9, 206.1; 
HRMS calculated for (C18H18FNO4S) requires m/z [M+Na] 386.0838, found m/z 
386.0852. 
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1-((4-Chlorophenyl)sulfonyl)-2-(4-methoxyphenyl)piperidin-4-one (1.24). The residue 
was purified by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to afford 
the title compound 1.24 (37 mg, 20%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.24–2.28 
(m, 1H), 2.40–2.49 (m, 1H), 2.69–2.74 (m, 1H), 2.88–2.92 (m, 1H), 3.10–3.18 (m, 1H), 
3.77 (s, 3H), 3.99–4.04 (m, 1H), 5.60 (d, 1H, J = 8 Hz), 6.81 (d, 2H, J = 8 Hz), 7.12 (d, 
2H, J = 8 Hz), 7.56 (d, 2H, J = 8 Hz), 7.93 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, 
CDCl3) δ 40.1, 40.4, 43.7, 55.3, 56.1, 114.1, 127.1, 128.6, 129.5, 130.1, 133.1, 140.6, 
159.3, 206.4; HRMS calculated for (C18H18ClNO4S) requires m/z [M+Na] 402.0543, 
found m/z 402.0533. 
 
 
2-Ethyl-1-tosylpiperidin-4-one (1.25). The residue was purified by silica gel 
chromatography (gradient, 10–30% EtOAc/hexanes) to furnish the title compound 1.25 
(388 mg, 44%) as a film. 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 8 Hz), 1.40–1.48 
(m, 2H), 2.20–2.27 (m, 2H), 2.34–2.39 (m, 1H), 2.43 (s, 3H), 2.50–2.55 (m, 1H), 3.23–
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3.30 (m, 1H), 4.11–4.17 (m, 1H), 4.27–4.32 (m, 1H), 7.33 (d, 2H, J = 8 Hz), 7.78 (d, 2H, 
J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 10.5, 21.5, 25.4, 40.0, 40.3, 45.1, 56.1, 127.0, 
130.0, 137.6, 143.8, 206.5; HRMS calculated for (C14H19NO3S) requires m/z [M+Na] 
304.0983, found m/z 304.0985. 
 
 
2-Ethyl-1-((4-fluorophenyl)sulfonyl)piperidin-4-one (1.26). The residue was purified 
by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to yield the title 
compound 1.26 (219 mg, 51%) as a film. 1H NMR (400 MHz, CDCl3) δ 0.80 (t, 3H, J = 8 
Hz), 1.41–1.49 (m, 2H), 2.26–2.32 (m, 2H), 2.40–2.45 (m, 1H), 2.56–2.61 (m, 1H), 3.23–
3.31 (m, 1H), 4.11–4.16 (m, 1H), 4.26–4.31 (m, 1H), 7.20–7.24 (m, 2H), 7.90–7.94 (m, 
2H); 13C NMR (100 MHz, CDCl3) δ 10.5, 25.4, 40.0, 40.5, 45.3, 56.2, 116.7, 129.8, 
136.6, 166.4, 206.2; HRMS calculated for (C13H16FNO3S) requires m/z [M+Na] 
308.0733, found m/z 308.0740. 
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1-((4-Chlorophenyl)sulfonyl)-2-ethylpiperidin-4-one (1.27). The residue was purified 
by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to provide the title 
compound 1.27 (200 mg, 50%) as a film. 1H NMR (400 MHz, CDCl3) δ 0.80 (t, 3H, J = 8 
Hz), 1.42–1.46 (m, 2H), 2.26–2.32 (m, 2H), 2.39–2.48 (m, 1H), 2.55–2.58 (m, 1H), 3.24–
3.30 (m, 1H), 4.10–4.15 (m, 1H), 4.28–4.31 (m, 1H), 7.51 (d, 2H, J = 8 Hz), 7.84 (d, 2H, 
J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 10.5, 25.4, 40.0, 40.4, 45.3, 56.3, 128.5, 129.7, 
139.3, 139.4, 206.3; HRMS calculated for (C13H16ClNO3S) requires m/z [M+Na] 
324.0437, found m/z 324.0444. 
 
 
2-(4-Chlorophenyl)-1-tosylpiperidin-4-one (1.28). The residue was purified by silica 
gel chromatography (gradient, 10–30% EtOAc/hexanes) to afford the title compound 
1.28 (39 mg, 30%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.22–2.27 (m, 1H), 2.40–
2.48 (m, 4H), 2.69–2.75 (m, 1H), 2.91–2.95 (m, 1H), 3.10–3.18 (m, 1H), 3.98–4.04 (m, 
1H), 5.63 (d, 1H, J = 8 Hz), 7.23 (d, 2H, J = 8 Hz), 7.30 (d, 2H, J = 8 Hz), 7.35 (d, 2H, J 
= 8 Hz), 7.82 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 21.6, 40.3 (2C), 43.4, 
56.4, 127.1, 127.3, 128.0, 128.8, 130.1, 137.5, 138.3, 144.0, 206.3; HRMS calculated for 
(C18H18ClNO3S) requires m/z [M+Na] 386.0594, found m/z 386.0601. 
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2-(4-Chlorophenyl)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one (1.29). The residue 
was purified by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to furnish 
the title compound 1.29 (96 mg, 69%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.30–2.33 
(m, 1H), 2.49–2.50 (m, 1H), 2.78–2.80 (m, 1H), 2.94–2.97 (m, 1H), 3.16–3.21 (m, 1H), 
3.99–4.01 (m, 1H), 5.61 (d, 1H, J = 8 Hz), 7.19 (m, 4H), 7.28 (m, 2H), 7.92 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 40.4 (2C), 43.8, 56.6, 116.8, 127.2, 128.2, 128.9, 129.9, 
136.4, 138.1, 166.5, 205.8; HRMS calculated for (C17H15ClFNO3S) requires m/z [M+Na] 
390.0343, found m/z 390.0339. 
 
 
2-(4-Chlorophenyl)-1-((4-chlorophenyl)sulfonyl)piperidin-4-one (1.30). The residue 
was purified by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to give the 
title compound 1.30 (38 mg, 31%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.30–2.34 
(m, 1H), 2.47–2.55 (m, 1H), 2.76–2.79 (m, 1H), 2.95–2.98 (m, 1H), 3.15–3.21 (m, 1H), 
3.98–4.01 (m, 1H), 5.61 (d, 1H, J = 8 Hz), 7.18 (m, 2H), 7.29 (m, 2H), 7.51 (m, 2H), 7.83 
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(m, 2H); 13C NMR (100 MHz, CDCl3) δ 40.5 (2C), 43.8, 56.6, 127.2, 128.2, 128.5, 
128.9, 129.7, 138.0, 138.9, 139.6, 205.7; HRMS calculated for (C17H15Cl2NO3S) requires 
m/z [M+Na] 406.0047, found m/z 406.0039. 
 
 
1-Tosylpiperidin-4-one (1.31). The residue was purified by silica gel chromatography 
(gradient, 10–30% EtOAc/hexanes) to get the title compound 1.31 (376 mg, 91%) as a 
film. 1H NMR (400 MHz, CDCl3) δ 2.39 (s, 3H), 2.47–2.50 (m, 4H), 3.32–3.35 (m, 4H), 
7.30 (d, 2H, J = 8 Hz), 7.63 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 21.5, 40.6, 
45.8, 127.5, 129.9, 133.3, 144.1, 205.6; HRMS calculated for (C12H15NO3S) requires m/z 
[M+Na] 276.0670, found m/z 276.0673. 
 
 
1-((4-Fluorophenyl)sulfonyl)piperidin-4-one (1.32). The residue was purified by silica 
gel chromatography (gradient, 10–30% EtOAc/hexanes) to afford the title compound 
1.32 (389 mg, 93%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.54–2.57 (m, 4H), 3.39–
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3.42 (m, 4H), 7.22–7.27 (m, 2H), 7.81–7.85 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
40.6, 45.8, 116.5, 116.8, 130.2, 130.3, 132.6, 166.6, 205.2; HRMS calculated for 
(C11H12FNO3S) requires m/z [M+Na] 280.0420, found m/z 280.0422. 
 
 
1-((4-Chlorophenyl)sulfonyl)piperidin-4-one (1.33). The residue was purified by silica 
gel chromatography (gradient, 10–30% EtOAc/hexanes) to provide the title compound 
1.33 (760 mg, 85%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.53–2.56 (m, 4H), 3.39–
3.42 (m, 4H), 7.54 (d, 2H, J = 8 Hz), 7.75 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, 
CDCl3) δ 40.5, 45.7, 128.9, 129.6, 135.0, 139.7, 205.1; HRMS calculated for 
(C11H12ClNO3S) requires m/z [M+Na] 296.0124, found m/z 296.0126. 
 
 
2-(Thiophen-2-yl)-1-tosyl-2,3-dihydropyridin-4(1H)-one (1.34). The residue was 
purified by silica gel chromatography (gradient, 10–30% EtOAc/hexanes) to furnish the 
title compound 1.34 (0.18 g, 52%) as a film. 1H NMR (400 MHz, CDCl3) δ 2.40 (s, 3H), 
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2.70 (dd, 1H, J1 = 6.6 Hz, J2 = 16.6 Hz), 2.83 (dd, 1H, J1 = 6.6 Hz, J2 = 16.6 Hz), 5.44 (d, 
1H, J = 9.3 Hz), 5.79 (d, 1H, J = 6.6 Hz), 6.81 (dd, 1H, J1 = 3.6 Hz, J2 = 5.1 Hz), 6.90 (d, 
1H, J = 3.5 Hz), 7.11 (dd, 1H, J1 = 1.1 Hz, J2 = 5.1 Hz), 7.25 (d, 2H, J = 8.2 Hz), 7.60–
7.65 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 21.6, 42.2, 54.3, 108.5, 125.9, 126.3, 126.9, 
127.0, 130.1, 135.5, 139.9, 141.5, 145.0, 190.3; HRMS calculated for (C16H15NO3S2) 
requires m/z [M+Na] 356.0391, found m/z 356.0398. 
 
 
1-((4-Fluorophenyl)sulfonyl)-2-(thiophen-2-yl)-2,3-dihydropyridin-4(1H)-one (1.35) 
The residue was purified by silica gel chromatography (gradient, 10–30% 
EtOAc/hexanes) to get the title compound 1.35 (0.15 g, 43%) as a film. 1H NMR (400 
MHz, CDCl3) δ 2.71 (dd, 1H, J1 = 6.8 Hz, J2 = 16.5 Hz), 2.95 (dd, 1H, J1 = 6.8 Hz, J2 = 
16.5 Hz), 5.49 (d, 1H, J = 8.4 Hz), 5.84 (d, 1H, J = 6.5 Hz), 6.80 (m, 1H), 6.89 (d, 1H, J 
= 3.1 Hz), 7.09 (m, 3H), 7.64 (d, 1H, J = 8.4 Hz), 7.69–7.72 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 42.7, 54.6, 108.8, 116.6, 126.1, 126.3, 127.1, 129.9, 134.4, 139.5, 141.2, 
166.8, 190.1; HRMS calculated for (C15H12FNO3S2) requires m/z [M+Na] 360.0140, 
found m/z 360.0145. 
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1-((4-Chlorophenyl)sulfonyl)-2-(thiophen-2-yl)-2,3-dihydropyridin-4(1H)-one (1.36). 
The residue was purified by silica gel chromatography (gradient, 10–30% 
EtOAc/hexanes) to give the title compound 1.36 (0.20 g, 55%) as a film. 1H NMR (400 
MHz, CDCl3) δ 2.71 (dd, 1H, J1 = 6.8 Hz, J2 = 16.5 Hz), 2.94 (dd, 1H, J1 = 6.8 Hz, J2 = 
16.5 Hz), 5.49 (d, 1H, J = 9.3 Hz), 5.83 (d, 1H, J = 6.7 Hz), 6.80 (dd, 1H, J1 = 3.6 Hz, J2 
= 5.0 Hz), 6.89 (d, 1H, J = 3.4 Hz), 7.10 (dd, 1H, J1 = 1.1 Hz, J2 = 5.1 Hz). 7.38 (d, 2H, J 
= 8.7 Hz), 7.61–7.64 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 42.6, 54.6, 108.9, 126.1, 
126.3, 127.1, 128.4, 129.6, 136.8, 139.4, 140.5, 141.1, 190.0; HRMS calculated for 
(C15H12ClNO3S2) requires m/z [M+Na] 375.9845, found m/z 375.9847. 
 
4.3 Chapter 2 
For chapter 2 experiments, the 19F NMR spectra for the optimization reactions were 
recorded at 376 MHz and were referenced based on the internal standard C6F6 (d = –
161.7 ppm); all reactions were carried out in clear 2–dram vials used after drying; all the 
reported yields are averages of at least two experimental runs. 
 
4.3.1 Synthesis of Starting Enaminones 
Cyclic enaminones for preparing compounds 2.2, 2.14, 2.16–2.18 and 1,3,-dimethyluracil 
for the synthesis of compound 2.15, were commercially available. The other cyclic 
	   140	  
enaminones were prepared according to the reported procedures6,8,10,96,337-339 by former 
group member Dr. Yiyun Yu. 
 
4.3.2 Synthesis of 5-Trifluoromethylated Cyclic Enaminones 
General Procedures for the C5–Trifluoromethylation of Cyclic Enaminones:  
In a 2-dram PTFE sealed glass vial the enaminone (0.1 mmol) and PhI(OAc)2 (64.4 mg, 
0.2 mmol) were added. The glass vial was transferred to a glove box to add KF (23.5 mg, 
0.4 mmol). The vial was then capped and taken out of the glove box. TMSCF3 (59.7 µL, 
0.4 mmol) and anhydrous MeCN (1.0 mL) were added by syringes. The reaction mixture 
was then stirred at rt for 24 h. After completion of the reaction, the mixture was diluted 
by addition of acetone, filtered over a pad of Celite and eluted with acetone. After the 
eluent was concentrated in vacuo, the residue was purified by silica gel chromatography 
(0-100% EtOAc/hexanes, gradient) using the Combiflash Rf system, to give the desired 
compounds 2.2–2.18. 
 
1-Benzyl-2-(4-methoxyphenyl)-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one 
(2.2). The title compound 2.2 was obtained as a yellow oil (21.3 mg, 59%). IR (thin film) 
2925, 1658, 1618, 1513, 1394, 1357, 1326, 1253, 1122, 1030 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 2.69 (dd, 1H, J = 16.5, 6.6 Hz), 2.89 (dd, 1H, J = 16.5, 7.3), 3.81 (s, 3H), 4.25 
(d, 1H, J = 15.0 Hz), 4.43 (d, 1H, J = 15.0 Hz), 4.51 (t, 1H, J = 7.0), 6.88 (d, 2H, J = 8.6 
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Hz), 7.10–7.14 (m, 4H) 7.35–7.42 (m, 3H), 7.73 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
43.3, 55.4, 58.1, 59.7, 100.0 (q, J = 29.8 Hz), 114.7, 123.9 (d, J = 268.0 Hz), 127.7, 
128.2, 128.8, 129.1, 130.4, 134.6, 152.5 (q, J = 5.4 Hz), 159.9, 185.2; 19F NMR (376 
MHz, CDCl3) δ –60.9 (s, 3F); HRMS calculated for (C20H18F3NO2) requires m/z [M+Na] 
384.1182, found m/z 384.1187. 
 
 
1-Benzyl-2-isopropyl-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.3). The 
title compound 2.3 was obtained as a yellow oil (23.2 mg, 78%). IR (thin film) 2967, 
1655, 1618, 1454, 1396, 1351, 1329, 1099, 1024, 700 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 0.97 (d, 3H, J = 6.8 Hz), 1.00 (d, 3H, J = 6.9 Hz), 2.21–2.31 (m, 1H), 2.48 (dd, 1H, J = 
16.7, 7.7 Hz), 2.62 (dd, 1H, J = 16.7, 7.7 Hz), 3.29–3.32 (m, 1H), 4.49–4.61 (m, 2H), 
7.28 (d, 2H, J = 7.3 Hz), 7.37–7.45 (m, 3H), 7.61 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
17.8, 19.6, 29.2, 36.5, 59.6, 61.3, 99.5 (q, J = 30.1 Hz), 124.0 (q, J = 270.0 Hz), 127.4, 
128.8, 129.3, 135.3, 151.8 (q, J = 5.4 Hz), 185.9; 19F NMR (376 MHz, CDCl3) δ –60.8 (s, 
3F); HRMS calculated for (C16H18F3NO) requires m/z [M+Na] 320.1233, found m/z 
320.1238. 
 
	   142	  
 
3-(Trifluoromethyl)-1,6,7,8,9,9a-hexahydro-2H-quinolizin-2-one (2.4). The title 
compound 2.4 was obtained as a pale yellow oil (14.5 mg, 66%). IR (thin film) 2943, 
2862, 1655, 1620, 1450, 1397, 1372, 1346, 1214, 1184, 1139, 1102, 999 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 1.40–1.67 (m, 3H), 1.81–1.92 (m, 3H), 2.41 (dd, 1H, J = 16.6, 5.9 
Hz), 2.60 (dd, 1H, J = 16.5, 12.1 Hz), 3.16–3.23 (m, 1H), 3.43–3.54 (m, 2H), 7.34 (s, 
1H); 13C NMR (100 MHz, CDCl3) δ 22.9, 25.7, 31.6, 42.6, 53.9, 56.6, 100.5 (q, J = 29.8 
Hz), 123.8 (q, J = 270.0 Hz), 152.7 (q, J = 5.5 Hz), 186.4; 19F NMR (376 MHz, CDCl3) δ 
–61.1 (s, 3F); HRMS calculated for (C10H12F3NO) requires m/z [M+Na] 242.0763, found 
m/z 242.0763. 
 
 
(4aR*,8aR*)-1-Methyl-3-(trifluoromethyl)-4a,5,6,7,8,8a-hexahydroquinolin-4(1H)-
one (2.5). The title compound 2.5 was obtained as a colorless oil (14.2 mg, 61%). IR 
(thin film) 3046, 2946, 2867, 1641, 1618, 1441, 1388, 1355, 1319, 1311, 1179, 1119, 
1096, 1073 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.03–1.20 (m, 2H), 1.26–1.33 (m, 1H), 
1.37–1.46 (m, 1H), 1.83 (d, 1H, J = 12.5 Hz), 1.89 (d, 1H, J = 12.6 Hz), 2.08–2.14 (m, 
1H), 2.23–2.27 (m, 1H), 2.43 (d, 1H, J = 12.8 Hz), 3.09 (s, 3H), 3.12–3.19 (m, 1H), 7.44 
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(s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.3, 24.4, 24.5, 30.0, 40.0, 48.0, 61.2, 100.0 (q, 
J = 29.5 Hz), 124.0 (q, J = 269.8 Hz), 153.4 (q, J = 5.5 Hz), 188.4; 19F NMR (376 MHz, 
CDCl3) δ –60.9 (s, 3F); HRMS calculated for (C11H14F3NO) requires m/z [M+Na] 
256.0920, found m/z 256.0919. 
 
 
1-Benzyl-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.6). The title compound 
2.6 was obtained as a pale yellow oil (17.1 mg, 67%). IR (thin film) 3033, 1655, 1619, 
1453, 1399, 1361, 1334, 1253, 1148, 1121, 1098, 1017 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 2.51 (t, 2H, J = 7.8 Hz), 3.47 (t, 2H, J = 7.8 Hz), 4.50 (s, 2H), 7.28 (d, 2H, J = 
7.0 Hz), 7.37–7.45 (m, 3H), 7.65 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 35.1, 46.0, 60.6, 
100.3 (q, J = 29.8 Hz), 124.0 (q, J = 270.0 Hz), 127.7, 128.9, 129.3, 134.3, 152.6 (q, J = 
5.5 Hz), 186.0; 19F NMR (376 MHz, CDCl3) δ –60.9 (s, 3F); HRMS calculated for 
(C13H12F3NO) requires m/z [M+Na] 278.0763, found m/z 278.0774. 
 
 
1-Phenyl-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.7). The title compound 
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2.7 was obtained as a pale yellow oil (19.5 mg, 81%). IR (thin film) 1666, 1619, 1590, 
1497, 1396, 1354, 1324, 1267, 1127, 1045, 1012, 755, 695, 605 cm–1; 1H NMR (400 
MHz, CDCl3) δ 2.67 (t, 2H, J = 7.6 Hz), 4.04 (t, 2H, J = 7.6 Hz), 7.14 (d, 2H, J = 8.2 
Hz), 7.23 (t, 1H, J = 6.9 Hz), 7.39 (t, 2H, J = 7.8 Hz), 7.80 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 35.6, 47.9, 103.6 (q, J = 30.0 Hz), 119.5, 123.5 (q, J = 270.0 Hz), 126.3, 129.9, 
144.4, 149.4 (q, J = 5.7 Hz), 186.3; 19F NMR (376 MHz, CDCl3) δ –61.4 (s, 3F); HRMS 
calculated for (C12H10F3NO) requires m/z [M+Na] 264.0607, found m/z 264.0608. 
 
 
1-(3-((tert-Butyldimethylsilyl)oxy)propyl)-2-phenyl-5-(trifluoromethyl)-2,3-
dihydropyridin-4(1H)-one (2.8). The title compound 2.8 was obtained as a yellow oil 
(16.5 mg, 40%). IR (thin film) 2954, 2930, 2858, 1661, 1619, 1452, 1396, 1346, 1326, 
1258, 1154, 1102, 972, 837, 777, 699 cm–1; 1H NMR (400 MHz, CDCl3) δ 0.00 (s, 6H), 
0.84 (s, 9H), 1.66–1.72 (p, 2H, J = 6.6, 6.2 Hz), 2.69 (dd, 1H, J = 16.5, 6.2 Hz), 2.94 (dd, 
1H, J = 16.5, 7.4 Hz), 3.28 (dt, 1H, J = 13.6, 6.1 Hz), 3.41 (dt, 1H, J = 14.6, 7.5 Hz), 3.60 
(qt, 2H, J = 10.8, 5.4 Hz), 4.66 (t, 1H, J = 6.8 Hz), 7.21 (d, 2H, J = 6.9 Hz), 7.30–7.35 
(m, 3H), 7.63 (s, 1H); 13C NMR (100 MHz, CDCl3) δ –5.5, 18.1, 25.8, 31.2, 43.2, 51.1, 
58.7, 60.6, 100.0 (q, J = 30.0 Hz), 123.9 (q, J = 270.0 Hz), 126.6, 128.8, 129.3, 137.4, 
152.9 (q, J = 5.4 Hz), 184.7; 19F NMR (376 MHz, CDCl3) δ –60.8 (s, 3F); HRMS 
calculated for (C21H30F3NO2Si) requires m/z [M+Na] 436.1896, found m/z 436.1903. 
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1-Benzyl-6-phenyl-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.9). The title 
compound 2.9 was obtained as a pale yellow oil (24.8 mg, 75%). IR (thin film) 3031, 
2918, 1652, 1533, 1463, 1439, 1383, 1322, 1255, 1240, 1119, 1092, 766, 701 cm–1; 1H 
NMR (400 MHz, CDCl3) δ 2.45 (t, 2H, J = 7.2 Hz), 3.67 (t, 2H, J = 7.2 Hz), 4.28 (s, 2H), 
7.14 (d, 2H, J = 7.1 Hz), 7.31–7.36 (m, 5H), 7.42–7.51 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 36.0, 46.9, 55.6, 102.9 (q, J = 27.8 Hz), 124.4 (q, J = 270.0 Hz), 127.2, 127.9, 
128.4, 128.8, 129.1, 130.2, 133.2, 135.9, 165.0, 187.9; 19F NMR (376 MHz, CDCl3) δ –
52.3 (s, 3F); HRMS calculated for (C19H16F3NO) requires m/z [M+Na] 354.1076, found 
m/z 354.1083. 
 
 
tert-Butyl 4-oxo-5-(trifluoromethyl)-3,4-dihydropyridine-1(2H)-carboxylate (2.10). 
The title compound 2.10 was obtained as a yellow oil (17.5 mg, 66%). IR (thin film) 
2983, 1741, 1687, 1625, 1387, 1372, 1322, 1279, 1261, 1248, 1124, 1049, 1012, 883, 
842, 759, 735, 684 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.56 (s, 9H), 2.62 (t, 2H, J = 7.4 
Hz), 4.01 (t, 2H, J = 7.4 Hz), 8.31 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 27.9, 35.4, 
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42.2, 85.3, 107.9 (q, J = 30.4 Hz), 122.5 (q, J = 271.3 Hz), 144.9 (q, J = 6.3 Hz), 150.5, 
187.7; 19F NMR (376 MHz, CDCl3) δ –62.9 (s, 3F); HRMS calculated for (C11H14F3NO3) 
requires m/z [M+Na] 288.0818, found m/z 288.0820. 
 
 
Benzyl 4-Oxo-5-(trifluoromethyl)-3,4-dihydropyridine-1(2H)-carboxylate (2.11). The 
title compound 2.11 was obtained as a colorless to pale yellow oil (18.3 mg, 61%). IR 
(thin film) 2984, 1742, 1687, 1627, 1388, 1322, 1270, 1238, 1206, 1135, 1049, 1002, 
952, 756, 699 cm–1; 1H NMR (400 MHz, CDCl3) δ 2.64 (t, 2H, J = 7.4 Hz), 4.09 (t, 2H, J 
= 7.4 Hz), 5.32 (s, 2H), 7.41 (s, 5H), 8.36 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 35.4, 
42.5, 70.1, 109.0 (q, J = 30.1 Hz), 122.3 (q, J = 271.5 Hz), 128.8, 128.9, 129.2, 134.2, 
144.4 (q, J = 5.9 Hz), 152.0, 187.4; 19F NMR (376 MHz, CDCl3) δ –63.0 (s, 3F); HRMS 
calculated for (C14H12F3NO3) requires m/z [M+Na] 322.0661, found m/z 322.0668. 
 
 
2-Phenyl-5-(trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.12). The title 
compound 2.12 was obtained as a colorless flaky semi-solid to sticky oil (5.5 mg, 23%). 
IR (thin film) 3219, 1640, 1599, 1539, 1388, 1358, 1322, 1271, 1246, 1197, 1106, 1021, 
	   147	  
746, 699, 606, 543 cm–1; 1H NMR (400 MHz, CDCl3) δ 2.61 (dd, 1H, J = 16.4, 5.1 Hz), 
2.78 (dd, 1H, J = 16.3, 5.1 Hz), 4.82 (dd, 1H, J = 14.1, 5.0 Hz), 5.80 (br s, 1H), 7.34–7.44 
(m, 5H), 7.72 (d, 1H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 43.8, 57.9, 102.0 (q, J 
= 30.2 Hz), 123.7 (q, J = 268.0 Hz), 126.5, 129.1, 129.3, 138.4, 150.2 (q, J = 5.5 Hz), 
186.7; 19F NMR (376 MHz, CDCl3) δ –61.4 (s, 3F); HRMS calculated for (C12H10F3NO) 
requires m/z [M+Na] 264.0607, found m/z 264.0600. 
 
 
1-Benzyl-3-(trifluoromethyl)pyridin-4(1H)-one (2.13). The title compound 2.13 was 
obtained as a colorless to pale yellow oil (11.5 mg, 45%). IR (thin film) 1662, 1593, 
1490, 1456, 1335, 1208, 1161, 1123, 1054, 838, 733, 700 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 5.02 (s, 2H), 6.52 (d, J = 7.7 Hz, 1H), 7.21–7.23 (m, 2H), 7.38–7.46 (m, 4H), 
7.79 (s, 1H); 13C NMR (100 MHz, CDCl3) 60.8, 119.1 (q, J = 29.5 Hz), 121.4, 125.6 (q, J 
= 270.8 Hz), 127.6, 129.5, 129.6, 133.7, 139.8 (q, J = 6.4 Hz), 140.5, 174.0; 19F NMR 
(376 MHz, CDCl3) δ –65.2 (s, 3F); HRMS calculated for (C13H10F3NO) requires m/z 
[M+Na] 276.0607, found m/z 276.0615. 
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1-Methyl-3-(trifluoromethyl)quinolin-4(1H)-one (2.14). The title compound 2.14 was 
obtained as a white to very pale yellow oil (10.0 mg, 44%). IR (thin film) 1644, 1596, 
1508, 1477, 1367, 1251, 1228, 1175, 1112, 1081, 879, 760, 704 cm–1; 1H NMR (400 
MHz, CDCl3) δ 3.88 (s, 3H), 7.46 (m, 2H), 7.74 (m, 1H), 7.93 (s, 1H), 8.48 (d, 1H, J = 
8.0 Hz); 13C NMR (100 MHz, CDCl3) δ 41.3, 100.0, 110.9 (q, J = 29.5 Hz), 115.6, 120.8 
(q, J = 270.2 Hz), 125.1, 127.2, 127.6, 133.2, 140.3, 142.9 (q, J = 6.1 Hz), 173.8; 19F 
NMR (376 MHz, CDCl3) δ –63.6 (s, 3F); HRMS calculated for (C11H8F3NO) requires 
m/z [M+Na] 250.0450, found m/z 250.0457. 
 
 
1,3-Dimethyl-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.15). The title 
compound 2.15 was obtained as a colorless oil (9.6 mg, 46%) (61% bsrm). The spectral 
data of the title compound was in agreement with those found in the literature.164 IR (thin 
film) 3082, 1720, 1674, 1492, 1459, 1385, 1326, 1212, 1127, 1019, 782, 759, 699 cm–1; 
1H NMR (400 MHz, CDCl3) δ 3.36 (s, 3H), 3.48 (s, 3H), 7.67 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 28.0, 37.7, 104.1 (q, J = 33.0 Hz), 122.0 (q, J = 270.0 Hz), 143.5 (q, J = 
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5.8 Hz), 150.9, 158.7; 19F NMR (376 MHz, CDCl3) δ –63.8 (s, 3F); HRMS calculated for 
(C7H7F3N2O2) requires m/z [M+Na] 231.0352, found m/z 231.0357. 
 
 
3-Amino-2-(trifluoromethyl)cyclohex-2-en-1-one (2.16). The title compound 2.16 was 
obtained as a yellow ochre oil (4.7 mg, 26%). IR (thin film) 3212, 1663, 1601, 1552, 
1443, 1102 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.62 (br s, 2H), 1.97 (p, 2H, J = 6.4 Hz), 
2.39 (t, 2H, J = 6.5 Hz), 2.51 (t, 2H, J = 6.2 Hz); 13C NMR (100 MHz, CDCl3) δ 20.3, 
31.8, 37.1, 104.1 (q, J = 34.7 Hz), 125.6 (d, J = 270.0 Hz), 163.2, 192.5; 19F NMR (376 
MHz, CDCl3) δ –55.4 (s, 3F); HRMS calculated for (C7H8F3NO) requires m/z [M+Na] 
202.0450, found m/z 202.0451. 
 
 
5,5-Dimethyl-3-(methylamino)-2-(trifluoromethyl)cyclohex-2-en-1-one (2.17). The 
title compound 2.17 was obtained as a yellow oil (5.8 mg, 26%). IR (thin film) 3216, 
2960, 1636, 1575, 1470, 1411, 1338, 1240, 1095 cm–1; 1H NMR (400 MHz, CDCl3) δ 
1.09 (s, 6H), 1.65 (br s, 1H), 2.23 (s, 2H), 2.38 (s, 2H), 2.99 (d, 3H, J = 5.0 Hz); 13C 
NMR (100 MHz, CDCl3) δ 28.3, 30.6, 30.8, 50.3, 98.9 (d, J = 25.1 Hz), 125.8 (d, J = 
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274.0 Hz), 164.1, 191.4; 19F NMR (376 MHz, CDCl3) δ –54.1 (s, 3F); HRMS calculated 
for (C10H14F3NO) requires m/z [M+Na] 244.0920, found m/z 244.0921. 
 
 
3-(Dimethylamino)-5,5-dimethyl-2-(trifluoromethyl)cyclohex-2-en-1-one (2.18). The 
title compound 2.18 was obtained as a yellow oil (8.5 mg, 36%). IR (thin film) 2958, 
1634, 1558, 1415, 1330, 1252, 1217, 1157, 1080, 1006 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 1.07 (s, 6H), 2.17 (s, 2H), 2.41 (s, 2H), 3.08 (s, 6H); 13C NMR (100 MHz, 
CDCl3) δ 28.4, 29.8, 43.5, 44.0, 49.9, 100.1 (q, J = 28.3 Hz), 125.8 (d, J = 272.0 Hz), 
164.1, 191.4; 19F NMR (376 MHz, CDCl3) δ –53.9 (s, 3F); HRMS calculated for 
(C11H16F3NO) requires m/z [M+Na] 258.1076, found m/z 258.1077. 
 
4.3.3 General Procedure for a Radical Clock Experiment 
Diethyl diallylmalonate (24.0 mg, 0.1 mmol), PhI(OAc)2 (64.4 mg, 0.2 mmol) and KF 
(23.2 mg, 0.4 mmol) were added into a 2-dram PTFE sealed glass vial, followed by 
anhydrous MeCN (1.0 mL) and TMSCF3 (59.3 µL, 0.4 mmol) through syringes. The 
reaction mixture was stirred at room temperature for 24 h. The mixture was then diluted 
with acetone, filtered over a pad of Celite and eluted with acetone. The eluent was 
concentrated in vacuo. To the residue were added anisole (10.9 µL, 0.1 mmol) and 
monofluorobenzene (9.4 µL, 0.1 mmol) as 1H and 19F NMR internal standards 
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respectively. The crude mixture was analyzed by 1H and 19F NMR and LC-MS, and 
purified by silica gel chromatography (0-20% ethyl acetate/hexanes) to furnish two major 
products 2.19 (5.5 mg, 17%) and 2.20 (13.8 mg, 36%). Other trifluoromethylated 
byproducts were also observed in the crude 19F NMR spectrum (present in 1–5% yield), 
but could not be isolated. 
 
 
Diethyl 3-methyl-4-(2,2,2-trifluoroethyl)cyclopentane-1,1-dicarboxylate (2.19).212 1H 
NMR (500 MHz, CDCl3) δ 0.86 (d, J = 6.8 Hz, 3H), 1.24 (t, J = 7.0 Hz, 6H), 1.96–2.23 
(m, 4H), 2.29 (td, J = 14.6, 11.9, 7.4 Hz, 2H), 2.46 (ddd, J = 13.8, 10.5, 6.7 Hz, 2H), 4.18 
(q, J = 7.1 Hz, 4H); 13C NMR (126 MHz, CDCl3) δ 14.2, 15.0, 33.9 (q, J = 27.2 Hz), 
36.1, 36.6, 38.1, 41.3, 58.8, 61.7, 61.7, 127.3 (q, J = 274.6 Hz), 172.7, 172.7; 19F NMR 
(376 MHz, CDCl3) δ –64.9 (s, 3F); LCMS (ESI) calculated for (C14H22F3O4) requires m/z 
[M+H] 311.2, found 311.3. 
 
 
Diethyl 3-(acetoxymethyl)-4-(2,2,2-trifluoroethyl)cyclopentane-1,1-dicarboxylate 
(2.20). 1H NMR (400 MHz, CDCl3) δ 1.24 (t, J = 7.0 Hz, 6H), 2.04 (s, 3H), 2.10–2.21 
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(m, 2H), 2.22–2.40 (m, 2H), 2.40–2.57 (m, 4H), 3.92–4.11 (m, 2H), 4.18 (q, J = 7.1 Hz, 
4H); 13C NMR (126 MHz, CDCl3) δ 14.1, 21.0, 33.9 (q, J = 28.5 Hz), 35.2, 36.4, 39.1, 
40.4, 58.8, 61.8, 61.9, 63.9, 128.8 (q, J = 271.3 Hz), 170.9, 172.0, 172.3; 19F NMR (376 
MHz, CDCl3) δ –64.9 (s, 3F); LCMS (ESI) calculated for (C16H24F3O6) requires m/z 
[M+H] 369.2, found 369.3. 
 
4.3.4 Utility of 5-Trifluoromethylated Cyclic Enaminones 
 
1-Benzyl-3-(trifluoromethyl)piperidin-4-one (2.23). L-Selectride (1.0 M solution in 
THF, 0.056 mL, 0.056 mmol) was added dropwise to a stirred solution compound 2.6 
(14.2 mg, 0.056 mmol) in THF (1.50 mL) at –78 °C. The resulting mixture was stirred at 
this temperature for 1 h, quenched by a sat. aq. NH4Cl solution (1.50 mL) and then 
extracted with diethyl ether (3 X 5 mL). The combined organic extracts were washed 
with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. Silica gel flash 
chromatography (15% EtOAc/hexanes) furnished the title compound 2.23 (9.30 mg, 
65%) as a colorless oil. IR (thin film) 2907, 2791, 1731, 1360, 1267, 1244, 1151, 1116, 
1093, 1023, 756, 721 cm–1; 1H NMR (400 MHz, CDCl3) δ 2.45–2.65 (m, 4H), 3.06–3.08 
(m, 1H), 3.29–3.38 (m, 2H), 3.68 (q, 2H, J = 13.2 Hz), 7.30–7.38 (m, 5H); 13C NMR 
(100 MHz, CDCl3) δ 37.7, 48.9, 49.2, 49.4, 57.9, 123.9, 124.8, 125.0, 125.6 (q, J = 270 
Hz), 133.6, 196.9; 19F NMR (376 MHz, CDCl3) δ –70.9 (s, 3F); HRMS calculated for 
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(C6H8F3NO) requires m/z [M+H] 258.1100, found m/z 258.1101. 
 
 
5-(Trifluoromethyl)-2,3-dihydropyridin-4(1H)-one (2.24). Compound 2.11 (26.1 mg, 
0.087 mmol) was dissolved in MeOH (2.00 mL). 10% Pd/C (20.0 mg) was added to 
reaction mixture and was hydrogenated under atmospheric pressure at rt. After stirring 
overnight, the reaction mixture was filtered through a pad of Celite, followed by a short 
plug of silica gel, and the solvent was evaporated to obtain the title compound 2.24 as a 
pale yellow oil (11.9 mg, 83%). IR (thin film) 3331, 2927, 1611, 1513, 1455, 1255, 1167, 
1136, 1030, 833, 735, 699, 474 cm–1; 1H NMR (400 MHz, CDCl3) δ 2.56 (t, 2H, J = 7.8 
Hz), 3.65–3.69 (m, 2H), 6.16 (br s, 1H), 7.66 (d, 1H, J = 7.1 Hz); 13C NMR (100 MHz, 
CDCl3) δ 35.3, 41.3, 101.5 (q, J = 30.0 Hz), 122.5 (q, J = 265 Hz), 150.9 (q, J = 5.5 Hz), 
187.4; 19F NMR (376 MHz, CDCl3) δ –61.3 (s, 3F); HRMS calculated for (C6H6F3NO) 
requires m/z [M+Na] 188.0294, found m/z 188.0290. 
 
4.4 Chapter 3 
4.4.1 Synthesis of Photoprobe 3.1 
Epothilone A (3.5) and epothilone E (3.8) were provided to us by Dr. Höfle. 
Intermediates 3.6 and 3.7 for the synthesis of compound 3.8 were synthesized in Dr. 
Höfle’s laboratory. 
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4-((E)-2-((1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-5,9-
dioxo-4,17-dioxabicyclo[14.1.0]heptadecan-3-yl)prop-1-en-1-yl)thiazole-2-
carbaldehyde (3.9). Epothilone E (3.8, 30.0 mg, 58.9 µmol) was dissolved in CH2Cl2 
(2.00 mL) at rt under N2. To the reaction mixture was added MnO2 (8 X 55.0 mg) after 
10 min each. After that, Celite was added and the mixture filtered. The pellet was washed 
two times with a 8:2 mixture of CH2Cl2/MeOH. After the reaction was complete as 
deemed by the TLC, the solvent was evaporated and the residue was purified by silica gel 
chromatography (0–5% MeOH/CH2Cl2 gradient elution) to furnish the title compound 
3.9 as a colorless oily substance (29.0 mg, 97%). 1H NMR (400 MHz, CDCl3) δ 1.01 (d, 
3H, J = 8 Hz), 1.11 (s, 3H), 1.19 (d, 3H, J = 8 Hz), 1.38 (s, 3H), 1.53–1.76 (m, 7H), 
1.97–2.00 (m, 1H), 2.08–2.10 (m, 1H), 2.20 (s, 3H), 2.50–2.57 (m, 2H), 2.91–2.95 (m, 
1H), 3.03–3.07 (m, 1H), 3.22–3.29 (m, 1H), 3.80–3.82 (m, 1H), 4.12–4.15 (m, 1H), 5.48–
5.51 (m, 1H), 6.68 (s, 1H), 7.55 (s, 1H), 9.99 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
14.6, 15.5, 17.3, 21.0, 21.6, 23.9, 26.8, 30.2, 31.2, 36.1, 38.7, 44.0, 52.5, 54.2, 57.5, 73.9, 
75.2, 76.5, 118.8, 124.1, 139.4, 155.6, 164.9, 170.5, 183.7, 220.1; HRMS calculated for 
(C26H37NO7S) requires m/z [M+H] 508.2369, found m/z 508.2375. 
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(1S,3S,7S,10R,11S,12S,16R)-3-((E)-1-(2-((E/Z)-Hydrazonomethyl)thiazol-4-yl)prop-
1-en-2-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.10). Aldehyde 3.9 (14.0 mg, 27.6 mmol) 
was dissolved in MeOH (1.00 mL). To this solution, with stirring, 4 portions of hydrazine 
monohydrate (1.75 mL each, total 148 mmol) were added at rt. After stirring for 10 more 
min, a sat. Na2CO3 solution (0.50 mL) was added to the reaction mixture and extracted 
with EtOAc (3 X 3 mL). The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude residue obtained was a mixture of E- and Z-hydrazones 
the title compound 3.10 as glassy oil (9.8 mg, 64%), which was used directly for the next 
step without further purification. 
 
 
(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-
(thiazolo[3,2-c][1,2,3]triazol-6-yl)prop-1-en-2-yl)-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.1). The mixture of E- and Z-hydrazones 
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3.10 (9.8 mg, 18.8 mmol) was dissolved in CH2Cl2 (2.00 mL). With stirring, three 
portions of nickel peroxide monohydrate (NiO2.H2O) (8.59 mg X 3 times, total 284 
mmol) were added each 15 min. After 15 more min, the reaction mixture was filtered 
over Celite, washed with CH2Cl2 and the filtrates were evaporated. The residue was 
purified by silica gel chromatography (2–5% MeOH/CH2Cl2 gradient elution) to afford 
the title compound 3.1 as a colorless oil (4.00 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 
0.98 (d, 3H, J = 4 Hz), 1.09 (s, 3H), 1.19 (d, 3H, J = 4 Hz), 1.32–1.34 (m, 2H), 1.66–1.93 
(m, 7H), 2.16 (s, 3H), 2.22–2.35 (m, 3H), 2.56–2.62 (m, 1H), 2.95–3.04 (m, 2H), 3.24–
3.27 (m, 1H), 3.72–3.74 (m, 1H), 4.63–4.68 (m, 1H), 5.08–5.09 (m, 1H), 5.53–5.56 (m, 
1H), 6.94 (s, 1H), 7.08 (s, 1H), 7.86 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 14.1, 15.8, 
16.5, 18.1, 22.1, 22.7, 23.3, 28.0, 31.4, 32.0, 36.6, 39.5, 41.2, 54.7, 55.2, 57.7, 72.9, 74.9, 
109.1, 115.5, 124.8, 129.1, 136.4, 145.1, 169.9, 220.1; HRMS calculated for 
(C26H37N3O6S) requires m/z [M+H] 520.2481, found m/z 520.2484. 
 
4.4.2 Synthesis of Photoprobes 3.2 and 3.3 
4.4.2.1 Synthesis of the Epothilone A Aziridine Fragment 3.11 
Intermediates 3.14–3.19 and 3.11 were synthesized according to the literature 
procedure.272 The spectral data of these compounds was in agreement with that found in 
the literature.272 
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(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-((E)-1-(2-methylthiazol-4-
yl)prop-1-en-2-yl)-7,11-bis((triethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-
5,9-dione (3.14). To a DMF (14.5 mL) solution of epothilone A (3.5) (2.00 g, 4.05 
mmol) at 25 °C, N,N-diisopropylethylamine (55.0 mL, 315 mmol), imidazole (7.15 g, 
105 mmol) and Et3SiCl (4.88 mL, 28.8 mmol) were added sequentially. Then, the 
reaction mixture was heated to 55 °C for 6.5 h, solvent was evaporated and the reaction 
mixture was concentrated in vacuo. The residue was then diluted with CH2Cl2 (20.0 mL) 
and the organic extracts were washed with aq. NaHCO3 (6.00 mL), dried over Na2SO4 
and concentrated in vacuo. The residue was then purified by silica gel flash 
chromatography (100% hexanes to 15% EtOAc/hexanes gradient elution) to afford the 
title compound 3.14 as a white foam (2.70 g, 92%). 1H NMR (400 MHz, CDCl3) δ 0.43–
0.59 (m, 12H), 0.78–0.91 (m, 24H), 0.97–0.99 (d, 3H, J = 8 Hz), 1.03 (s, 3H), 1.06 (s, 
3H), 1.32–1.59 (m, 4H), 1.65–1.74 (m, 2H), 2.00 (s, 3H), 2.10–2.14 (m, 1H), 2.58 (s, 
3H), 2.66 (br s, 1H), 2.70–2.73 (m, 1H), 2.88–2.93 (m, 2H), 3.81–3.84 (d, 1H, J = 12 
Hz), 3.92–3.95 (d, 1H, J = 12 Hz), 5.13–5.15 (d, 1H, J = 8 Hz), 6.45 (s, 1H), 6.87 (s, 
1H); 13C NMR (100 MHz, CDCl3) δ 5.1, 5.5, 5.8, 6.6, 6.8, 7.1, 14.6, 17.5, 19.0, 19.4, 
23.5, 25.1, 25.2, 27.0, 33.0, 38.9, 48.4, 53.2, 55.2, 57.8, 76.5, 80.1, 116.5, 120.2, 137.4, 
152.2, 164.5, 170.8, 214.6; HRMS calculated for (C38H67NO6SSi2) requires m/z [M+H] 
722.4306, found m/z 722.4293. 
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(4S,7R,8S,9S,13R,14R,16S)-14-Bromo-13-hydroxy-5,5,7,9-tetramethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.15). To a CH2Cl2 (28.5 mL) solution of bis-TES-epothilone A 3.14 (2.7 g, 3.74 
mmol) at –20 °C under Ar, MgBr2•OEt2 (3 x 1.49 g, 16.0 mmol total) was added in three 
portions every two h while maintaining an internal temperature between –15 and –5 °C. 
After 7 h, the reaction mixture was quenched with pH 7 aqueous phosphate buffer (54 
mL) and brine (54 mL), carefully extracted with EtOAc (3 x 133 mL), dried over 
Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash 
chromatography (10–20% EtOAc/hexanes gradient elution) to provide the title compound 
3.15 as a white foam [1.11 g, 37 % (57% based on 0.8 g of recovered starting material)]. 
1H NMR (400 MHz, CDCl3) δ 0.59–0.68 (m, 12H), 0.92–0.97 (m, 22H), 1.08 (d, 3H, J = 
8 Hz), 1.13 (s, 3H), 1.19 (s, 3H), 1.23–1.30 (m, 2H), 1.58–1.72 (m, 4H), 2.10 (s, 3H), 
2.40–2.46 (m, 1H), 2.51–2.61 (m, 2H), 2.66–2.71 (m, 4H), 2.93–3.00 (m, 1H), 3.63–3.64 
(m, 1H), 3.85–3.87 (m, 1H), 4.23–4.26 (m, 1H), 4.32–4.36 (m, 1H), 5.40–5.42 (m, 1H), 
6.51 (s, 1H), 6.93 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 5.3, 5.4, 7.0, 7.1, 15.0, 17.4, 
17.8, 19.2, 22.4, 23.5, 25.2, 32.6, 35.2, 38.8, 39.9, 40.6, 46.2, 53.7, 61.7, 73.6, 74.8, 76.5, 
78.1, 116.5, 119.5, 137.5, 152.3, 164.7, 170.0, 216.2; HRMS calculated for 
(C38H68BrNO6SSi2) requires m/z [M+H] 802.3568, found m/z 802.3535. 
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(4S,7R,8S,9S,13R,14S,16S)-14-Azido-13-hydroxy-5,5,7,9-tetramethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.16). To a solution of bromohydrin 3.15 (1.11 g, 1.38 mmol) in DMF (13.1 mL) 
under Ar was added sodium azide (0.897 g, 13.8 mmol) and the resulting suspension was 
warmed to 43 °C. After 36–48 h, the solvent was removed in vacuo and the residue was 
directly purified by silica gel flash chromatography (10–20% EtOAc/hexanes gradient 
elution) to give the title compound 3.16 as a white foam (0.634 g, 62%). 1H NMR (400 
MHz, CDCl3) δ 0.58–0.67 (m, 12H), 0.90–0.99 (m, 21 H), 1.06–1.14 (m, 8H), 1.19 (s, 
3H), 1.36–1.44 (m, 2H), 1.57–1.61 (m, 3H), 1.67–1.72 (m, 1H), 2.09 (s, 3H), 2.24–2.31 
(m, 1H), 2.55–2.62 (m, 1H), 2.70 (s, 3H), 2.80–2.84 (m, 1H), 2.93–3.00 (m, 1H), 3.46–
3.48 (m, 1H), 3.81–3.84 (m, 1H), 3.96–3.98 (m, 1H), 4.02–4.05 (m, 1H), 5.28–5.31 (m, 
1H), 6.57 (s, 1H), 6.97 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 5.4, 5.5, 7.0, 7.1, 14.9, 
17.6, 19.0, 19.1, 23.6, 24.3, 25.0, 31.1, 33.1, 34.2, 37.1, 39.3, 48.0, 53.3, 62.5, 74.2, 76.2, 
78.3, 79.6, 116.6, 120.5, 137.2, 152.1, 164.8, 170.7, 214.8; HRMS calculated for 
(C38H68N4O6SSi2) requires m/z [M+H] 765.4476, found m/z 765.4437. 
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(2S,4S,5S,9S,10S,11R,14S)-4-Azido-9,11,13,13-tetramethyl-2-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-12,16-dioxo-10,14-
bis((triethylsilyl)oxy)oxacyclohexadecan-5-yl 4-Nitrobenzoate (3.17). To a solution of 
cis-azido alcohol 3.16 (0.634 g, 0.829 mmol) in THF (9.05 mL) under Ar was 
sequentially added 4-nitrobenzoic acid (0.346 g, 2.07 mmol), triphenylphosphine (0.543 
mg, 2.07 mmol), and diethyl azodicarboxylate (40 wt% solution in toluene, 0.901 mL, 
2.07 mmol). The reaction mixture was stirred at 25 °C for 4 h, concentrated in vacuo and 
the residue was purified by silica gel flash chromatography (10–20% EtOAc/hexanes 
gradient elution) to provide the title compound 3.17 as a white foam (0.584 g, 77%). 1H 
NMR (400 MHz, CDCl3) δ 0.61–0.69 (m, 12H), 0.94–0.99 (m, 22 H), 1.04–1.09 (m, 1H), 
1.12–1.14 (m, 6H), 1.21 (s, 3H), 1.51–1.60 (m, 3H), 1.73–1.79 (m, 1H), 1.91–1.97 (m, 
1H), 2.02–2.05 (m, 1H), 2.08–2.14 (m, 4H), 2.52–2.57 (m, 1H), 2.65–2.71 (m, 4H), 2.99–
3.06 (m, 1H), 3.91–3.96 (m, 2H), 4.44–4.47 (m, 1H), 5.24–5.28 (m, 1H), 5.61–5.64 (m, 
1H), 6.58 (s, 1H), 6.95 (s, 1H), 8.21 (d, 2H, J = 8 Hz), 8.29 (d, 2H, J = 8 Hz); 13C NMR 
(100 MHz, CDCl3) δ 5.4, 5.4, 7.0, 7.1, 14.9, 17.7, 19.2, 22.4, 30.5, 30.7, 36.3, 39.0, 41.6, 
45.6, 54.4, 59.0, 73.5, 76.8, 77.2, 117.0, 121.0, 123.7, 130.9, 135.0, 136.7, 150.7, 152.1, 
163.8, 164.9, 170.2, 216.5; HRMS calculated for (C45H71N5O9SSi2) requires m/z [M+H] 
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914.4589, found m/z 914.4581. 
 
 
(4S,5R,7R,8S,9S,13S,14S,16S)-14-Azido-13-hydroxy-5,7,9-trimethyl-16-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-4,8-bis((triethylsilyl)oxy)oxacyclohexadecane-2,6-
dione (3.18). The intermediate 3.17 (0.584 g, 0.639 mmol) was treated with 2.0 M 
ammonia in methanol (5.81 mL) at 25 °C under Ar overnight. The solvent was removed 
in vacuo and the residue was directly purified by silica gel flash chromatography (10-
30% EtOAc/hexanes gradient elution) to afford the title compound 3.18 as a white foam 
(0.488 g, 100%). 1H NMR (400 MHz, CDCl3) δ 0.60–0.67 (m, 12H), 0.92–0.99 (m, 
21H), 1.02–1.11 (m, 7H), 1.16 (s, 3H), 1.31–1.33 (m, 1H), 1.50–1.67 (m, 4H), 1.81–1.84 
(m, 1H), 2.02–2.03 (m, 2H), 2.12 (s, 3H), 2.54–2.60 (m, 1H), 2.70–2.73 (m, 4H), 2.98–
3.05 (m, 1H), 3.60–3.68 (m, 2H), 3.92–3.95 (m, 1H), 4.40 (br s, 1H), 5.52–5.53 (m, 1H), 
6.59 (s, 1H), 6.96 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 5.4, 5.5, 7.0, 7.1, 14.9, 17.6, 
18.3, 19.2, 21.6, 21.9, 22.1, 29.7, 33.4, 37.0, 38.1, 41.0, 45.9, 54.2, 61.6, 73.0, 74.0, 77.6, 
78.6, 116.7, 120.7, 137.0, 152.2, 164.8, 170.3, 215.9 ppm; HRMS calculated for 
(C38H69N4O6SSi2) requires m/z [M+H] 765.4476, found m/z 765.4514. 
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(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-((E)-1-(2-methylthiazol-4-
yl)prop-1-en-2-yl)-7,11-bis((triethylsilyl)oxy)-4-oxa-17-
azabicyclo[14.1.0]heptadecane-5,9-dione (3.19). A solution of trans-azido alcohol 3.18 
(0.171 g, 0.224 mmol) in CH2Cl2 (4.00 mL) was cooled to 0 °C. To this, triethylamine 
(0.125 mL, 0.896 mmol) was added. After stirring for 5 min, methanesulfonyl chloride 
(52.0 mL, 0.672 mmol) was added slowly over a period of 5 min. After 15 min, the 
reaction mixture was removed from the ice bath and stirred for 3 h at rt. After 3 h, sat. aq. 
NaHCO3 (15 mL) was added to the reaction mixture, extracted with CH2Cl2 (3 times X 5 
mL), dried over Na2SO4, concentrated in vacuo. The residue was taken to next step 
without further purification. The crude mesylate was dissolved in a 10:1 mixture of 
THF:Water (6.60 mL). Triethylamine (94.1 mL, 0.672 mmol) and trimethylphosphine 
(0.448 mL, 0.448 mmol of 1.0 M solution in THF) were added and the reaction mixture 
was stirred at rt. After 3 h, the reaction mixture was heated at 45 °C for 12 h and then the 
solvent was removed under a constant flow of nitrogen. Then the residue was purified by 
silica gel flash chromatography (0–6% MeOH/CH2Cl2 gradient elution) to furnish the 
title compound 3.19 as a film (137 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 0.57–0.67 
(m, 12H), 0.87–0.99 (m, 24H), 1.05–1.07 (d, 3H, J = 8 Hz), 1.12 (s, 3H), 1.15 (s, 3H), 
1.47–1.70 (m, 5H), 1.91–1.95 (m, 1H), 2.07–2.10 (m, 4H), 2.14–2.18 (m, 1H), 2.68–2.76 
(m, 5H), 2.95–3.02 (m, 1H), 3.89–3.91 (m, 1H), 4.01–4.03 (m, 1H), 5.19–5.21 (m, 1H), 
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6.53 (s, 1H), 6.94 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 5.2, 5.6, 7.0, 7.2, 14.6, 17.6, 
19.2, 19.6, 23.7, 27.0, 28.1, 31.0, 36.5, 39.0, 48.5, 53.3, 76.5, 78.6, 80.2, 116.4, 120.2, 
138.1, 152.4, 164.6, 171.2, 215.1 ppm; HRMS calculated for (C38H69N2O5SSi2) requires 
m/z [M+H] 721.4466, found m/z 721.4439. 
 
 
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-5,9-dioxo-4-oxa-17-
azabicyclo[14.1.0]heptadecan-17-ium 2,2,2-Trifluoroacetate (3.11). Compound 3.19 
(49.0 mg, 68.0 µmol) was treated with 20% trifluoroacetic acid in CH2Cl2 (1.50 mL) at 0 
°C under N2 for 10 min. The reaction mixture was concentrated under a constant stream 
of nitrogen at 0 °C and the residue was purified by silica gel chromatography (2–10% 
MeOH/CH2Cl2 gradient elution) to obtain the title compound 3.11 as a white film (37.4 
mg, 91%). 1H NMR (400 MHz, CDCl3) δ 0.98 (d, 3H, J = 8 Hz), 1.10 (s, 3H), 1.15 (d, 
3H, J = 8 Hz), 1.37 (s, 3H), 1.43–1.59 (m, 4H), 1.67–1.84 (m, 3H), 2.07 (s, 3H), 2.13–
2.29 (m, 2H), 2.41–2.45 (m, 1H), 2.53–2.59 (m, 1H), 2.70 (s, 3H), 2.83–2.95 (m, 2H), 
3.22–3.28 (m, 1H), 3.75–3.78 (m, 1H), 4.09–4.12 (m, 1H), 5.39–5.42 (m, 1H), 6.60 (s, 
1H), 7.02 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 13.8, 15.3, 17.2, 18.9, 21.0, 21.4, 23.7, 
24.1, 27.9, 29.9, 35.5, 36.9, 39.9, 44.1, 52.8, 74.0, 74.6, 117.0, 117.9, 120.5, 136.2, 151.1, 
162.3, 165.5, 170.7, 220.1; HRMS calculated for (C28H42F3N2O7S) requires m/z [M+H] 
	   164	  
607.2665, found m/z 607.2662. 
 
4.4.2.2 Synthesis of the meta– and the para–Acids 3.12 and 3.13 
The m-trifluoromethyldiazirino benzoic acid 3.12 was synthesized in Dr. Höfle’s lab and 
was sent to us for our experiments. The p-trifluoromethyldiazirino benzoic acid 3.13 was 
commercially available. It was purchased from Chem-Impex International Inc., and used 
directly without any further purification. 
 
4.4.2.3 General Procedure for the Synthesis of Photoprobes 3.2 and 3.3. 
Solution of the aziridine 3.11 (14.0 mg, 23.0 mmol) in CH2Cl2 (2.00 mL) was stirred with 
Hunig’s base (4.90 mL, 28.0 mmol) at rt. In a separate flask, to a solution of the 
trifluoromethyldiazirino benzoic acid (3.12 or 3.13, 6.65 mg, 28.0 mmol) in CH2Cl2 (3.00 
mL), Hünig’s base (10.5 mL, 60.0 mmol) and benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (12.8 mg, 28.0 
mmol) were added sequentially. After stirring for 10 min, the solution of aziridine 3.11 
was added to the acid solution. The reaction mixture was allowed to react for 16 h in the 
dark at rt. After 16 h, the reaction mixture was diluted with CH2Cl2 (3.00 mL) and then 
washed with pH 3 buffer (citric acid, 3 X 10 mL), sat. aq. NaHCO3 (3 X 10 mL)  and 
water (1 X 10 mL). The organic layer was dried over Na2SO4, and concentrated in vacuo. 
The residue was purified by silica gel chromatography (2–5% MeOH/CH2Cl2 gradient 
elution) to afford the desired compound 3.2 or 3.3. 
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(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-17-(3-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzoyl)-4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione (3.2). The title 
compound 3.2 was obtained as a colorless oil (13.1 mg, 81%). 1H NMR (400 MHz, 
CDCl3) δ 1.03 (d, 3H, J = 8 Hz), 1.15 (s, 3H), 1.19 (d, 3H, J = 8 Hz), 1.37 (s, 3H), 1.51–
1.57 (m, 3H), 1.71–1.75 (m, 2H), 1.93–1.99 (m, 2H), 2.11 (s, 3H), 2.35–2.56 (m, 5H), 
2.65–2.70 (m, 4H), 3.15–3.22 (m, 1H), 3.80–3.82 (m, 1H), 4.12–4.15 (m, 1H), 5.34–5.38 
(m, 1H), 6.58 (s, 1H), 6.98 (s, 1H), 7.39 (d, 2H, J = 8 Hz), 7.51 (t, 3H, J = 8 Hz), 7.77 (s, 
1H), 7.99 (d, 2H, J = 8 Hz); 13C NMR (100 MHz, CDCl3) δ 13.6, 15.3, 17.3, 19.0, 20.2, 
22.8, 24.0, 28.3 (q, J = 40.5 Hz), 31.2, 31.8, 36.3, 39.2, 40.1, 43.2, 43.6, 52.8, 73.1, 73.6, 
78.1, 116.3, 120.3, 122.0 (q, J = 273.1 Hz), 127.1, 129.2, 129.6, 130.2, 130.4, 134.1, 
138.1, 151.7, 165.2, 170.8, 178.7, 220.1; 19F NMR (376 MHz, CDCl3) δ –65.0 (s, 3F); 
HRMS calculated for (C35H44F3N4O6S) requires m/z [M+Na] 727.2753, found m/z 
727.2777. 
 
	   166	  
 
(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-
methylthiazol-4-yl)prop-1-en-2-yl)-17-(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzoyl)-4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione (3.3). The title 
compound 3.3 was obtained as a colorless oil (14.7 mg, 91%). 1H NMR (400 MHz, 
CDCl3) δ 1.03 (d, 3H, J = 8 Hz), 1.15 (s, 3H), 1.19 (d, 3H, J = 8 Hz), 1.37 (s, 3H), 1.50–
1.57 (m, 3H), 1.67–1.75 (m, 2H), 1.90–1.99 (m, 2H), 2.11 (s, 3H), 2.33–2.56 (m, 5H), 
2.65–2.71 (m, 4H), 3.15–3.21 (m, 1H), 3.80–3.82 (m, 1H), 4.12–4.14 (m, 1H), 5.34–5.37 
(m, 1H), 6.58 (s, 1H), 6.99 (s, 1H), 7.25–7.27 (m, 2H), 7.94–7.97 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 13.7, 15.3, 17.4, 19.1, 20.3, 22.8, 24.0, 25.6, 28.4 (q, J = 40.5 Hz), 
31.2, 31.9, 36.3, 39.2, 40.1, 43.3, 52.8, 68.0, 73.3, 73.8, 78.3, 116.4, 120.5, 121.8 (q, J = 
273.1 Hz), 126.5, 129.4, 133.6, 134.3, 138.1, 151.7, 165.2, 170.7, 178.8, 220.0; 19F NMR 
(376 MHz, CDCl3) δ –64.9 (s, 3F); HRMS calculated for (C35H44F3N4O6S) requires m/z 
[M+Na] 727.2753, found m/z 727.2777. 
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4.4.3 Attempts at Synthesizing the Photoprobe 3.4  
4.4.3.1 Suzuki Coupling Strategy 
4.4.3.1.1 Synthesis of Fragment 3.26 
 
1-(4-Bromothiazol-2-yl)-2,2,2-trifluoroethan-1-one (3.29). 2,4-Dibromothiazole (3.28, 
2.00 g, 8.23 mmol, 1.00 equiv) was dissolved in diethyl ether (35.0 mL), cooled to –78 
°C and with stirring n-butyllithium (3.50 mL, 8.73 mmol, 1.06 equiv, diluted with 3.00 
ml of diethyl ether) was added dropwise. After 1 h, N,N-diethyl trifluoroacetamide (1.52 
mL, 10.7 mmol, 1.30 equiv) was added to the above mixture over a period of 30 min and 
the reaction mixture was stirred –78 °C. After 1 h, the reaction mixture was warmed to –
10 °C and kept for 4 h. Then the reaction was quenched with sat. aq. NH4Cl solution. The 
organic phase was separated from the aqueous phase, dried over Na2SO4, and 
concentrated in vacuo to get the crude trifluoromethyl ketone 3.29 (2.14 g) This 
intermediate was used directly for the next step without further purification. 
 
 
(Z)-1-(4-Bromothiazol-2-yl)-2,2,2-trifluoroethan-1-one O-Tosyl Oxime (3.30). The 
crude trifluoromethyl ketone 3.29 (2.14 g, 8.23 mmol, 1.00 equiv) obtained from the 
earlier step was dissolved in ethanol (18.0 mL) and hydroxylammonium chloride (2.00 g, 
28.8 mmol, 3.50 equiv) and pyridine (4.35 mL, 53.8 mmol, 6.53 equiv) were added and 
	   168	  
the mixture was refluxed for 4 h. After 4 h, the mixture was evaporated and the residue 
was distributed between water and diethyl ether. The ether phase was evaporated, and the 
pyridine was removed in vacuo with toluene to furnish the crude oxime (2.26 g). The 
crude oxime (2.26 g, 8.22 mmol, 1.00 equiv), triethylamine (2.30 mL, 16.4 mmol, 2.00 
equiv), DMAP (0.101 g, 0.822 mol, 0.10 equiv) and tosyl chloride (2.39 g, 12.4 mmol, 
1.51 equiv) were dissolved in dichloromethane (25 mL) and stirred at rt for 1 h. The 
reaction mixture was washed with water (1 X 25 mL) and the organic phase was 
separated. The organic phase was dried over Na2SO4, evaporated and purified by flash 
chromatography on silica gel (10:1 to 5:1 EtOAc/petroleum ether gradient elution) to 
yield the title compound 3.30 as a yellow solid (2.63 g, 37% over 3 steps), and 1.15 g of 
impure 3.30. 1H NMR (400 MHz, CDCl3) δ 2.48 (s, 3H), 7.41 (d, 2H, J = 8.1 Hz), 7.74 
(s, 1H), 7.94 (d, 2H, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) δ 21.8, 119.0 (q, J = 278.5 
Hz), 125.3, 127.0, 128.3, 129.5, 130.2, 144.9 (q, J = 33.5 Hz), 147.1, 149.1; 19F NMR 
(376 MHz, CDCl3) –64.8; HRMS calculated for (C12H8BrF3N2O3S2) requires m/z [M+H] 
428.9190, found m/z 428.9195. 
 
 
4-Bromo-2-(3-(trifluoromethyl)diaziridin-3-yl)thiazole (3.31). In a flask, O-
tosyloxime 3.30 (1.23 g, 2.87 mmol, 1.00 equiv) was dissolved in abs. diethyl ether (17.0 
mL) and cooled to –78 °C. Then, ammonia gas (ca. 12.3 mL) was condensed to the 
reaction flask. After 2 h stirring, the temperature was slowly raised to rt. The reaction 
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mixture was quenched with water (15 mL) and the aq. phase was extracted with diethyl 
ether (1 X 20 mL). The separated organic phase was dried over Na2SO4, evaporated, and 
the residue purified by flash chromatography (8–16% EtOAc/petroleum ether gradient 
elution) to furnish the title compound 3.31 (0.623 g, 79%). 1H NMR (400 MHz, CDCl3) δ 
3.07 (s, 2H), 7.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 55.4 (q, J = 38.1 Hz), 120.1, 
122.2 (q, J = 276 Hz), 126.1, 161.3; 19F NMR (376 MHz, CDCl3) –74.5; HRMS 
calculated for (C5H3BrF3N3S) requires m/z [M+H] 273.9261, found m/z 273.9262. 
 
 
4-Bromo-2-(3-(trifluoromethyl)-3H-diazirin-3-yl)thiazole (3.26). Diaziridine 3.31 
(0.104 g, 0.379 mmol, 1.00 equiv) was dissolved in dry CH2Cl2 (2.50 mL) and Ag(I) 
oxide (0.704 g, 3.04 mmol, 8.00 equiv) was added. The resulting suspension was stirred 
for 24 h in the dark. After stirring, the slurry was applied to a silica gel column, soaked in 
and eluted with low boiling petroleum ether/diethyl ether (20:1). The solvents were 
evaporated from the eluent at 40 °C under a slight vacuum to get the title compound 3.26 
(0.077 g, 75%). 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δ 28.7 (q, J = 43.3 Hz), 119.3, 120.9 (q, J = 276.6 Hz), 126.8, 158.8; 19F NMR (376 
MHz, CDCl3) –66.5; HRMS calculated for (C5HBrF3N3S) requires m/z [M+H] 271.9105, 
found m/z 271.9112. 
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4.4.3.1.2 Synthesis of Fragment 3.32 
 
(1S,3S,7S,10R,11S,12S,16R)-3-Acetyl-8,8,10,12-tetramethyl-7,11-
bis((trimethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.32). 
Compound 3.32 was synthesized in Dr. Höfle’s lab and was shipped to us for use in the 
further experiments. 
 
4.4.3.1.3 Synthesis of Fragment 3.33 
 
Tris(ethylenedioxyboryl)methane (3.33). In a dry round bottom flask, boron trichloride 
3.35 (1.0 M in hexanes) (100 mL, 100 mmol, 1.00 equiv) was added under nitrogen and 
the flask cooled to –50 °C. Trimethyl borate 3.36 (22.3 mL, 200 mmol, 2.00 equiv) was 
then added with stirring at this temperature over a period of 5 min to form 
dimethoxyboron chloride 3.37. After slowly warming to rt, chloroform (8.05 mL, 100 
mmol, 1.00 equiv) was added to the above mixture to get the ‘mixture A’, which was 
transferred to a 250 mL dropping funnel. In a dry 1000 mL three–necked flask, lithium 
metal chunks (3.75 g, 540 mmol, 5.4 equiv) were added under nitrogen and the flask was 
fitted with an internal thermometer and the dropping funnel with ‘mixture A’ in it. Dry 
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THF (156 mL) was then added to the lithium and the flask was cooled to –40 °C. Then 
slowly ‘mixture A’ was added over a period of 2 h. The temperature was kept between –
40 to –30 °C and vigorous stirring was maintained during the addition. Then the mixture 
was allowed to warm up to rt over 2 h and stirred overnight at that temperature. The next 
day, the reaction mixture was filtered under a stream of nitrogen through a Büchner 
funnel and the residue was washed with dry THF (15 mL). The filtrate was concentrated 
in vacuo to ~60 mL and mixed with dry hexanes (30 mL). The resulting precipitate was 
removed by filtration. The filtrate was evaporated and the residue was shaken vigorously 
with diethyl ether (20 mL). The slurry was filtered and the filtrate was concentrated to 
dryness in vacuo to yield 15.4 g of crude tris(dimethoxyboryl)methane (3.39). Compound 
3.39 (15.4 g, 66.4 mmol, 1.00 equiv) was dissolved in dry THF (36 mL), cooled to 0 °C 
and then ethylene glycol (9.00 mL, 161 mmol, 2.43 equiv) was added. After stirring for 
30 min at this temperature, the solvent was evaporated. The residue was heated at 70 °C 
under reduced pressure to remove excess ethylene glycol and volatile by-products to 
yield the crude product tris(ethylenedioxyboryl)methane (3.33). This was dissolved in 30 
mL of boiling THF, filtered and cooled down to 5 °C. After one to three days at 5 °C, 
2.05 g of colorless crystals of pure solid product 3.33 were collected (mp = 170–172 °C). 
The mother liquor was concentrated to about half of the volume and kept again at 5 °C 
for several days to yield a second batch of 0.573 g of 3.3. The total yield was 2.62 g 
(18%). The spectroscopic data of product 3.33 agreed with those reported in literature.327 
1H NMR (400 MHz, CDCl3) δ 0.78 (br s, 1H), 4.21 (s, 12H); 13C NMR (100 MHz, 
CDCl3) δ 47.4, 65.7; HRMS calculated for (C7H13B3O6) requires m/z [M+H] 227.1070, 
found m/z 227.1075. 
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4.4.3.2 Cross Metathesis Strategy 
4.4.3.2.1 Synthesis of Fragment 3.40 
 
2-Bromo-4-vinylthiazole (3.43). In a round bottom flask 2-bromothiazole-4-
carbaldehyde (3.42, 2.00 g, 8.23 mmol, 1.00 equiv) was dissolved in THF (30.0 mL) and 
stirred at rt. In a separate flask, potassium tert-butoxide (1.84 g, 15.6 mmol, 1.50 equiv) 
was dissolved in dry THF (20.0 mL) under nitrogen and stirred for 15 min. 
Simultaneously in another flask, methyl triphenylphosphonium bromide salt (7.59 g, 20.8 
mmol, 2.00 equiv) was dissolved in dry THF (70.0 mL) at rt and then cooled to 0 °C. The 
THF solution of potassium tert-butoxide was added to the Wittig salt solution slowly 
over 5 min. The mixture was then refluxed for 1 h, then removed from the oil bath and 
cooled to rt within 30 min. To this, the aldehyde solution was slowly added over 5 min at 
rt. The reaction mixture was then stirred at rt untill the reaction was completed as 
monitored by the TLC. At this point, water (120 mL) was added to the reaction mixture 
and the aq. layer was extracted with diethyl ether (3 X 100 mL). The separated organic 
layer was washed once with brine (100 mL), dried over Na2SO4, evaporated and purified 
by flash chromatography on silica gel (10–15% diethyl ether/petroleum ether gradient 
elution) to afford the title compound 3.43 (1.57 g, 79%). 1H NMR (400 MHz, CDCl3) δ 
5.35 (d, 1H, J = 10.8 Hz), 6.02 (d, 1H, J = 17.2 Hz), 6.58 (dd, 1H, J1 = 10.8 Hz, J2 = 17.2 
Hz), 6.99 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 117.7, 118.6, 128.6, 136.0, 154.5; 
HRMS calculated for (C5H4BrNS) requires m/z [M+Na] 211.9146, found m/z 211.9152. 
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2,2,2-Trifluoro-1-(4-vinylthiazol-2-yl)ethan-1-one O-Tosyl Oxime (3.44). 2-Bromo-4-
vinylthiazole (3.43, 1.99 g, 10.5 mmol, 1.00 equiv) was dissolved in diethyl ether (45.0 
mL), cooled to –78 °C and with stirring n-butyllithium (6.96 mL, 11.1 mmol, 1.06 equiv, 
diluted with 3.76 mL of diethyl ether) was added dropwise. After 1 h, N,N-diethyl 
trifluoroacetamide (1.94 mL, 13.7 mmol, 1.30 equiv) was added to the above mixture 
over a period of 30 min and the reaction mixture was stirred –78 °C. After 1 h, the 
reaction mixture was warmed to –10 °C and kept for 4 h. Then the reaction was quenched 
with sat. aq. NH4Cl solution. The organic phase was separated from the aqueous phase, 
dried over Na2SO4, and concentrated in vacuo to obtain the crude trifluoromethyl ketone 
(2.18 g). The crude trifluoromethyl ketone (2.18 g, 10.5 mmol, 1.00 equiv) was dissolved 
in ethanol (22.5 mL) and hydroxylammonium chloride (2.55 g, 36.7 mmol, 3.50 equiv) 
and pyridine (5.55 mL, 68.6 mmol, 6.53 equiv) were added and the mixture was refluxed 
for 4 h. After 4 h, the mixture was evaporated and the residue was distributed between 
water and diethyl ether. The ether phase was evaporated, and the pyridine was removed 
in vacuo with toluene to afford the crude oxime (2.33 g). The crude oxime (2.33 g, 10.5 
mmol, 1.00 equiv), triethylamine (2.94 mL, 21.0 mmol, 2.00 equiv), DMAP (0.130 g, 
1.05 mol, 0.100 equiv) and tosyl chloride (3.03 g, 15.8 mmol, 1.51 equiv) were dissolved 
in dichloromethane (29 mL) and stirred at rt for 1 h. The reaction mixture was washed 
with water (1 X 25 mL) and the organic phase was separated. The organic phase was 
dried over Na2SO4, evaporated and purified by flash chromatography on silica gel (5–
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20% diethyl ether/petroleum ether gradient elution) to give the title compound 3.44 as a 
pale yellow solid (mp = 113–114 °C) (2.47 g, 62% over 3 steps). 1H NMR (400 MHz, 
CDCl3) δ 2.48 (s, 3H), 5.49 (d, 1H, J = 10.8 Hz), 6.16 (d, 1H, J = 18.5 Hz), 6.78 (dd, 1H, 
J1 = 10.8 Hz, J2 = 17.3 Hz), 7.40 (d, 2H, J = 8.2 Hz), 7.58 (s, 1H), 7.96 (d, 2H, J = 8.4 
Hz); 13C NMR (100 MHz, CDCl3) δ 21.8, 119.2, 119.3 (q, J = 276.7 Hz), 121.9, 128.6, 
129.4, 130.0, 130.6, 146.0 (q, J = 36.7 Hz), 146.7, 148.1, 155.4; 19F NMR (376 MHz, 
CDCl3) –64.8, –61.4; HRMS calculated for (C14H11F3N2O3S2) requires m/z [M+Na] 
399.0061, found m/z 399.0068. 
 
 
2-(3-(Trifluoromethyl)diaziridin-3-yl)-4-vinylthiazole (3.45). In a flask, O-tosyloxime 
3.44 (1.38 g, 3.24 mmol, 1.00 equiv) was dissolved in abs. diethyl ether (17.0 mL) and 
cooled to –78 °C. Then, ammonia gas (ca. 13.8 mL) was condensed to the reaction flask. 
After 2 h stirring, the temperature was slowly raised to rt. The reaction mixture was 
quenched with water (15 mL) and the aq. phase was extracted with diethyl ether (1 X 20 
mL). The separated organic phase was dried over Na2SO4, evaporated, and the residue 
purified by flash chromatography (6–16% diethyl ether/petroleum ether gradient elution) 
to furnish the title compound 3.45 (0.752 g, 93%). 1H NMR (400 MHz, CDCl3) δ 3.09 (d, 
1H, J = 8.9 Hz), 3.27 (d, 1H, J = 9.0 Hz), 5.41 (d, 1H, J = 10.9 Hz), 6.08 (d, 1H, J = 17.3 
Hz), 6.69 (dd, 1H, J1 = 10.9 Hz, J2 = 17.3 Hz), 7.20 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δ 55.4 (q, J = 38.1 Hz), 117.2, 118.0, 120.5 (q, J = 273.3 Hz), 128.9, 154.9, 159.9; 19F 
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NMR (376 MHz, CDCl3) –74.7; HRMS calculated for (C7H6F3N3S) requires m/z [M+H] 
244.0132, found m/z 244.0142. 
 
 
2-(3-(Trifluoromethyl)-3H-diazirin-3-yl)-4-vinylthiazole (3.40). Diaziridine 3.45 
(0.104 g, 0.379 mmol, 1.00 equiv) was dissolved in dry CH2Cl2 (2.50 mL) and Ag(I) 
oxide (0.704 g, 3.04 mmol, 8.00 equiv) was added. The resulting suspension was stirred 
for 24 h in the dark. After this, the slurry was applied on a silica gel column, soaked in 
and eluted with low boiling petroleum ether/diethyl ether (20:1). The solvents were 
evaporated from the eluent at 40°C under a slight vacuum to yield the title compound 
3.26 (0.077 g, 75%). 1H NMR (400 MHz, CDCl3) δ 5.43 (d, 1H, J = 10.8 Hz), 6.08 (d, 
1H, J = 17.3 Hz), 6.68 (dd, 1H, J1 = 10.8 Hz, J2 = 17.3 Hz), 7.17 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 28.9 (q, J = 42.4 Hz), 116.3, 118.6, 121.1 (q, J = 273.3 Hz), 128.6, 155.4, 
157.6; 19F NMR (376 MHz, CDCl3) –66.4; HRMS calculated for (C7H4F3N3S) requires 
m/z [M+Na] 241.9976, found m/z 241.9982. 
 
4.4.3.2.2 Synthesis of Fragment 3.46 
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(1S,3S,7S,10R,11S,12S,16R)-8,8,10,12-Tetramethyl-3-(prop-1-en-2-yl)-7,11-
bis((trimethylsilyl)oxy)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (3.46). The 
bis-TMS epothilone A ketone 3.32 (0.022 g, 0.041 mmol, 1.00 equiv) was charged into 
an oven dried flask and dry THF (1.50 mL) was added to it under nitrogen. The flask was 
cooled to 0 °C. Then, the Tebbe reagent (0.5M in toluene, 0.130 mL, 0.065 mmol, 1.60 
equiv) was added dropwise to the ketone solution and the reaction mixture was stirred at 
0 °C for 30 min. After the reaction was complete as deemed by TLC, it was quenched 
with 0.1 M NaOH (1 mL), stirred and diluted with diethyl ether (10 mL). Then the slurry 
was filtered over a short pad of silica gel. The filtrate was concentrated and the residue 
was purified by flash chromatography (6–12% diethyl ether/petroleum ether gradient 
elution) to obtain the title compound 3.46 as colourless foam (0.012 g, 53%). 1H NMR 
(400 MHz, CDCl3) δ 0.05 (s, 19H), 0.15 (s, 9H), 0.97 (d, 3H, J = 8 Hz), 1.07 (d, 3H, J = 
8 Hz), 1.13 (s, 3H), 1.18 (s, 3H), 1.20–1.24 (m, 1H), 1.39–1.49 (m, 3H), 1.53–1.58 (m, 
1H), 1.62–1.71 (m, 2H), 1.74–1.82 (m, 4H), 2.19 (dd, 1H, J1 = 3.3 Hz, J2 = 14.8 Hz), 
2.69–2.78 (m, 2H), 2.81–2.84 (m, 1H), 2.95–3.02 (m, 2H), 3.89 (d, 1H, J = 9.9 Hz), 4.04 
(dd, 1H, J1 = 3.1 Hz, J2 = 9.7 Hz), 4.90 (s, 1H), 4.98 (s, 1H), 5.21 (d, 1H, J = 10.7 Hz); 
13C NMR (100 MHz, CDCl3) δ 0.0, 0.5, 17.6, 17.8, 19.1, 23.0, 24.7, 25.1, 26.7, 30.0, 
30.7, 32.6, 35.5, 38.5, 48.1, 52.9, 55.2, 57.6, 74.4, 80.6, 112.3, 143.1, 171.1, 214.4; 
HRMS calculated for (C28H52O6Si2) requires m/z [M+Na] 563.3200, found m/z 563.3214. 
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